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Abstract 
Colorectal cancer (CRC) is the most common cause of deaths in the West. 
Despite many therapeutic opportunities, drug resistance or recurrence has 
significant rates among patients. Nearly 50% of CRC patients develop 
metastases. Therefore, sensitive biomarker and effective treatments with 
minimal toxicity are needed. Genetic and epigenetic alterations play major 
roles in initiation, development, and chemoresistance of CRC. Histone 
deacetylase2 (HDAC2) over-expression is well-known in CRC. Many 
studies have associated HDAC2 over-expression and TP53 mutations with 
late stages of metastatic CRC (mCRC). However, the relationship between 
HDAC2 expression level and TP53 status and mCRC drug resistance is 
unclear. Here, I have investigated HDAC2 role in drug resistance and 
assessed the synergistic effects of DNA chemotherapeutics agents and 
HDAC inhibitors (HDACIs) on TP53 status in mCRC cell lines. I have 
shown for the first time that in mutated p53 mCRC cells (Sw480 and HT-
29) the steady-state level of HDAC2 is low compared to wild-type p53 
cells (HCT116 p53+/+). I have also found that increase in HDAC2 
expression level in the highly resistant cell line HT-29 enhances drug 
resistance and its depletion by shRNA sensitises HT-29 to 5Fluorouracil 
(5FU) or Oxaliplatin (Oxa). The combined treatment of suberoylanilide 
hydroxamic acid (SAHA)/5FU and SAHA/Oxa was able to reduced 
HDAC2 expression level and induced mitotic cell death. However, 
SAHA/Doxorubicin combined treatment induced cell death in wild-type 
p53 (HCT116 p53+/+), null p53 (HCT116 p53-/-), and SW480 cell lines. 
This cell death associated with decrease in HDAC2 level. I have shown the 
association between sensitivity to treatment and reduction of HDAC2 level 
via bioluminescence imaging in combination with liposomal-encapsulated 
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SAHA/Doxorubicin delivery to monitor tumour growth. I have observed a 
significant decrease in tumour growth and HADC2 level. Therefore, I 
suggest that unlike mutated p53, HDAC2 could be an epigenetic 
prognostic biomarker to predict therapeutic response in mCRC.  
ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 | P a g e  
 
Table of Contents 
Thesis title page 1    
Copyright Declaration 2 
Declaration of originality 2 
Acknowledgements 3 
Abstract 4 
Table of contents 6 
Publication    12 
List of abbreviations                                                  13 
Chapter 1: Introduction                               16 
Chapter at Glance 17 
1. Colorectal cancer (CRC) 19 
    1.1 Definition and Epidemiology 19 
    1.2 The aetiology of colorectal cancer 21 
      1) Familial (hereditary) CRC 22 
      2) Sporadic CRC  23 
    1.3 The emergence and progress of CRC 24 
    1.4 Signs and Symptoms of CRC 24 
    1.5 Pathological staging of CRC 26 
    1.6 Pathogenesis of CRC 28 
      1. Chromosomal Instability (CIN) pathway 28 
      2. CpG Island Methylator Phenotype (CIMP) pathway 29 
      3. Microsatellite Instability (MSI) pathway 31 
      4. Serrated pathway 33 
    1.7 Human p53 and CRC 38 
• General background 38 
• p53 and CRC 47        
6 | P a g e  
 
    1.8 Diagnosis of CRC 51 
 Biochemical tests 51 
1- Faecal occult blood testing (FOBT) 51 
2- Genetic stool testing 51 
3- M2-PK Testing 52 
 Imaging tests 52 
1- Colonoscopy 52 
2- Computed tomography (CT) scans 53 
    1.8 Treatment for CRC 53 
          Surgery 54 
          Radiation 54 
          Chemotherapy 54 
2. Epigenetics and colorectal cancer 55 
• DNA Hypomethylation 55 
• DNA Hypermethylation 55 
• Loss of imprinting 56 
• Post-Translational Histone Modifications 56 
• Post-translational histone modifications in CRC 59 
1- CRC histone methylation 59 
2- CRC histone phosphorylation 59 
3- CRC histone acetylation 59 
3. Histone deacetylase inhibitors (HDACIs) 63 
1- History and discovery 63 
2- Effect and structure 63 
3- Efficacy and functionality 66 
4- Combination therapies with HDACIs 68 
5- Resistance to HDACIs 70 
1- Drug efflux 70 
7 | P a g e  
 
2- HDACs overexpression and desensitization 70 
3- Epigenetic and chromatin alterations 71 
4- Stress response mechanisms 72 
5- Antiapoptotic/prosurvival mechanisms 72 
6- Survivin and CRC 74 
4. Objectives and Hypothesis 78 
Chapter 2: Materials and methods 81 
Chapter at Glance 82 
1-In vitro study 84 
• Cell lines used in this study 84                                          
• Reagents used in this study 84 
• Cell culture 86 
• Cell collection 86 
• Cell subculturing 87 
• Luciferase-stable HCT116 p53+/+ and HCT116 p53-/- 89 
• HDAC2-Knocked down HCT116 p53-/- and HT-29 stable clones 90 
• Transient HDAC2-overexprssion in SW480 cells 90 
• Flow cytometry (FCM) 91 
• Immunofluorescence 93 
• Total protein extraction 94 
• Histones extraction 95 
• Bradford protein assay 97 
• Immunoblotting (western blot) 98 
1. Sample preparation 98 
2. Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis 99 
3. Transfer and immunoblotting 100 
• Real time PCR 101 
8 | P a g e  
 
• Statistical analysis for in vitro study 102 
• The list of the antibodies used for immunoblotting 102 
• The chemotherapeutic drugs used in this study 104 
1. Doxorubicin (Dox) 104 
2. Camptothecin-11 (CPT-11) 104 
3. Valproic Acid (VPA) 104 
4. Vorinostat or Suberoylanilide Hydroxamic Acid (SAHA) 105 
5. Sodium Butyrate (NaB) 105 
6. Cisplatin (Cisp) 106 
7. Oxaliplatin (Oxa) 106 
8. 5 Fluorouracil (5FU) 107 
• The quantification of synergistic and antagonistic effects of combined drugs 
used in this study 107 
2-In vivo study   108 
• Cells preparation 108 
• Liposomes’preparation 108 
• In vivo tumour model development 109 
• Tumour regression assessment by size and by bioluminescent imaging luciferase  
                                                                                                                           110 
• Tumour histological study 111 
• Human samples used in this study 113 
• Statistical analysis for in vivo study 113 
Chapter 3: Results 114 
Chapter at Glance 115 
1-Characterization of response of wild-type, null, and mutated p53 mCRC cell lines 
to DNA damaging agents 117 
Summary 117 
Laboratory work and results 117 
 
9 | P a g e  
 
2-Selective combined treatment with HDAC inhibitors and DNA damaging agents 
induces different levels of sensitivity in mCRC cells 123 
Summary 123 
Laboratory work and results 124 
3-Doxorubicin combined with SAHA or VPA triggers decrease in histone acetylation 
correlating with the degree of response to applied treatments 126 
Summary 126 
Laboratory work and results 127 
4-Increased HDAC2 expression linked with p53 status represents a key factor in drug 
resistance when Dox is combined with VPA or SAHA in the mCRC lines used in this 
study 131 
Summary 131 
Laboratory work and results 132 
5-Correlation between survivin and HDAC2 levels determines cell death on treatment 
with Dox combined with VPA or SAHA in the mCRC lines used in this study 139 
Summary 139 
Laboratory work and results 140 
6-HDAC2 depletion sensitizes HCT 116 p53-/- to Dox/ VPA treatment, whereas its 
over-expression erases SW480 sensitivity to the same treatment 143 
Summary 143 
Laboratory work and results 144 
7-HDAC2 controls chromatin plasticity and its depletion enhances mitotic cell death 
in drug resistant HT-29 cells upon 5FU and Oxa treatment 147 
Summary 147 
Laboratory work and results 147 
8-In vivo imaging and immunohistochemistry validation of Dox/SAHA combined 
treatment effects and the related role of HDAC2 in obtained response 154 
Summary 154 
Laboratory work and results 155 
Chapter 4: Discussion 163 
Chapter at Glance 164 
10 | P a g e  
 
1. Discussion 165 
2. Study limitation 176 
3. Future works emerging from this study 176 
4. A schematic summary of the results obtained in this project 179  
References 181 
                                                          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                       
 
11 | P a g e  
 
Publication 
The following paper has been submitted to Cancer Research Journal. 
Histone deacetylase2 regulation controls metastatic colorectal cancer response to HDAC 
inhibitor combined with DNA damaging agents  
Mr Samer Alzoubi1, Miss Leigh Brody2, Mr Sunniyat Rahman1, Dr Nicolas Mercado3, Dr Kazuhiro 
Ito 3, Dr Mona El-Bahrawy4, Professor Alan Boobis1, Professor Jimmy Bell2 and Dr Nabil Hajji1. 
 
1Centre for Pharmacology & therapeutics, Toxicology Unit, Division of Experimental Medicine, 
Department of Medicine, Imperial College London,2 MRI Unit, Imaging Sciences Department, 
Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK.3Airway Disease Section, 
National Heart and Lung Institute, Imperial College, Dovehouse Street, London, SW3 6LY, United 
Kingdom. 4 Department of Histopathology, Imperial College London. 
        ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
12 | P a g e  
 
List of Abbreviations 
5FU 
APC  
BLI  
CI           
CIMP                 
CIN                
Cisp  
COX-2 
CPT-11 
CRC 
CT 
DNMTIs 
Dox 
DSB 
FAP 
FCM 
FOBT               
H3K9ME3    
HATs                
HDACIs 
HDACs 
HCC 
IBD 
IBS 
IGF2 
IHC 
: 5Fluorouracil 
: Adenomatous polyposis coli 
: Bioluminescence imaging 
: Combination index 
: CpG Island methylator phenotype 
: Chromosomal instability  
: Cisplatin 
: Cyclooxygenase-2 
: Camptothecin-11 
: Colorectal cancer 
: Computed tomography 
: DNA methyltransferase inhibitors 
: Doxorubicin 
: Double-strand breaks 
: Familial adenomatous polyposis 
: Flow cytometry 
: Faecal occult blood testing 
: Trimethylation of histone H3 lysine 9 
: Histone acetyltransferase enzymes 
: Histone deacetylase inhibitors 
: Histone deacetylase enzymes 
: Hepatocellular carcinoma  
: Inflammatory bowel disease 
: Irritable bowel syndrome 
: Insulin-like growth factor II 
: Immunohistochemistry 
13 | P a g e  
 
LOH 
MAPK 
: Loss of heterozygosity 
: Mitogen-activated protein kinase 
mCRC 
MCD 
MLH1 
MMR 
MRI 
MSI 
MSI-H     
MSI-L 
MSS 
NaB 
NAD+ 
NF-кB   
NSAIDs 
Oxa 
PARP 
PARPc 
PBS 
PEI 
PET 
PI 
PK 
ROI 
ROS 
RPM 
SAHA 
SDS-PAGE 
: Metastatic colorectal cancer 
: Mitotic cell death  
: MutL homolog1 
: Mismatch repair 
: Magnetic resonance imaging   
: Microsatellite instability 
: High-frequency MSI 
: Low-frequency MSI 
: Microsatellite stable 
: Sodium butyrate 
: Nicotinamide adenine dinucleotide 
: Nuclear factor кB 
: Nonsteroidal anti-inflammatory drugs 
: Oxaliplatin  
: Poly (ADP-ribose) polymerase 
: PARP cleavage 
: Phosphate buffer saline 
: Polyethylenimine 
: Positive emission tomography 
: Propidium iodide 
: Pyruvate kinase 
: Region of interest 
: Reactive oxygen species 
: Revolutions per minute 
: Suberoylanilide hydroxamic acid  
: Sodium dodecyl sulphate polyacrylamide gel ectrophoresis 
14 | P a g e  
 
Ser10H3 
SSA 
TCF 
TNM 
TRAIL 
TSA 
TSA 
VPA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
: Serine 10 residue in histone 3 
: Sessile serrated adenomas 
: T-cell factor  
: Tumour, node, metastasis 
: Tumour-necrosis factor-related apoptosis inducing ligand 
: Traditional serrated adenomas 
: Trichostatin A 
: Valproic acid 
ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
15 | P a g e  
 
Chapter 1 
Introduction
16 | P a g e  
 
Chapter at Glance: 
1. Colorectal cancer (CRC) 19 
    1.1 Definition and Epidemiology 19 
    1.2 The aetiology of colorectal cancer 21 
      1) Familial (hereditary) CRC 22 
      2) Sporadic CRC  23 
    1.3 The emergence and progress of CRC 24 
    1.4 Signs and Symptoms of CRC 24 
    1.5 Pathological staging of CRC 26 
    1.6 Pathogenesis of CRC 28 
      1. Chromosomal Instability (CIN) pathway 28 
      2. CpG Island Methylator Phenotype (CIMP) pathway 29 
      3. Microsatellite Instability (MSI) pathway 31 
      4. Serrated pathway 33 
    1.7 Human p53 and CRC 38 
• General background 38 
• p53 and CRC 47        
    1.8 Diagnosis of CRC 51 
 Biochemical tests 51 
1- Faecal occult blood testing (FOBT) 51 
2- Genetic stool testing 51 
3- M2-PK Testing 52 
 Imaging tests 52 
1- Colonoscopy 52 
2- Computed tomography (CT) scans 53 
    1.8 Treatment for CRC 53 
          Surgery 54 
17 | P a g e  
 
          Radiation 54 
          Chemotherapy 54 
2. Epigenetics and colorectal cancer 55 
• DNA Hypomethylation 55 
• DNA Hypermethylation 55 
• Loss of imprinting 56 
• Post-Translational Histone Modifications 56 
• Post-translational histone modifications in CRC 59 
1- CRC histone methylation 59 
2- CRC histone phosphorylation 59 
3- CRC histone acetylation 59 
3. Histone deacetylase inhibitors (HDACIs) 63 
1- History and discovery 63 
2- Effect and structure 63 
3- Efficacy and functionality 66 
4- Combination therapies with HDACIs 68 
5- Resistance to HDACIs 70 
1- Drug efflux 70 
2- HDACs overexpression and desensitization 70 
3- Epigenetic and chromatin alterations 71 
4- Stress response mechanisms 72 
5- Antiapoptotic/prosurvival mechanisms 72 
6- Survivin and CRC 74 
4. Objectives and Hypothesis 78 
 
 
 
18 | P a g e  
 
1. Colorectal Cancer (CRC) 
1.1. Definition and Epidemiology 
The word colorectal is derived from the colon and the rectum which 
form the large bowel in the gastrointestinal tract of the human body, 
figure 1.1. Colorectal cancer (CRC) is a tumour which occurs in colon 
or rectum. CRC or cancer of the large bowel has a high incidence in 
the developed countries in comparison with the other parts of the 
world. This cancer is ranked third in prevalence in the UK after breast 
and lung cancer and about 110 new patients with colorectal cancer are 
diagnosed each day (Cancer Research UK, http://info.cancerresearch- 
uk.org/cancerstats/types/bowel/incidence/). The worldwide incidence 
of CRC is high, especially in the western countries (WHO website, 
http://www.who.int/gho/ncd/mortality_morbidity/cancer_text/en/), and 
the highest incidence rate is the United States (Stallmach et al., 2011). 
In most parts of the world, CRC in women comes second in incidence 
after breast cancer and in men, CRC is the third most common cancer 
in incidence after lung and prostate cancer (Ballinger and Anggiansah, 
2007); hence CRC is a major health problem globally (Siegel et al., 
2011). Also, the mortality from CRC is high across the world (Cidon, 
2010), and it differs among countries, depending on how early 
diagnosis is performed and the treatment offered, both of which can 
reduce deaths from CRC (Cai et al., 2011). It is estimated that 
approximately 16000 deaths a year are caused by CRC and the 
survival rate at 5 years is only 50% in the UK (Logan et al., 2011).  
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Figure 1.1: The large bowel location inside the human abdomen. 
The gastrointestinal tract in our bodies starts with the mouth and continues to the 
oesophagus which connects to the stomach. The latter, in turn, connects to the small 
intestine that at its end joins the colon (which has three distinct parts: the ascending 
colon, the transverse colon, and the descending colon). The descending colon leads 
to the rectum which opens into the outside of the body through the anus. Both the 
colon and the rectum form the large bowel which is highly surrounded by lymph 
nodes. The figure was taken from:  
http://www.cancer.gov/cancertopics/wyntk/colon-and-rectal/page2. 
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1.2. The aetiology of colorectal cancer  
The aetiology of CRC is multifactorial (Ponz de Leon and Roncucci, 
2000). This means that genetic and non-genetic factors are involved.  
The risk factors which increase the predisposition to CRC include 
autosomal dominant inheritance, sex, age, family history, current and 
previous clinical history, and nutrition (Cunningham et al., 2010). Diet 
alone is considered to be the cause of about 70-90% of all CRC cases 
(Araújo et al., 2011). The high consumption of red meat, uncontrolled 
alcohol consumption, the presence of inflammatory bowel disease, 
and smoking increase the risk of developing CRC.  
In addition, obesity and low levels of physical activity due to 
sedentary lifestyle has a noticeable role in CRC incidence (Dennis et 
al., 2011). However, a number of protective factors may lower the 
incidence of CRC.  A high-fibre food such as fruit, cereals, and 
vegetables (van den Brandt and Goldbohm, 2006) increases faecal 
bulk and decreases transit time (de Kok and van Maanen, 2000).  
Also, it has been shown that using aspirin on a frequent basis reduces 
the risk of CRC to 60%. The aspirin effect is similar to the effect of 
the nonsteroidal anti-inflammatory drugs (NSAIDs) which decrease 
prostaglandin production by inhibition the over-expression of 
cyclooxygenase-2 (COX-2) enzyme in CRC. COX-2 expression is 
inducible upon an inflammatory stimulus, and it is not usually 
expressed in normal colorectal epithelium but it is highly expressed in 
many colorectal tumours in absence of the inflammatory stimulus 
(Boland et al., 2000). Another protective factor that has been 
highlighted in CRC is physical activity which reduces the risk for 
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CRC (Song et al., 2011). Etiologically, CRC is conventionally 
classified into two types (Cheah, 2009):  
 
1) Familial (hereditary) CRC: 
This type comprises about 15-20% of the CRC cases, and it 
arises as a result of mutations in one or more genes involved in 
cell cycle control such as tumour suppressor genes and mismatch 
repair genes (Dietrich et al., 2011). The most common 
syndromes representing this type of CRC are: 
 
 Familial Adenomatous Polyposis (FAP): is an autosomal 
dominant syndrome caused by a germ-line mutation in the 
tumour suppressor gene the adenomatous polyposis coli 
(APC) gene located on the long arm of chromosome 5 (5q). 
Carrier patients develop hundreds to thousands of 
adenomatous polyps in their colon or rectum depending on 
the degree of penetrance. Some of these polyps transform 
to CRC later in life if they are not treated in early stages of   
their development (de Campos et al., 2010).  
 
 Hereditary nonpolyposis colorectal cancer (HNPCC): is 
another autosomal dominant syndrome which involves 
germ-line mutations in four genes (MLH1, MSH2, PMS2, 
and MSH6) of the DNA mismatch repair system (MMR 
system). The defects in these genes lead to microsatellite 
instability (MSI). Microsatellites are short DNA tandem 
repeats found within the coding (exons) or non-coding 
(introns) regions of the human genome. They play crucial 
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roles in DNA repair function and when they have 
mutations  (Li et al., 2004), they result in DNA instability 
which leads to cancer development. Patients who have 
HNPCC develop CRC in an early age of life (Vasen, 
2005).  
 
2) Sporadic CRC:  
Forms around 70 to 80% of all CRC cases, and it usually takes 
place without any existence  for a familial history as an isolated 
tumour in the colon or rectum (Moran et al., 2010). However, 
complex interactions between genetic and environmental factors 
are implicated in development of sporadic CRC (Naccarati et al., 
2007). In contrast to the hereditary CRC, sporadic CRC usually 
appears in the late age of life (about 60 years old) as a result of 
the accumulation of multiple mutations in a single or a few 
epithelial cells of the colon- rectum tract (Patel et al., 2012). 
Studies for sporadic CRC show that most patients exhibit 
epigenetic changes like hypermethylation in multiple CpG 
islands of very important genes like the MMR genes (Park et al., 
2003), hence about 15-20% of sporadic CRC cases show MSI 
(Imai and Yamamoto, 2008a). This PhD thesis has dealt with 
sporadic CRC, and cell lines used in this study were derived 
from sporadic CRC patients. 
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1.3. The emergence and progress of CRC  
CRC like other cancer diseases occurs as result of successive 
accumulation of genetic mutations and epigenetic changes in a normal 
cell (Pierce, 2011). The rate of mutations and the mutated genes are 
different among cancer types (Pritchard and Grady, 2011). In CRC, 
these genetic and epigenetic changes transform the cells lining the 
large bowel into benign neoplasia (adenoma) in the form of 
microscopic polyps (Pierce, 2011). These polyps grow to form 
invasive carcinoma which eventually becomes metastatic cancer 
invading other tissues, as shown in figure 1.2. The model, 
adenoma/carcinoma progression sequence, was proposed by Fearon 
and Vogelstein in 1990 (Fearon and Vogelstein, 1990). 
 
1.4. Signs and Symptoms of CRC  
Signs and symptoms include loose and/or frequent stools, bleeding 
that may be visible (dark) or not in the stool, iron-deficiency anaemia 
(due to the bleeding); obstruction and palpable mass (usually with 
right colon cancer) which are associated with perforation or abscess 
formation. Secondary signs and symptoms are intermittent abdominal 
pain, nausea or vomiting, weight loss, and mucus in the stool (Hall, 
2011, Labianca et al., 2010, de Campos et al., 2010). 
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Figure 1.2: The origin and progression of colorectal cancer. 
CRC starts in the epithelial cells of the colon as small polyps which grow to form 
adenoma. The progression of genetic and epigenetic abnormality in the adenoma 
cells leads to formation of a carcinoma that invades other tissues. This figure was 
taken from: Pierce, B.A., Genetics: A Conceptual Approach 2011: W H Freeman & 
Company. 
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1.5. Pathological staging of CRC 
Determining the size and the spread of the tumour within the large 
bowel is called staging which is very important for CRC treatment 
plan (adjuvant treatment). The staging of CRC is performed 
histologically post surgery. The most commonly used classification of 
CRC stages in the UK is Duke’s staging system (Bull et al., 1997). 
However tumour, node, metastasis staging system (TNM) is now 
being used besides Dukes’ staging system. TNM staging system is 
more accurate than Dukes’ staging system, but it has many subgroups 
which make it less useful clinically. Table 1.1 summarizes the Duke’s 
stages and the equivalent TNM stages used in the UK (Hall, 2011). 
Figure 1.3 shows a cartoon of Dukes’ stages and the corresponding 
TNM stages for CRC. 
 
 
 
 
 
 
 
 
 
 
 
Table 1.1: Dukes’ and TNM staging for colorectal cancer 
Duke’s stage 
(equivalent TNM stage) Description 
 
A (T1 and T2) 
 
Localised to mucosa and sub mucosa 
 
B (T3 and T4) 
 
Extending into or through muscle layer 
without lymph node involvement 
C (N0-N2) 
 
 
Lymph node involvement 
 
D (M0-M1) 
 
 
Distant metastases 
 
Adapted from: Hall, N., Colorectal cancer: features and 
investigation. Medicine, 2011. 39(5): p. 250-253 
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Figure 1.3: A cartoon illustrates Dukes' and TNM staging systems. 
Dukes’ staging system has four stages from A to D, whereas TNM staging system has 
three main stages (T, N, and M), in which each stage has subgroups (T1-T4, N0-N2, 
M0-M1). Dukes’ A stage equals T1and T2, the tumour does not pass beyond 
muscularis propria. Dukes’ B tumour matches T3 and T4 wherein the tumour 
penetrates the muscle layer and it could reach the peritoneum or adjacent organs as 
in T4 of TNM system. Dukes’ C stage parallels N stage of TNM system in which the 
tumour involves the lymph nodes. N1 refers to 1 to 3 lymph nodes having the tumour, 
whereas N2 denotes that 4 or more lymph nodes invaded by the tumour. Finally, 
Dukes’ D stage is M stage in TNM system. The tumour in this stage transfers to the 
distant organs such as the liver, ovaries, and the lungs. The figure was taken from the 
reference (Hall, 2011).   
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1.6. Pathogenesis of CRC 
Recent research has shown that CRC is a heterogeneous disease, and 
there are mainly four molecular pathways consistent with the adenoma 
/carcinoma progression sequence.  Genetic and epigenetic alterations 
are implicated in these pathways which are (Harrison and Benziger, 
2011):  
1. Chromosomal Instability (CIN) pathway. 
2. CpG Island Methylator Phenotype (CIMP) pathway. 
3. Microsatellite Instability (MSI) pathway. 
4. Serrated pathway. 
 
1- Chromosomal Instability (CIN) pathway 
It is the most common pathway in sporadic CRC as it exists in 70-
85% of sporadic CRC cases. It is, therefore, known as the canonical 
pathway of CRC. Its initiation involves mutations in tumour 
suppressor genes, hence it is also called the suppressor pathway 
(Worthley et al., 2007). All CRC cases which fall under this 
pathway have loss of heterozygosity (LOH) in adenomatous 
polyposis coli (APC) gene in the early stage. APC is a tumour 
suppressor gene operating in the Wnt signalling pathway, and it 
plays a crucial role in β-catenin degradation (Kennell and Cadigan, 
2009). When APC is mutated, increased levels of β-catenin 
accumulate in the cytoplasm and translocate to the nucleus (Sena et 
al., 2006) to promote transcription of genes involved in cell 
proliferation and survival which starts the development of 
adenomas in the colon or rectum (Phelps et al., 2009). Alongside 
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the progression of the tumour according to adenoma/carcinoma 
model, LOH in other genes such as DCC, KRAS, SMAD2, SMAD4, 
and TP53 occurs in a sequential progression consistent with the 
transformation to the metastasis state (Rowan et al., 2005) as shown 
in figure 1.4. These changes lead to aneuploidy and structural 
alterations to chromosomes, for example a deletion in the long arm 
of chromosome 5 (5q), and a deletion in chromosome 18 or 17 (18q 
or 17q). These alterations together result in chromosomal instability 
(CIN) which characterizes this pathway (Grady, 2004). 
 
 
2- CpG Island Methylator Phenotype (CIMP) pathway 
CIMP pathway is ranked the second most common pathway after 
CIN pathway as it is found in 15% of sporadic CRC cases 
(Worthley and Leggett, 2010). It represents the most epigenetic 
alterations in sporadic CRC through hypermethylation of promoters 
of tumour suppressor and DNA repair genes accompanied by 
hypomethylation of global DNA (Jass, 2007). These epigenetic 
alterations of methylation status in colon epithelial cells lead to the 
silencing of tumour suppressor genes. It can also promote the 
transformation of these cells to adenoma which, in turn, becomes 
carcinoma according to Fearon and Vogelstein model (Kim et al., 
2010). Sporadic CRC cases having these alterations are called 
CIMP positive (CIMP+), and they are classified into: CIMP low (or 
CIMP-2) and CIMP high (or CIMP-1) (Shen et al., 2007). CIMP-1 
tumours often associate with microsatellite instability and BRAF 
mutations, whereas CIMP-2 tumours often are characterised by a 
high rate of K-RAS mutations, rare micro-satellite instability, and 
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less BRAF and TP53 mutations (Coppede, 2011). The difference 
between CIMP-1 and CIMP-2 reflects on the tumour’s localization, 
prognosis, and therapy (Issa, 2008), figure 1.5. 
 
 
 
 
Figure 1.4: The suppressor pathway in CRC. 
The sequential progression of CRC pathological stages is accompanied by molecular 
alterations of crucial genes involved in the cell cycle control, DNA repair, cells 
adhesion, and chromosome segregation. Mutations and loss of heterozygosity (LOH) 
form the most common genetic alteration in this pathway. APC and K-RAS mutations 
occur in the early stage of this pathway; however P53 mutations take place in the late 
stage. Adapted from the references (Moran et al., 2010, Steele, 2006). 
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Figure 1.5: CIMP sub-pathways of sporadic CRC. 
CpG Island Methylator Phenotype (CIMP) pathway arises in two different ways: 
CIMP-1 (or CIMP high) and CIMP-2 (or CIMP low), each of them has its own 
clinical implications on the prognosis and the treatment of the tumour. CIMP-1 is 
characterised by serrated adenomas located in the proximal colon, has mostly BRAF 
mutations, and associates with good prognosis. However, CIMP-2 is characterised 
by villous adenomas, has K-RAS, APC and TP53 mutations, and shows the worse 
prognosis (it has poor response to chemotherapy). The figure is adapted from 
reference (Issa, 2008). 
 
 
 
3- Microsatellite Instability (MSI) pathway 
Microsatellites are one type of DNA repetitive sequences. They 
consist of 1-5 nucleotides in length occurring in tandem repeats, 
and hence are also called short tandem repeats. These repeats 
spread throughout the human genome, including the introns and 
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coding exons, in a unique pattern characterising each individual 
from another (Booth, 2007). Microsatellite instability (MSI) occurs 
when the Mismatch Repair (MMR) system is impaired. 
MMR genes are responsible for checking and correcting the errors 
made by DNA polymerases during the DNA replication step. When 
MMR is not functional, a loss or gain happens in DNA sequence 
including microsatellite repeats, and it leads to MSI (2012). MMR 
system consists of at least seven different genes (MLH1, MLH3, 
MSH2, MSH3, MSH6, PMS1 and PMS2) that encode proteins 
acting together in heterodimeric form which detects and repairs 
mismatch errors during DNA replication (Poulogiannis et al., 
2010). In familial (hereditary) CRC, the inactivation of MMR 
genes by germ-line mutations in one or more of the MMR genes 
results in microsatellite instability. However, the micro-satellite 
instability in sporadic CRC results from promoter hypermethylation 
of MMR genes (Armaghany et al., 2012), although some CRCs 
with intact MMR function develop MSI due to frameshift 
mutations at microsatellites in other genes (2012). Based on a 
standardized marker panel of the five mononucleotide markers 
(BAT-25, BAT-26, NR-21, NR-24 and MONO-27) and three 
dinucleotides (D2S123, D5S346, D17S250), which were chosen by 
a National Cancer Institute consensus conference, MSI were 
divided into three categories depending on the degree of  the 
presence of unstable loci among the markers which have a high 
sensitivity and specificity (Bacher JW et al., 2004).  These 
categories are (Imai and Yamamoto, 2008b): 
a) High-frequency MSI (MSI-H): the tumour has ≥ 30-40% of 
the marker panel mutated. 
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b) Low- frequency MSI (MSI-L): the tumour has < 30-40% of 
at least 1 of the marker panel mutated. 
c) Microsatellite stable (MSS): the tumour does not show any 
instability in the marker panel. 
 
Clinically and in contrast to CIN pathway which has abnormal 
chromosome number, MSI pathway has a normal karyotype with 
unique molecular genetic changes (Walther et al., 2009). In 
addition, MSI CRC tumours show a better prognosis than the 
negative MSI tumours (Boland and Goel, 2010). Figure 1.6 shows 
MSI pathway development. 
 
4- The Serrated pathway 
This pathway has been recently considered as a distinct pathway in 
sporadic CRC carcinogenesis (Leggett and Whitehall, 2010). In the 
past, it was thought there are two types of polyps in CRC-adenomas 
and hyperplastic polyps. The latter were accounted as benign 
without malignant potential. However, it is now proved that these 
hyperplastic polyps actually are heterogeneous polyps classified 
now as traditional serrated adenomas (TSA), sessile serrated 
adenomas (SSA) and true hyperplastic polyps (Farris et al., 2008). 
True hyperplastic polyps form about 80–90% of all serrated polyps 
and mostly are innocuous lesions (Higuchi et al., 2005). In contrast, 
TSA and SSA together represent around 0.5 to 1.3% of CRC 
polyps, and have a great risk to become malignant (Patel et al., 
2012).  
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Figure 1.6: MSI pathway development. 
MSI arises as a result of the inactivation of MMR system, which happens in two 
different ways. 1) Lynch syndrome: individuals have a germ-line mutation in one of 
the MMR genes. When a second mutation hits the wild-type copy (functional) via 
LOH, methylation, or point mutation, MMR system becomes defective. This results in 
MSI and rapid accumulation of somatic mutations, for example KRAS and β-catenin. 
2) Sporadic methylation-induced silencing of MLH1 which is one gene of MMR 
system, and its inactivation in this situation is not inherited, but it involves the 
presence of CIMP. Methylated promoter of MLH1 leads to the MMR activity failure 
and MSI development. BRAF mutations are observed in most CIMP and MSI 
tumours, but do not exist in tumours of patients having Lynch syndrome. The figure is 
taken from reference (Boland and Goel, 2010). 
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Morphologically, TSA has a homogeneous population of abnormal 
cells, whereas SSA does not (Torlakovic et al., 2008). This 
difference also reflects on the molecular level as most serrated 
adenocarcinomas have microsatellite stable (MSS) or low-level 
microsatellite instability (MSI-L), and they arise from TSA. On the 
other hand, 15-20% of serrated adenocarcinomas are MSI-H and 
they arise from SSA polyps (O'Brien et al., 2006). In addition, 
KRAS mutations are present in 80% of TSA lesions, but they are 
rare in SSA (Harvey and Ruszkiewicz, 2007). In contrast, SSA 
polyps show a high ratio of BRAF mutations which are rare in TSA 
(Sandmeier et al., 2009). Both oncogenes (BRAF and KRAS) are 
key components of the ERK/MAPK pathway, and their activation 
through the normal pathway sequence or through a point mutation 
in each of them leads to inhibition of apoptosis, cell proliferation, 
survival (Leggett and Whitehall, 2010), and trigger malignant 
change in intact colorectal tissue (Young et al., 2007), as shown in 
figure 1.7.  
 
Furthermore, TSA and SSA differ in the location of incidence. TSA 
usually occurs in the left colon. However, SSA is found in the right 
colon like enlarged folds (Noffsinger, 2009). Figure 1.8 summaries 
the difference between TSA and SSA pathways. 
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Figure 1.7: KRAS/BRAF pathway and CRC. 
Both KRAS and BRAF proteins participate in the transduction of intracellular signals 
via the mitogen-activated protein kinase (MAPK) signalling. The final activated 
kinase in this pathway, extracellular signal-regulated kinase (ERK), translocates to 
the nucleus and induces transcription genes that regulate cell growth and 
proliferation. KRAS and BRAF genes are preferentially mutated in most CRC 
pathways. The figure was modified from reference (Leggett and Whitehall, 2010). 
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Figure 1.8: SSA versus TSA pathway in sporadic CRC. 
This illustrative figure shows the differences between the two pathways (SSA and 
TSA) of serrated adenocarcinoma. The green area represents the features of the 
traditional serrated pathway: morphologic (light shade) and molecular (dark shade), 
whereas the blue area represents the features of the sessile serrated pathway. The 
yellow colour depicts the most common colon area affected in each pathway. The 
figure was taken from reference (Noffsinger, 2009). 
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1.7. Human p53 and CRC 
As mentioned above, the chromosomal instability pathway is 
characterized by mutations in tumour suppressor genes in which TP53 
is mutated in more that 50% of CRC cases. Mutations in TP53 gene 
occur in the late stages of CRC (Einspahr JG et al., 2006). Here, I am 
giving a brief background about p53, and then I will talk about its 
mutations in CRC.  
• General background 
Human p53 protein was discovered in 1979 by Crawford and his 
colleagues while they were working on Simian Virus 40-transformed 
cells (the p53 web site, http://p53.free.fr/p53_info/p53_disco.html).  
First, p53 was considered a tumour antigen with transforming 
properties because it interacts with the viral SV40 T‑antigen (Lane 
and Crawford, 1979). However, it has been revealed later that p53 is 
actually a tumour suppressor and mutant p53 induce cancer (Weisz et 
al., 2007). The discovery of p53 has opened the door to many ongoing 
studies about the structure and functionality of p53 in the cell 
(Braithwaite et al., 2005, Momand et al., 1992, Feng Z et al., 2007). 
Even more than 30 years after p53 discovery, there is much to learn 
about it. The TP53 website (http://p53.free.fr/index.html) database 
contains useful and huge amount of scientific work on p53.  
p53 is a 393 amino acids protein encoded by TP53 gene which is 
located in 17p13.1 (OMIM, http://omim.org/entry/191170). This 
protein structurally consists of 5 main domains  (Joerger and Fersht, 
2010), as shown in figure 1.9. 
38 | P a g e  
 
1- The transactivation domain starts from the amino terminal. This 
region plays a role in activation and stabilization of p53. It also 
contains the mdm2 protein binding site (the p53 web site, 
http://p53.free.fr/p53_info/p53_Protein.html). 
2- Prolin rich cassette region which is conserved in the majority of 
p53 and is essential for p53 apoptotic function (the p53 web site, 
http://p53.free.fr/p53_info/p53_Protein.html). 
3- DNA binding domain in the central region of p53. This domain 
is the target of 90% of p53 mutations (the p53 web site, 
http://p53.free.fr/p53_info/p53_Protein.html). 
4- The oligomerization or tetramerization domain which is 
necessary for dimerization as p53 works as a dimer of two 
dimers which each of them consists of two p53 molecule (the 
p53 web site, http://p53.free.fr/p53_info/p53_Protein.html).  
5- The carboxy-terminus of p53 contains three nuclear localization 
signals (NLS) and a non-specific DNA binding domain (it bind 
to damaged DNA). This region plays a role in downregulation of 
DNA binding of the central domain (the p53 web site, 
http://p53.free.fr/p53_info/p53_Protein.html).  
p53 is active biologically as  a homotetramer, especially to perform its 
function as a transcription factor (Weinberg et al., 2004).  p53 binds to 
its double- stranded DNA target in a sequence-specific manner which 
consists of two motifs separated by 0–13 base pairs (Wei CL et al., 
2006). Each motif (half-site) consists of 10 base pairs of the general 
form RRRCWWGYYY whereas (R = A, G; W = A, T; Y = C, T) (Ho 
et al., 2006).  
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Figure 1.9: The domains of p53. 
Human p53 protein consists of five domains, each has specific functions. 
1) The amino-terminus region begins from1-42 amino acid. This region contains the 
acidic transactivation domain and the mdm2 protein binding site. It also includes the 
Highly Conserved Domain I (HCD I)  
2) Proline rich domain starts from 40-92 amino acids. The proline residues are 
conserved in the majority of p53. 
3) The DNA binding domain expands from101-306. It contains HCD II to V. Almost 
90% of p53 mutations occur in this region. 
4) The oligomerization domain starts from 307-355 (4D in the figure). It is necessary 
for dimerization of p53, and also contains a nuclear export signal (NES). 
5) The carboxy-terminus of p53 from 356-393. It contains 3 nuclear localization 
signals (NLS) and a non-specific DNA binding domain. This region is also involved 
in down regulation of DNA binding of the central domain. The figure was taken from 
reference (the p53 web site, http://p53.free.fr/p53_info/p53_Protein.html).  
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p53 is a member of a proteins family that includes p63 and p73 (Wei 
et al., 2012). However, p53 differs from p63 and p73 in structure and 
function (Dötsch V et al., 2010). p53 lacks a sterile alpha motif 
(SAM) domain which forms an additional extension for the 
tetramerization domain in p63 and p73 (Lu et al., 2009), as shown in 
figure 1.10. In addition, specific amino-acid substitutions are found 
different within the canonical tetramerization domain motif 
(Coutandin et al., 2009). This may explain why p53 forms a 
homotetramer and does not interact with tetramerization domain of 
p63 and p73 which form mixed tetramers in vitro (Joerger et al., 
2009). 
 p63 and p73 are a tissue-specific and play essential roles in normal 
development (Moll and Slade, 2004). It has been shown that mice 
deficient for either of p63 or p73 genes are embryonic lethal (Yang A 
et al., 1999, Yang A et al., 2000), whereas mice deficient for p53 are 
viable but have a tendency to develop tumours (Berrigan et al., 2002). 
However, in some circumstances p63 and p73 can function as tumour 
suppressors (Finlan and Hupp, 2007, Rosenbluth and Pietenpol, 2008). 
This means that in response to DNA damage, both proteins p63 and 
p73 can bind DNA, transactivate p53-responsive genes, and mediate 
cell cycle arrest cellular senescence, and apoptosis (Keyes et al., 2005, 
Melino G et al., 2004).  
In normal tissues, wild type p53 is often maintained at low levels by 
its negative regulators mdm2 (also known as hDM2) and mdm4 (also 
known as mdmx) (Iwakuma and Lozano, 2003). While Mdm2 is E3 
ubiquitin ligase which tags p53 with ubiquitin promoting its 
degradation through the ubiquitin-dependent proteasome pathway 
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(Marine JC et al., 2006, Toledo and Wahl, 2006), mdmx per se is not 
E3 ligase (Finch et al., 2002). Nonetheless, Mdmx binds to p53 DNA 
binding domain and inhibits the role of p53 in inducing cell cycle 
arrest and apoptosis  (Jin et al., 2006). 
 
 
 
 
 
 
Figure 1.10: Schematic representation of the protein structure of the p53 family 
members. 
p63 and p73 contain a sterile alpha motif (SAM), a putative protein–protein 
interaction domain found in many signalling proteins and transcription factors. 
Identity shared by p73 and p63 with p53 is indicated by percentage (%). The three 
proteins consist of an amino-terminal transactivation domain (TAD), a central DNA 
binding domain (DBD) and a carboxy-terminal oligomerization domain (OD). PR 
denotes Proline rich sequence, aa denotes amino acids. The figure was reshaped 
from reference (Dötsch V et al., 2010). 
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Upon various cellar stresses, including oncogenes activation and DNA 
damage, naturally low level of p53 in the cell markedly increase and 
translocate nucleus  to regulate (activate or repress) the transcription 
of many genes involved in growth arrest, apoptosis, DNA repair and 
differentiation in damaged cells (Oren, 2003). 
p53 function and regulation are controlled by post-translational 
modifications which are a part of signalling processes to direct p53 to 
perform a specific task according to  the inducing stimulus (Hoeller et 
al., 2006). More than 50 individual post-translational modifications 
modify p53 function and regulation, and these modifications vary in 
type, position, and function (Meek and Anderson, 2009). The known 
post-translational modifications in p53 are phosphorylation, poly-
ribosylation, glycosylation, acetylation, methylation, ubiquitination, 
sumoylation, and neddylation (Gu and Zhu, 2012). Figure 1.11 
summarises these modifications with their functions and sites of 
action. The paradigm for these modifications is phosphorylation of 
p53 at amino-terminal in specific residues including Ser15, Thr18, and 
Ser20 blocks MDM2–p53 binding and leads to decrease of p53 
degradation (p53 stabilization) (Shieh SY et al., 1997, Schon O et al., 
2002, Dumaz et al., 2001). Moreover, it has been shown that the 
phosphorylation of p53 at these residues induces p53 association with 
p300/CBP and stimulates p53 transactivation function (Lambert et al., 
1998, Dornan et al., 2003, Finlan and Hupp, 2004). Such these 
proteins which modulate p53 transactivation at specific promoters are 
called p53 co-factors. They are divided to co-activators (which 
enhance p53 transactivation function) and co-repressors (which 
repress p53 transactivation function) (Vousden and Prives, 2009, 
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Espinosa, 2008). Most of these co-factors are histone-modifying 
enzymes, for example, histone acetyltransferases (p300/CBP and 
PCAF), histone deacetylases (HDAC1), histone methyltransferase 
(PRMT1 and CARM1) (An et al., 2004), and other co-activator 
complexes such as NuA4–Tip60 and SAGA (Ard et al., 2002, Berger, 
2002). However, there are a number of proteins that selectively alter 
the function of p53. These proteins are called p53- binding partners 
(Naumovski and Cleary, 1996, Iwabuchi et al., 1994). p53-binding 
partners work either by changing the p53 affinity to a specific subset 
of response elements in p53 target genes, or by affecting the ability of 
p53 to recruit transcriptional coactivators at specific loci (Beckerman 
and Prives, 2010). Figure 1.12 shows p53-binding partners, their 
interaction sites on p53, and their functions. One well-known example 
of p53-binding partner is the three members of the apoptosis-
stimulating of p53 protein (ASPP) family of proteins, ASPP1, ASPP2 
and iASPP (inhibitory member of the ASPP family) (Samuels-Lev Y 
et al., 2001, Bergamaschi D et al., 2003, Notari M et al., 2011). While 
ASPP1 and ASPP2 bind to p53 DNA binding domain to direct the cell 
toward an apoptosis by inducing transactivation of bax and puma but 
not p21 (Patel S et al., 2008), iASPP protein binds to p53 and repress 
the transactivation of pro-apoptotic genes (Bergamaschi et al., 2006). 
Interaction of p53 with its binding partners is affected by p53 post-
translational modifications. For example, phosphorylation p53 at S46 
triggers the binding of prolyl-isomerase Pin1 (p53-binding partner) 
with the p53 transactivation domain. This important interaction 
promotes the release of iASPP from p53 allowing the apoptosis 
induction upon DNA damage (Mantovani F et al., 2007). 
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Figure 1.11: Human p53 post-translational modifications. 
The figure shows the functional domains of p53 protein with the post-translational 
modifications in each domain and their effects. Also, the responsible modifying and 
demodifying enzymes for these modifications are shown. The figure was taken from 
reference (Meek and Anderson, 2009). 
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Figure 1.12: p53-binding partners. 
p53 function is affected by its binding to different proteins called p53-binding 
partners. These proteins have a specificity binding to p53 domains to induce 
differential transactivation of target genes and outcome as shown in the figure. For 
example, Muc1, YB1, APAK, BRCA, Hzf, Brn3a, and c-abl induce transcription of 
genes involved in cell cycle arrest, whereas ASPP1, ASPP2, JMY, Pin1, NFkB/p52, 
Brn3b, and p53b induce transcription of apoptotic genes. The figure was taken from 
reference (Beckerman and Prives, 2010). 
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• p53 in CRC 
The function of p53 is almost compromised in many human cancers, 
usually because of somatic mutations which take place during 
tumorigenesis (Vogelstein et al., 2000). The rates of reported TP53 
mutations vary between cancer types. For example, TP53 mutations 
range around 10% in haematopoietic cancer (Peller and Rotter, 2003) 
to 50–70% in colorectal (Iacopetta, 2003), ovarian (Schuijer and 
Berns, 2003) and head and neck (Blons and Laurent-Puig, 2003). 
Usually, germline TP53 mutations are rare (Ginsburg et al., 2009) and 
lead to predisposition to cancer type known as Li – Fraumeni 
Syndrome (LFS) (Malkin D et al., 1990, Dickson, 2012). However, 
somatic TP53 mutations are found in the fast majority of sporadic 
cancers (Olivier M et al., 2010).  All TP53 mutations can be classified 
as DNA contact (the mutations occur in the DNA binding domain and 
do not affect p53 structure) and structural mutations (the mutations 
usually occur in the p53 tetramerization domain and lead to change in 
p53 conformation) (Bullock and Fersht, 2001). According to their 
effects on function, TP53 mutations fall in two categories, which are 
(Sigal and Rotter, 2000):  
 
1. Loss of function:  p53 loses its tumour suppressive function and 
acquire dominant‑negative activities (Lubin et al., 2010). 
 
2. Gain of function: p53 gains new oncogenic properties (Oren and 
Rotter, 2010). 
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Half of all colorectal cancer cases have TP53 mutaions (Berg et al., 
2010), and this occurs mostly in the late stages of the sequential 
progression from adenoma to carcinoma (Rivlin et al., 2011). These 
mutations lead to loss of heterozygosity (LOH) in the late stages after 
the early deletion of chromosome 17p region containing the p53 gene 
which occurs frequently in CRC (Iacopetta, 2003). The mutant p53 
associates with its nuclear accumulation in CRC tissues, and p53 over-
expression is linked with poor prognosis in human CRC patients (Liu 
and Bodmer, 2006, Iacopetta, 2003, Vogtmann E et al., 2013, Nasif 
WA et al., 2006). According to the data published on IARC TP53 
Database (http://p53.iarc.fr/), the majority of TP53 mutations in CRC 
are point mutations in which missense mutations comprising more 
than 89% , as shown in figure 1.13. These missense mutations result 
from transitions GC to AT at cytosine phosphate guanine 
dinucleotides in seven hotspot codons (175, 213, 244, 245, 248, 273, 
and 282) (Russo A et al., 2005), figure 1.14. In addition, most of TP53 
mutations occur in exons 5 to 8, as appeared in figure 1.15. These 
mutations result in non-functional p53 protein as it cannot bind to 
DNA at responsive elements (Vogelstein et al., 2000, Russo A et al., 
2005) http://p53.iarc.fr/TP53SomaticMutations.aspx) 
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Figure 1.13: Types of TP53 mutation in CRC. 
The majority of mutations in TP53 gene are point mutation in CRC. More than 89% 
of TP53 mutations are missense and about 9% are nonsense. These mutations result 
in non-functional p53. Less than 2% of TP53 mutations are silent and do not mostly 
affect p53 functionality. The figure was taken from IARC TP53 Database, 
http://p53.iarc.fr/TP53SomaticMutations.aspx.  
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Figure 1.14: Hotspot positions of TP53 point mutations in CRC. 
Seven codons in DNA binding domain of TP53 gene show high rate of substitution 
mutations from GC to AT. These hotspot positions are 175, 213, 244, 245, 248, 273, 
and 282. The figure was taken from IARC TP53 Database, 
http://p53.iarc.fr/TP53SomaticMutations.aspx.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.15: Distribution of the point mutations within TP53 exon/intron in 
CRC. 
Most TP53 point mutations fall within exon 5 to 8 region which encode DNA binding 
domain. These mutations result in non-functional p53 protein. The figure was taken 
from IARC TP53 Database, http://p53.iarc.fr/TP53SomaticMutations.aspx. 
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1.8. Diagnosis of CRC 
The symptoms involved in CRC do not necessarily indicate the real 
existence of cancer as these symptoms also occur with other colorectal 
problems such as inflammatory bowel disease (IBD), irritable bowel 
syndrome (IBS), haemorrhoids, and diverticulosis and its 
complications (Labianca et al., 2010). Therefore, the need for accurate 
diagnosis is essential for confirming CRC. Generally, the time of any 
cancer diagnosis (including CRC) significantly impacts on the 
survival time for patients. The earlier the diagnosis time of CRC is, 
the longer survival time and the better treatment management for 
patients is (Steele, 2006). The available diagnosis methods are: 
 
 Biochemical tests:  
1- Faecal occult blood testing (FOBT): blood existence in the stool 
does not confirm colorectal cancer as the bleeding could be due 
to several reasons; also the blood test should be accompanied 
with a full blood count to detect anaemia. However, this test is a 
good, non-invasive indicator for further investigations and is 
widely used in CRC screening. The test used for detecting the 
blood in the faeces is called faecal occult blood testing (FOBT) 
(Lindholm et al., 2008). 
 
2- Genetic stool testing: another non-invasive test involves genetic 
screening of the colonic cancer cells shed in the stool samples 
for tumour-specific mutations, particularly for the mutations in 
genes implicated in CRC (KRAS, BRAF, P53, APC, and BAT26). 
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Compared to analyses of DNA extracted from colon tumours, 
genetic stool testing gives consistent results (Calistri et al., 
2003).  
 
 
3- M2-PK Testing: this test also depends on the faecal samples to 
detect M2-PK enzyme which is an isomer of the pyruvate kinase 
(PK) enzyme. M2-PK is involved in the glycolysis pathway as it 
catalyzes the final step in this pathway in which phosphoenol-
pyruvate is converted to pyruvate. It has been demonstrated that 
M2-PK is found in elevated levels in proliferating gastro-
intestinal cancer cells and is detectable in the stool (Haug et al., 
2008). Recently, this test has reached overall sensitivity of 79% 
and specificity of 81% for CRC detection (Li et al., 2012). 
 
 
 Imaging tests: 
1- Colonoscopy: This has superseded the methods depending on 
barium enema (Spinzi and Minoli, 2001). Colonoscopy is 
considered the gold-standard investigation for polyps in 
colorectal track, and is the only technique that enables the 
identification, biopsy, and removal of premalignant polyps (in 
their early stages) throughout the entire colon and rectum. 
Moreover, Colonoscopy has the advantage of placing a tattoo at 
the sites of the biopsies to recognize them at subsequent 
laparoscopic resection (Zauber et al., 2012), however 
colonoscopy has risks of bleeding and perforation which are 
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associated with the invasive techniques (Rabeneck L et al., 
2008).  
 
2- Computed tomography (CT) scans: these are non-invasive, 
preoperative clinical staging techniques. Particularly, they are 
used for elderly patients to scan the abdomen and pelvis, and 
chest in order to detect distant spread after CRC has been 
confirmed. The most widely used CT scans are conventional 
computed tomography, positive emission tomography (PET), 
and CT Colonography (Lucidarme et al., 2012, Flanagan et al., 
1998, Chaparro et al., 2009). In addition, magnetic resonance 
imaging (MRI) has recently come to the fore as a preferred 
evaluation for CRC metastases in the liver among patients who 
had not previously undergone therapy (Niekel et al., 2010). 
The main challenge in CRC diagnosis is not related very much to the 
primary tumour detection, but rather to the accurate identification of 
the presence of lymph node invasion and/ or micro-metastatic disease 
which have an essential impact on patient management (Kim et al., 
2006).  
 
1.9.Treatment for CRC 
Treatment management for CRC is associated with the stage of the 
tumour and the patient’s general health. The following choices are 
available depending on the situation. 
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Surgery: involves local removal of the tumour, and is performed 
for invasive carcinoma. Surgery of CRC has a risk of recurrence with 
or without metastasized state (Burt et al., 2010). 
 
Radiation: is the local application of high energy X–rays to kill 
cancer cells. It is effective in specific stages of CRC development 
(particularly primary tumours). This therapy may be used alone or in 
combination with other treatments. The side effects of radiation 
treatment are fatigue, diarrhoea, hair loss, dental problems, and skin 
irritation in some patients (Cunningham et al., 2010). 
 
Chemotherapy: is the use of anti-cancer drugs to kill or stop the 
proliferation of cancer cells. It is used before or after the surgery, 
hence it is called adjuvant chemotherapy. Many drugs have been 
approved for use in CRC chemotherapy, for example: doxorubicin, 
fluorouracil, irinotecan, oxaliplatin, and others (Meyerhardt and 
Mayer, 2005). They can be given intravenously, orally, 
intramuscularly, and applied directly to skin. The risk of 
chemotherapy drugs is drug resistance, toxicity, loss of specificity, 
and other side effects such as nausea, fatigue, weight loss, and hair 
loss (2000). 
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2. Epigenetics and Colorectal Cancer 
Epigenetic changes are defined as heritable changes in gene 
expression that are not accompanied by changes in DNA sequence. As 
discussed above in the pathways of CRC, epigenetics play a key role 
in CRC development (van Engeland et al., 2011). The most important 
epigenetic alterations in CRC are summarised below. 
 
•DNA Hypomethylation  
This is the sharp reduction in the overall amount of 5-methylcytosine 
at CpG dinucleotides in repetitive sequences (Ehrlich, 2002). DNA 
hypo-methylation is one of the first noticeable epigenetic changes in 
cancer cells. It is linked to oncogene activation and chromosomal 
instability (CIN) in CRC (Rodriguez et al., 2006). 
 
•DNA Hypermethylation 
This takes place in the 5' region of a gene promoter, specifically in 
CpG islands which are normally unmethylated and transcriptionally 
active (Baylin and Herman, 2000). In most cancer types, including 
CRC, CpG islands in the promoters of crucial genes such as tumour 
suppressor and DNA repair genes become hypermethylated as a result 
of the epigenetic alterations associated with genetic changes. 
Eventually, these genes suffer down regulation transcriptionally 
(Baylin et al., 2001). The biallelic promoter CpG island 
hypermethylation of the mismatch repair gene, mutL homolog1 gene, 
MLH1 is one of the best known examples of CRC epigenetic 
alterations. 
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•Loss of imprinting 
When DNA hypomethylation in CRC occurs in imprinted loci, it 
abnormally activates them. One confirmed loss of imprinting example 
in CRC is the insulin-like growth factor II (IGF2) gene. This gene is 
normally silent by imprinting of the maternally inherited allele in 
normal cells. However, hypomethylation of the proximal promoter of 
IGF2 of the imprinted allele in CRC leads to activation of this gene, 
and this activation (over-expression of IGF2 protein) activates the 
IGF1 receptor (IGFR), which autophosphorylates and activates the 
IRS-1/PI3K/AKT and GRB2/RAS/ERK pathways which increase cell 
proliferation and tumour risk (Kaneda et al., 2007). 
 
 
•Post-Translational Histone Modifications  
Post-translational histone modifications play an important role in 
regulation of transcription within the cell (Kouzarides, 2007). They 
act within and between nucleosomes or recruit nonhistone proteins to 
change the higher-order chromatin structure. The change of the 
higher-order chromatin structure may be either relaxing the chromatin 
(transcription is active) or condensing the chromatin (transcription is 
deactivated) (Kouzarides, 2007). The results of post-translational 
modifications are determined by the amino acid type, the position in 
the histone tail, and the type of modification (Imhof, 2006), see table 
1.2. Post-translational modifications activate or repress crucial 
processes in the cell such as transcription, DNA replication, and DNA 
repair (Sawan and Herceg, 2010). Figure 2.1 represents the 
nucleosome with the histones tail post-translational modifications.  
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Table 1.2: different histone modifications and their effects  
Chromatin Modifications  
 
Residues Modified 
 
Functions Regulated 
 
Acetylation K-ac Transcription, Repair, Replication, Condensation 
Methylation (lysines) K-me1 K-me2 K-me3 Transcription, Repair 
Methylation (arginines) R-me1 R-me2a R-me2s Transcription 
Phosphorylation S-ph T-ph Transcription, Repair, Condensation 
Ubiquitylation K-ub Transcription, Repair 
Sumoylation K-su Transcription 
ADP ribosylation E-ar Transcription 
Deimination R > Cit Transcription 
Proline Isomerization P-cis > P-trans Transcription 
 
The table lists histone modifications, their occurrence sites, and the 
associated function.  
 
K: denotes lysine, ac: denotes acetylation, me: denotes methylation, me 1: 
denotes adding one methyl group, me 2a: denotes adding two methyl groups in 
an asymmetric position, me 2s: denotes adding two methyl groups in a 
symmetric position, Cit: denotes citrulline, S: denotes serine, T: denotes 
threonine, R: denotes arginine, E: denotes glutamic acid, P: donates proline, 
Ub: denotes ubiquitylation, Su: denotes sumoylation, and Ar: denotes ADP 
ribosylation. Adapted from: Kouzarides, T., Chromatin Modifications and 
Their Function. Cell, 2007. 128(4): p. 693-705. 
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 Figure 2.1: Post-translational histone modifications. 
A schematic illustration of the nucleosome showing different covalent modifications 
in histone tails residues. Active modifications which promote gene expression are 
represented in the upper part of the figure and the repressive modifications which 
deactivate gene expression are represented in the lower part of the figure. Lysine (K), 
arginine (R), serine (S), and threonine (T). Adapted from reference (Sawan and 
Herceg, 2010). 
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•Post-translational histone modifications in CRC 
 
1. CRC histone methylation: 
This mainly occurs on the lysine (K) residues of histone 3 and 4. In 
CRC, it has been shown that di- and trimethylation of histone H3 
lysine 4 (H3K4me2/me3) is abundant near the transcription start 
site of transcriptionally active genes, while trimethylation of 
histone H3 lysines 9 and 27 (H3K9me3 and H3K27me3) 
characterizes transcriptionally inactive genes (van Engeland et al., 
2011). 
 
2. CRC histone phosphorylation: 
Phosphorylation of Serine 10 in histone 3 (Ser10H3) is crucial in 
chromatin remodelling and cell cycle regulation during mitosis and 
meiosis (Nowak and Corces, 2004). The phosphorylation 
modification in Ser10H3 plays a dual action as it is associated with 
chromatin relaxation and transcriptionally active genes in 
interphase, but also it is associated with chromosome condensation 
in mitosis (Nowak and Corces, 2004). In CRC, it has been found 
that a mammalian Ipl1/ aurora kinase (AIM-1) which is involved in 
phosphorylation of Ser10H3, is over-expressed, and this is 
associated with Chromosome Number Instability (CIN) (Ota et al., 
2002). 
 
3. CRC histone acetylation:  
Acetylation is the most important post-translational histone 
modification because it contributes substantially to unfolding of 
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chromatin through neutralizing the basic charge of the lysine 
residue (K) (Kouzarides, 2007), hence acetylation is associated 
with active transcription process of genes (Sterner and Berger, 
2000). The acetylation is controlled by the balance between two 
types of enzymes: histone acetyl-transferase enzymes (HATs) and 
histone deacetylase enzymes (HDACs) (Yang and Seto, 2007), as 
shown in figure 2.2. Human HATs and HDACs are classified in 
super-families and classes respectively, as summarized in table 1.3. 
It has been shown in many human cancers that the balance between 
HATs and HDACs is lost (Peserico and Simone, 2011). A loss or 
decrease of acetylation in important residues of H3 and H4 such as 
lys9-H3 and lys16-H4 is a common characteristic of human cancer, 
including CRC. This leads to gene transcription-deregulation of 
crucial tumour suppressor genes, and induces cells transformation 
and tumour development (Pruitt K et al., 2006). 
Moreover, it has been demonstrated that histone acetylation 
decrease is not only involved in gastrointestinal tumour initiation, 
but also in tumour invasion and metastasis (Yasui et al., 2003). The 
change in acetylation status in cancer cells has been linked to 
increased expression of individual HDACs in indefinite patterns. 
For example, number of studies showed an increase in HDAC1 
expression in gastric (Choi et al., 2001), prostate (Halkidou et al., 
2004), and colon (Wilson et al., 2006) cancers. Over expression of 
HDAC2 is well confirmed in all colorectal carcinoma having APC 
mutation (Zhu P et al., 2004).  
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Figure 2.1: balance between HATs and HDACs in a normal cell 
Addition of acetyl group to lysine residue in histone tail is catalysed by HATs 
enzymes activity, whereas the opposite process is catalysed by HDACs enzymes 
activity. Specific gene expression and cell homeostasis as a result are maintained by 
the normal balance of HATs and HDACs activity in the cell. The figure is adapted 
from reference (Yang and Seto, 2007). 
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Table 1.3: human histone acetyltransferases (HATs) and histone 
deacetylases (HDACs) 
HATs super-families 
GNATs super- family 
 
General control non-derepressible 5 (Gcn5)-related 
N-acetyltransferases family (GNATs) includes 
Hat1, Gcn5, and PCAF.  
 
MYST super- family 
 
Includes Tip60, MOZ, MORF, and HBO1.  
 
P300/CBP proteins 
 
Two proteins: p300 and CBP work as a single 
entity.  
HDACs classes 
Class I 
 
Includes HDAC (1, 2, 3, and 8)  
 Class IIa 
 
Includes HDAC (4, 5, 7, and 9)  
 Class IIb 
 
Includes HDAC (6 and 10)  
 Class III 
 
Includes (Sirt1-7)  
 Class IV 
 
HDAC 11 
 
The table shows brief list of human HATs and HDACs.  
 
Human GANTs and MYST are super-families. They contain subfamilies listed 
in the table. Adapted from the references (Sterner and Berger, 2000) and 
(Yang and Seto, 2007). 
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3. Histone deacetylase inhibitors (HDACIs)  
 
1- History and discovery 
The story of HDAC inhibitors (HDACIs) development as therapeutic 
drugs is the opposite of the conventional principle of a targeted 
therapy development, in which a drug is usually designed to target an 
already studied cancer cell specific gene or pathway. However, in 
HDAC inhibitors case, the drugs came first and their target was 
defined later (Witt and Lindemann, 2009). In the late 1970s, it was 
noticed that the short chain fatty acid butyric acid induces 
accumulation of acetylated histone proteins, which lead to erythroid 
differentiation of Friend leukemic cells when applied to cell culture in 
millimolar concentrations (Mai A et al., 2005, Miller et al., 2003). 
Subsequently, other chemical compounds were discovered having the 
effects of induction of differentiation, cell cycle inhibition and 
apoptosis of transformed cells in culture accompanied by 
accumulation of acetylated histone proteins. Eventually, it was 
discovered that targets of these drugs were histone deacetylase 
enzymes (HDACs) (Witt and Lindemann, 2009).  
 
2- Effect and structure 
Nowadays, it is well known that HDACIs have the potency to induce 
growth arrest, differentiation, and/or apoptotic cell death of 
transformed cells in vitro and in vivo (Marks et al., 2000), whereas 
normal cells show relative resistance to the HDACIs in the same 
concentrations applied to transformed cells (Ungerstedt et al., 2005), 
as pictured in figure 2.3. 
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 Figure 2.3: tumour-specific effects of HDACIs in acute promyelocytic 
leukaemia. 
Histone deacetylase inhibitors (HDACIs) have little or no effect when they are 
applied to normal cells. For example, in acute promyelocytic leukaemia, HDACIs are 
able to induce apoptotic cell death through tumour-necrosis factor-related apoptosis 
inducing ligand (TRAIL) or FAS pathways, whereas there are no effects of HDACIs 
on cultures of normal haematopoietic progenitors in vitro or on haematopoiesis in 
normal mice. In addition, no effects of HDACIs have been noticed on preleukaemic 
stage cells which have an activation of oncogenes, but they have not reached the full 
transformation state. The figure is adapted from reference (Balasubramanian et al., 
2008). 
 
Many kinds of HDACIs are available for their potential therapeutic 
effects in cancer; some of them in clinical trials. Some HDACIs were 
derived from biological sources, for example Trichostatin A (TSA) 
which comes from a bacterial origin as an antifungal antibiotic, and 
many were designed and synthesized to target their HDAC (Zhang et 
al., 2010). Depending on the chemical structure, HDACIs were 
classified in classes summarised in tables 2.3.  
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Table 1.4:  Classification of Histone Deacetylase Inhibitors 
Class Inhibitor HDAC specificity Clinical Trial Status 
Short-chain 
fatty acid 
Butyrate Class I, IIa Phase II 
Valproic acid (VPA) Class I, IIa Phase II 
Hydroxamate 
Trichostatin A (TSA) Class I, II No clinical trial 
Suberoylanilide 
hydroxamic acid 
(SAHA, Vorinostat) 
Class I, II 
Approved for 
cutaneous 
T-cell lymphoma 
Tubacin Class IIb No clinical trial 
Benzamide 
MS-275 Class I Phase I, II 
CI-994 (tacedinaline) Unknown Phase I, II,III 
Cyclic 
tetrapeptide 
Apicidin HDACs 1 and 3 No clinical trial 
Depsipeptide Class I Phase I, II 
Electrophilic-
ketone 
Trifluoro-
methylketone 
 
Unknown No clinical trial 
The table shows HDACIs classes accompanied by brief examples of each 
class, specificity, and the corresponding clinical trial.  
There are five classes of HDACIs classified according to the chemical 
structure. This table is adapted from the references (Bolden et al., 2006, New 
et al., 2012). 
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3- Efficacy and functionality 
 
From activity perspective, some HDACIs have a broad inhibition 
effect such as Trichostatin A (TSA), Suberoylanilide hydroxamic acid 
(SAHA, Vorinostat), and LBH589. Therefore they are called pan 
HDACIs as they inhibit all HDAC members of class 1, and 2. Other 
HDACIs inhibit one class or some members of HDACs, for example 
valproic acid (VPA) inhibits Class I, IIa, whereas MS-275 inhibits just 
Class I (Bolden et al., 2006, New et al., 2012). Very few HDACIs 
work specifically to inhibit one HDAC per se, for example PCI-34051 
is a HDAC8-specific inhibitor (Balasubramanian et al., 2008). It is 
worth taking into consideration that the above mentioned HDACIs do 
not have any effects on class III of HDACs, (Sirt1-7) because this 
class depends on Nicotinamide adenine dinucleotide (NAD+) for its 
activity. Therefore HDACIs classes in table 1.4 do not inhibit Sirt 1-7 
(Dokmanovic and Marks, 2005a). All HDACs members of class I, 
class II, and class IV are Zn+ dependent (Balasubramanian et al., 
2009) as their active sites contain the zinc atom occupying the bottom 
of a channel delimited by a rim, which corresponds to the substrate 
pocket (acetyl-lysine). HDACIs exploit the zinc atom to inhibit 
HDACs activity, hence all HDACIs (either from natural or synthetic 
sources) pharmacophores primarily have a metal-binding domain 
(ZnC), which chelates zinc and blocks the enzymatic activity of 
HDACs, and two other domains known as a linker domain and a 
surface domain   (Minucci and Pelicci, 2006),  figure 2.4.  
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Figure 2.4: a representation of the crystal structure of the binding between 
HDACs and HDACIs. 
A: general structure of a HDACI: a surface recognition, a linker, and a zinc binding 
domain. B: a representation of the binding between a HDAC (the blue net) and SAHA 
(coloured beads excluding the pink bead). SAHA inserts into the pocket-like catalytic 
site of a HDAC enzyme, and it binds by its hydroxamic moiety to the zinc atom (the 
pink bead). This chelates the zinc and blocks the enzymatic activity of the HDAC 
enzyme. The figure is taken from reference (Marks, 2010). 
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4- Combination therapies with HDACIs 
 
HDACIs are promising new anti-cancer agents especially for the 
therapy of hematologic and solid neoplasms. Research is focused on 
developing more specific and effective HDACIs (Marks, 2010). Their 
use in combination with other types of cancer therapy (radiation, DNA 
damaging agents, and DNA demethylating agents) shows synergistic 
effects depending on the type of the combination and the sequence of 
drug administration (Bots and Johnstone, 2009). Moreover, many 
studies show that combination therapies with HDACIs may be the best 
therapeutic strategy in cancer treatment (Nolan L et al., 2008, Gore et 
al., 2006, Bishton et al., 2007). The role of HDACIs in combination 
treatments mainly falls in two concurrent ways (Miller et al., 2011). 
The first way is the mechanistic effect of HDACIs in combination 
treatments with DNA damaging drugs, in which HDACIs increase the 
acetylation of the histones leading to relaxed chromatin which 
facilitates the way for DNA damaging drugs to act (Hajji et al., 2010), 
figure 2.5. The second way is the transcriptional effect of HDACIs in 
combination treatments. For example, the combination of HDACIs 
with DNA methyltransferase inhibitors (DNMTIs) restores the 
expression of the epigenetically silenced tumour suppressor genes, 
and induces biological responses resulting in tumour regression 
(Seidel et al., 2012), figure 2.5. Also, it has been shown that HDACIs 
treatment increase the expression of several proapoptotic proteins, 
such as Bim and Bmf (Zhang Y et al., 2006). 
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 Figure 2.5: types of therapeutic combinations with HDACIs. 
Combinatorial HDACIs treatments showed synergistic cell death in different ways 
depending on the combined drug. For example, HDACIs with DNA-damaging agents, 
such as radiation and chemotherapies caused dramatic DNA damage in comparison 
with the singular treatment with each drug. This synergistic effect happens because of 
the increased accessibility to DNA which HDACIs cause. Also, histone demethylase 
inhibitors and DNA methyltransferase inhibitors acted synergistically with the 
actions of HDACIs. In addition, the combination of HDACIs and proteasome 
inhibitors increased the cell death in a synergistic way through cell cycle arrest and 
apoptosis owing to the increase (toxic levels) of reactive oxygen species (ROS) 
production which also occurred when HDACIs were combined with ROS-generating 
agents. The figure is adapted from reference (Miller et al., 2011). 
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5- Resistance to HDACIs 
Similar to any cancer drugs, HDACIs encounter a resistance in the 
cancerous cells, and this limits the HDACIs actions (Wagner et al., 
2010). A number of studies demonstrated several mechanisms 
involved in the biology of resistance to HDACIs. However, this 
resistance to HDACIs is not completely understood and more 
investigation is needed (Xu et al., 2007). The main mechanisms of 
resistance to HDACIs are: 
 
1. Drug efflux 
This mechanism is commonly associated with the multidrug 
resistance in cancer cells. It operates through overexpression 
of efflux pumps in the ATP-binding cassette transporter 
family, and it is associated with high levels of P-glycoprotein, 
the protein of the multidrug resistance-1 gene (MDR1), which 
activates effluxing chemotoxins from cells (Ruefli et al., 
2002). The drug efflux mechanism does not affect all 
HDACIs. However, romidepsin (depsipeptide) (Tabe Y et al., 
2006) and sodium butyrate (Morrow CS et al., 1994) are to 
date the only HDACIs shown to undergo efflux from the 
cancer cells including CRC cells (Jain and Zain, 2011). 
 
2. HDACs overexpression and desensitization 
Alterations in the level of HDAC enzymes in the treated cells 
render the cells resistant to HDACIs (Yoshida et al., 1990). 
For instance, overexpression of HDAC1 in melanoma cells 
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confers resistance to sodium butyrate (Bandyopadhyay et al., 
2004). In addition, inactivation mutations in HDACs play a 
role in building resistance to specific HDACIs. Recent studies 
showed that a frameshift mutation in HDAC2 are found in 
various CRC cell lines, and the deactivation of HDAC2 
induced a failure in triggering   histone acetylation and 
inhibiting proliferation after trichostatin A treatment. 
However, the cells remained sensitive to valproate and 
butyrate derivatives (Ropero et al., 2006). 
 
3. Epigenetic and chromatin alterations 
Silencing of tumour suppressor genes and induction of 
malignancy in many cells happens as results of epigenetic 
mechanisms such as hypermethylation at the promoter regions 
of these genes and hypoacetylation of histones H3 and H4 
(Jones and Baylin, 2007). It has been shown that methylation 
of DNA hinders the effects of HDACIs in fully restoring the 
expression of epigenetically silenced tumour suppressor 
genes, and this represents a mechanism of resistance to 
HDACIs. To prove the effect of DNA methylation in 
provoking resistance to HDACIs, a combination treatment of 
a demethylation agent (for example, 5-aza-2'-deoxycytidine) 
and a HDACI restores the effects of the HDACI (Zhang C et 
al., 2007). Besides the methylation of DNA, cellular 
polyamines (such as spermidine and spermine) that regulate 
gene expression through their effects on the chromatin 
microenvironment play a key a role in increasing  
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sensitization to HDACIs. Moreover, polyamines’ depletion 
increases resistance to HDACIs treatment (Saunders and 
Verdin, 2006). 
 
4. Stress response mechanisms 
Oxidative damage by producing reactive oxygen species is 
crucial in cell death induced by HDACIs treatment (Rosato 
RR et al., 2006, Rosato et al., 2003). According to this 
mechanism of resistance, cells showing resistance to HDACIs 
circumvent the oxidative stress by overexpressing proteins 
that work as reactive oxygen species scavengers, for example  
thioredoxins (Powis and Kirkpatrick, 2007). In contrast, down 
regulation of thioredoxin proteins through thioredoxin-
binding protein 2 augments the response to SAHA 
(vorinostat) (Butler et al., 2002). 
 
5. Antiapoptotic/prosurvival mechanisms 
The apoptotic cell death induced by HDACIs in various 
malignant cells proceeds via the intrinsic pathway which 
involves mitochondrial damage, cytochrome c release, and 
production of reactive oxygen species (Peart MJ et al., 2003). 
Therefore, overexpression of antiapoptotic proteins such as 
Bcl-2 or Bcl-XL is a key means by which transformed cells 
avoid the apoptotic effects of HDACIs (Maiso P et al., 2006). 
Moreover, it has been identified that the antiapoptotic 
transcription nuclear factor кB (NF-кB) is a mediator of 
HDACIs resistance (Mayo MW et al., 2003). HDACIs 
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treatment induces transcriptional activation of NF-кB which 
hinders HDACIs ability to trigger cell death in non–small cell 
lung cancer lines and leukaemia cell lines (Dai et al., 2005, 
Rundall BK et al., 2004). Therefore, using BAY-11-7085 (an 
inhibitor of NF-кB activation) restores the response to the 
effects of HDACIs in the malignant cells (Fantin and Richon, 
2007). Besides the above mentioned antiapoptotic 
mechanisms, there are prosurvival mechanisms playing a role 
in HDACIs resistance. For example, the cyclin-dependent 
kinase inhibitor p21 (CIP1/WAF1) which is involved in cell cycle 
arrest, has also a role in the regulation of programmed cell 
death (Gartel, 2005). It has been shown through several 
studies that HDACIs treatments in cancer cells up-regulate 
the expression of p21(CIP1/WAF1)  which, in turn, either mediates 
cell cycle arrest, differentiation, and apoptosis (Ocker and 
Schneider-Stock, 2007, Ju and Muller, 2003) or confers 
protection to colon cancer cells against the apoptotic effects 
of HDACIs (Wagner and Roemer, 2005). This dual effect of         
p21(CIP1/WAF1) is HDACIs dose dependent, as low 
concentration of Entinostat (MS-275, a potent HDAC 
inhibitor from Benzamide class, see table 1.4) caused cell 
cycle arrest in leukaemia cells, whereas that effect 
disappeared at high concentrations of Entinostat (Rosato et 
al., 2003, Frew et al., 2009). Finally, it has been demonstrated 
that autophagy mimics the dual effect of p21 (CIP1/WAF1) in the 
response of cancer cells to HDACIs, and this depends on the 
cellular context. While activation of autophagy results in cell 
death and enhances therapeutic efficacy in some cancer cells, 
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it induces a protective effect through coping with therapy 
induced oxidative stress and cellular damage in other cells 
(Amaravadi et al., 2007, Kondo and Kondo, 2006). In the 
latter scenario, combining autophagy inhibitors with HDACIs 
treatment enhances the therapeutic effects (Shao et al., 2004). 
Figure 2.6 summaries the above mentioned mechanisms of 
resistance to HDACIs. Another antiapoptotic protein which 
plays a role in CRC resistance to treatment and reduces 
apoptosis is survivin (Yang et al., 2009). The next paragraph 
will talk about survivin and its role in mCRC. 
 
 
6- Survivin and CRC  
The inhibitor-of-apoptosis (IAP) family of proteins were originally 
discovered in baculoviruses . 8 proteins of IAP family were identified 
in human: c-IAP1, c-IAP2, NAIP, Survivin, XIAP, Bruce, ILP-2, and 
Livin (Liston et al., 2003). IAP proteins share the ability to bind and 
inhibit specific caspases, hence they block apoptosis and participate in 
controlling the delicate balance between life and death in the cell 
(Deveraux and Reed, 1999).  Survivin is a 16.5 Kd protein encoded by 
BIRC5 gene which is located in 17q25.3 . The 142 amino acids protein 
is the only member in IAP family that plays an important role as a 
chromosome passenger during cell division (Altieri, 2006). Thus 
survivin has two roles: 1) inhibition of apoptosis, 2) regulation of 
mitosis (Knauer et al., 2007).  
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Figure 2.6: Mechanisms of resistance to HDACIs apoptotic effects. 
The cascade of events and outcomes following use of HDACIs in vitro are shown in 
the figure. Also the figure shows the factors that block HDACIs activity and confer 
resistance along the pathway of their action. The figure is taken from reference 
(Fantin and Richon, 2007). 
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The cytoplasmic survivin expression associates with its role in 
inhibiting apoptosis by binding and deactivating caspases 3, 7, and 9 
(Nachmias B et al., 2004). The role of survivin in cell division is 
associated with its nuclear expression which increases dramatically 
the G2/M phase (Li et al., 1998 , Liston et al., 2003). Survivin 
performs its role in cell division through interacting with Aurora 
kinase B (AURKB), inner centromere protein antigens (INCENP), and 
borealin (CDCA8) to form Chromosomal passenger complex. This 
complex then localizes to kinetochores at metaphase and facilitates 
chromosomes segregation on spindle microtubules (Kanwar et al., 
2010). This explains why survivin is over-expressed in many cancer 
including CRC (Altieri, 2003, Kim et al., 2003). Moreover, it has been 
shown that survivin is involved in the early stage of CRC 
tumorigenesis (Kim et al., 2003, Svec J et al., 2010), and its 
expression is stimulated by up-regulated (TCF)/β-catenin pathway as a 
result of the deactivation of APC gene which happens in the majority 
of sporadic CRC (Zhang T et al., 2001), see chromosomal instability 
(CIN) pathway of CRC. Over-expression of survivin is linked with 
poor survival and resistance to apoptosis in CRC (Sarela AI et al., 
2000, Wen et al., 2013, Di Stefano et al., 2010). In addition, survivin 
participates in CRC chemo-resistance as it inhibits drug-induced 
apoptosis (Prabhudesai et al., 2007). The anti-apoptotic effect of 
survivin can be strengthened by mutant p53 which takes place in the 
late stage of CRC.  Wild-type p53 transcriptionally represses survivin 
(Hoffman et al., 2002b, Mirza et al., 2002, Hoffman et al., 2002a). As 
above mentioned, p53 becomes mutant the late stage of metastatic 
CRC with the most mutation in DNA binding domain of TP53, and 
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this will lead to increase in survivin expression levels which are 
already elevated with initiation of chromosomal instability (CIN) 
pathway for CRC (Watson, 2006), as shown in figure 2.7. 
 
 
 
 
 
Figure 2.7: Up-regulation of survivin levels in the chromosomal instability 
pathway of colorectal cancer. 
Mutation in APC gene which occurs early in the chromosomal instability pathway 
leads to up-regulation of many genes transcribed by TCF/LEF1. Among these genes 
is survivin which happens in the early stage. TP53 becomes mutated in the late stage 
of CRC. All these alterations correlate with loss of apoptosis. Bub1 encodes a mitotic 
checkpoint serine/threonine-protein kinase Bub1; hCDC4 encodes F-box protein 
which targets cyclin E for ubiquitin-mediated proteolysis. The figure was taken from 
reference (Watson, 2006). 
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4.  Objectives and Hypothesis 
In the beginning of this project, I aimed to check the effect of 
exogenous wild-type p53 and mutated p53 transfection on the 
response of isogenic null p53 colorectal cancer cell line (HCT116 
p53-/-) to DNA damaging agent (Doxorubicin). The Ser15A, K373R, 
and K381R TP53 mutations were used. Therefore, HCT116 p53 were 
transfected with wild-type p53 and above mentioned mutations for 
p53. Stable clone for wild-type and the mutations were generated. The 
exogenous wild-type p53 and mutant p53 cells were treated with 
0.75µM and 1µM Doxorubicin for 24 hours. I checked the cell death 
by flow cytometry using Propidium iodide (PI) dye. Unfortunately, 
the results have not shown any difference in cell death between the 
exogenous wild-type p53 and mutant p53 cell lines, figure 2.8. This 
drew my attention to involvement of other factors that may play role 
in resistance of isogenic null p53 colorectal cancer cell line (HCT116 
p53-/-) to doxorubicin in comparison to its endogenous wild-type 
cells, HCT116 p53+/+. This could be on the epigenetic level as 
HCT116 p53+/+ and HCT116 p53-/- theoretically have the same 
genetic background. It is well-known that histone deacetylase2 
enzyme (HDAC2) is over-expressed in mCRC. However, its role in 
the resistance to combined treatment of HDACIs and DNA damaging 
agents have not been well-investigated.  
 
The hypothesis of this project is: HDAC2 may play a role in 
response of metastatic colorectal cancer to combined treatment of 
HDACIs and DNA damaging agent.  
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 The aims of this study are: 
 
1- To characterize the response of early stage mCRC cell lines (p53 
is intact) and late stage mCRC cell lines (p53 is mutated) to 
combined treatment of HDACIs and DNA damaging agent.  
 
2- To investigate the HDAC2 role in mCRC established cell lines 
upon specific combined treatments of HDACIs and DNA 
damaging agents. 
 
3- To select synergistic combined treatment of HDACIs/DNA 
damaging agents which induces cell death with minimal toxicity in 
mCRC established cell lines. 
 
4- To test the effect of the selected synergistic combined treatment of 
HDACIs/DNA damaging agents in vivo using xenograft mice. 
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   Figure 2.8: W
ild-type p53 or m
utant p53 transfection has not im
proved the response to doxorubicin in isogenic H
C
T116 P53-/- 
cells. 
C
ell death w
as investigated by flow
 cytom
etry using propidium
 iodide dye staining. Isogenic null p53 cells w
ere transfected w
ith either 
w
ild-type p53 or m
utant p53 (Ser15A, K
373R, K
381R). The results show
ed that neither the w
ild-type p53 nor any of the used m
utants 
induced any significant change in response to doxorubicin treatm
ent. All the m
easurem
ents w
ere norm
alized to H
C
T116 p53+
/+
 control 
sam
ple. D
ata w
as presented as m
ean ± S.E.M
.; n=
3. **P betw
een 0.001-0.01, ***P<
0.001. 
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1- In vitro study 
• Cell lines used in this study  
All the cell lines used in this study are established human metastatic 
colorectal cancer lines. I used four cell lines which are:  
1- HCT116 p53+/+ cells:  have wild type P53. 
 
2- HCT116 p53-/- cells: do not express P53 protein as both TP53 
gene copies were knocked down. 
 
 
3- SW480 cells: have two substitution mutations in TP53 gene. The 
first mutation is a GA substitution in codon 273 of the DNA 
binding domain of P53 gene resulting in an ArgHis change and 
the second mutation is CT in codon 309 of the oligomerization 
domain of TP53 gene resulting in a ProSer substitution .  
 
4- HT-29 cells: have one mutation in the DNA binding domain of 
TP53 gene. This mutation is similar to the first mutation in 
SW480 (a GA mutation in codon 273 resulting in ArgHis) . 
 
• Reagents used in this study  
 
 
Name of reagent The source 
Acetone (VWR, UK) 
Alexa Fluor® antibodies  (Invitrogen, UK) 
Ammonium persulfate (APS) (Sigma, UK) 
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 Bovine serum albumin (BSA)  (Sigma, UK) 
Chemiluminescence film  (GE Healthcare, UK) 
Chemi-luminescent reagent  (Thermo, UK) 
Cisplatin (Cisp)  (Sigma, UK) 
Control shRNA Plasmid (sc-108060)  (Santa Cruz Biotechnology, Inc, USA) 
Coomassie® Brilliant Blue G-250  (Bio-Rad, UK) 
D-luciferin  (Gold Biotechnology, USA) 
Doxorubicin  (Sigma, UK) 
Dulbecco’s modified Eagle’s medium  (Sigma-Aldrich, St. Louis, MO, USA) 
EDTA                    (Sigma, UK)                     
Fluorouracil or 5 Fluorouracil (5FU)  (Sigma, UK)                     
Foetal bovine serum (FBS) (Sigma, UK)                     
Glyserol (99%)              (Sigma, UK)                     
HEPES  (Sigma, UK) 
Irinotecan or Camptothecin-11 (Sigma, UK) 
MgCl2                     (Sigma, UK) 
NaCl                         (VWR Prolab, UK) 
Nitrocellulose membranes  (GE Healthcare, UK) 
Nonidet P40                        (Fluka, UK) 
Nupage lds sample buffer 4X  (Invitrogen, UK) 
Opti-MEM media  (Invitrogen, UK) 
Platinum® SYBR® Green qPCR 
SuperMix UDG 
 
(Invitrogen, UK) 
ThermoScript™ RT PCR System (Invitrogen, UK) 
Oxaliplatin (Oxa)  (Sigma, UK) 
PageRuler™ Prestained Protein 
Ladder  
(Fermentas, UK) 
Paraformaldehyde  (Thermo, UK) 
Penicillin- streptomycin  (Sigma, UK) 
pGL4.20 [luc2/Puro] Vector  (Promega, UK) 
Phosphate buffer saline (PBS) 10X  (GIBCO, CA) 
Polyacrylamide 40%   (Bio-Rad, UK) 
Polyethylenimine (PEI)  (Polysciences Inc, US) 
Protease inhibitors (Roche, Welwyn, UK) 
SDS (10%)  (Bio-Rad, UK) 
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• Cell culture  
All the cells were maintained at 37°C in Dulbecco’s modified Eagle 
medium (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 
10% foetal bovine serum (FBS; Sigma, UK) and penicillin (100U/ml) 
– streptomycin (100µg/ml) (Sigma, UK) in the presence of 5% CO2. 
 
• Cell collection 
Cell collection either before or after treatment was done as follows:  
1- Medium was transferred into a collection tube.  
2- Cells were washed with pre-warm trypsin 1X (Sigma, UK).  
The amount of washing trypsin depended on the cells container 
(1ml of trypsin was used for washing the cells seeded in 10 cm 
dish or T25 flask, whereas 3 ml of trypsin was used for T75 
flask). 
3- The washing trypsin was then transferred into the collection 
tube which has the medium from the first step. Then another 
amount of pre-warm trypsin was put into the cells container to 
detach them (1ml of trypsin was used for the cells seeded in 10 
cm dish, 3ml for T25 flask, and 5 ml of trypsin was used for 
T75 flask). 
4- The cells container was incubated in 37ºC incubator for 5 
minutes. 
5- The cells were homogenised with a pipette controller, then 1 ml 
of complete growth medium was added over the cells to 
homogenise them very well.  
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6- Then the cells suspension was transferred into the 
corresponding collection tube from the first step. 
7- The cells container was washed with 1ml of pre-warm 
phosphate buffer saline (PBS) 1X (GIBCO, CA) to remove any 
remaining cells from the previous step. Then the washing PBS 
was transfered to the corresponding collection tube from the 
first step and the cells container (flask or dish) was discarded. 
8- The collection tube was centrifuged at 2600 RPM (revolutions 
per minute) for 5 minutes, and the supernatant was removed 
with a tissue culture pump. 
9- The cells pellet was suspended in 1 ml of pre-warm PBS buffer 
1X and transferred to an eppendorf tube.  
10- The eppendorf tube was centrifuged at 2600 RPM for 5 
minutes. 
11-The supernatant was removed and either the cells pellets were 
transferred to the a specific tubes for flow cytometry analyses, 
or the eppendorf containing the cells pellet immediately was 
dropped in liquid nitrogen flask to kill the cells.  
12-The eppendorf was stored in -20°C freezer for further 
processing, proteins and histones extraction. 
 
• Cells Subculturing 
Cancer cells grow very fast and they need to be split and transferred 
to a new container when they become confluent in their container. 
The process is called subculturing or passaging and it should be done 
under the safety cabinet class II to prevent any contamination for the 
cells. 
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1. Culture medium was removed and discarded with a vacuum 
pump.  
2. Cells were rinsed with pre-warm trypsin 1X to remove any 
trace of cells medium. The amount of washing trypsin depends 
on the cells container (1ml of trypsin was used for washing the 
cells seeded in T25 flask, whereas 3 ml of trypsin was used for 
T75 flask). 
3. Then another amount of pre-warm trypsin was put into the cells 
container to detach them (3ml for T25 flask, and 5 ml of trypsin 
was used for T75 flask). 
4. The container was incubated in 37ºC incubator for 5 minutes. 
5. The cells were homogenised with a pipette controller, then 1 ml 
of medium was added over the cells and homogenised very 
well.  
6. 6 ml of complete growth medium was added for T25 flask or 
10 ml for T75 flask to neutralize the effect of trypsin, and very 
well homogenisation was applied. 
7.  1 ml was taken from the cells suspension in the previous step 
and transferred to a new flask and enough amount of complete 
growth medium was added according to the size of the flask (10 
ml for T25 and 20ml for T75). 
8.  The flask was incubated at 37ºC, in CO2 5% incubator. 
Replacing the medium is necessary in the next day to remove 
dead cells. 
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• Luciferase-stable HCT116 p53+/+ and HCT116 
p53-/- 
Xenograft mouse models become instrumental tools for increasing 
the understanding of human cancer(Aguirre et al., 2003). In addition, 
they provide an essential means to evaluate the efficacy of 
therapeutic intervention (Shah NP et al., 2004). Through the 
application of recent available imaging techniques and reagents, it is 
possible to measure the effects of a drug on xenograft tumour 
proliferation or apoptosis rate. One of these techniques is 
bioluminescence imaging (BLI) using luciferase and its substrate. 
The advantages of luciferase bioluminescence imaging are: non-
invasive, sensitive, and provides relative measure of cell viability or 
cell function and metabolism (Lyons, 2005). 
For generating luciferase-stable clones from HCT116 p53+/+ and 
HCT116 p53-/- for in vivo study , each cell line was cultured in a 10 
cm dish until the cells reach 60-70% confluency. The transfection 
was carried out with Polyethylenimine (PEI) (Polysciences Inc, US)  
polymer mixed with the pGL4.20 [luc2/Puro] Vector (Promega, UK) 
(a gift from Dr. Amin Hajitou, Department of Medicine, Imperial 
College London) in ratio 4:1 (V/W), and the mixture was completed 
to 200 µL with Opti-MEM media (Invitrogen, UK). The mixture was 
then dropped over the cells covered with the minimum amount of 
Dulbecco’s modified Eagle’s medium. Two days after the 
transfection, the stable clones from each cell line (HCT116 p53+/+ 
and HCT116 p53-/-) were selected in Puromycin for two weeks. To 
confirm the success of the stable clones and to check the luciferase 
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expression levels, Steady-Glo® Luciferase Assay System (Promega, 
UK) was used. 
 
• HDAC2-Knocked down HCT116 p53-/- and HT-29 
stable clones 
Each cell line was cultured in a 10 cm dish until the cells reached 60-
70% confluency. The transfection was carried out with 
Polyethylenimine (PEI) (Polysciences Inc, US) polymer mixed with 
HDAC2 shRNA Plasmid (sc-29345-SH, Santa Cruz Biotechnology, 
Inc.) in ratio 4:1, and the mixture was completed to 200 µL with 
Opti-MEM media (Invitrogen, UK). The mixture was then dropped 
over the cells covered with the minimum amount of Dulbecco’s 
modified Eagle’s medium. Two days after the transfection, the stable 
clones from each cell line (HCT116 p53-/- and HT-29) were selected 
in Puromycin for two weeks. The efficiency of HDAC2-knocking 
down compared to scramble shRNA Plasmid (sc-108060, Santa Cruz 
Biotechnology, Inc.) was assessed by immuno-blotting. 
 
• Transient HDAC2-overexpression in SW480 cells 
SW480 cells were cultured in a 10 cm dish until the cells reach 60-
70% confluency. The transfection was carried out with 
Polyethylenimine (PEI) (Polysciences Inc, US) polymer mixed with 
pcDNA3.1-HDAC2 plasmid in ratio 4:1 (the plasmid was obtained 
from collaboration with Dr. Nicolas Mercado, Airway Disease 
Section, National Heart and Lung Institute, Imperial College 
90 | P a g e  
 
London). The mixture was then dropped over the cells covered with 
the minimum amount of Dulbecco’s modified Eagle’s medium. 12 
hours after the transfection, the cells were treated with Dox, VPA, 
SAHA and a combination of them for 24 hours. Afterwards flow 
cytometry and immunoblotting analysis were performed. 
 
• Flow cytometry (FCM) 
This method could be applied to fixed or live cells. In this study, the 
flow cytometry (FCM) analyses were applied on live cells to measure 
their viability upon treatment using Propidium iodide (PI) dye. After 
cells were collected as stated above in the cells collection protocol 
(step 1 to 11), they were then incubated with PI dye as in the table 
2.6 and analysed using the FCM machine (BD FACSCaliburTM, BD 
Biosciences). The data were analyzed using the Flowing Software 
(free software downloaded from http://www.flowingsoftware.com/). 
Raw data was analysed using dot plots in which X-axis forward 
scatter (FSC) Y-axis (side scatter SSC). Cellular debris was excluded 
by gating. Percentages of live and dead cells were assessed by a 
histogram using X-axis FL3-H as shown in figure 2.9.  
 
 
 
 
 
 
 
Table 2.6:   FCM dye used in this study   
Dye Incubation period  Analysis filter  
PI 30 minutes at 37°C in dark FL3 
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Figure 2.9: Acquiring and gating the cells for FACS after PI staining. 
Cells were gated in order to exclude cellular debris and aggregates. The percentage 
of dead cells were acquired from 10000 cells after plotting the gated cells in 
histogram using X-axis FL3-H. 
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• Immunofluorescence 
It is a technique used for identifying simultaneously the localization, 
distribution, and quantifications of proteins within cells using 
labelled antibodies which transmit fluorescence when they are 
excited by laser. Confocal microscope TCS SP5 II (Leica) was used 
for this purpose. The protocol was as follows: 
Day 1: under the safety cabinet class II, three autoclaved glass cover-
slips were placed in each well of a 6 wells plate. The cells were then 
seeded over the cover-slips in a density of 150,000 - 200,000 
cells/well and the plate was incubated at 37ºC. 
Day 2: the medium was replaced with new one and the required 
treatment was applied. The plate was re-incubated at 37ºC. 
Day 3: the medium was removed and the cells were rinsed twice with 
pre-warm PBS 1X at room temperature. The cells were fixed with 1 
ml/well of 4% (w/v) paraformaldehyde in PBS 1X for 10 min at 4ºC. 
After the fixation, the cover-slips were rinsed three times with PBS 
1X followed by adding 1 ml/well of blocking/permeabilization buffer 
(10mM HEPES+ 0.3% TX-100+3% BSA, PH=7.4) for 1 hour at 
room temperature. The cover-slips were then incubated with the 
primary antibodies (the concentration is applied according to the 
manufacturer’s instruction) in a humid chamber over night at 4ºC. 
Day 4: the cover-slips were placed in the 6 wells plate and washed 
three times with PBS 1X. Afterwards the cover-slips were incubated 
with the corresponding secondary antibodies, Alexa Fluor® 
(Invitrogen, UK) for 1 hour in a humid chamber at 37ºC.  After 
washing three times with PBS 1X, the cover-slips were mounted on 
immuno-staining slides over a drop (10µl) of Vectashield mounting 
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medium (Vector Laboratories, UK) and sealed with nail polish. The 
slide were examined directly under the confocal microscope or stored 
in the dark at 4ºC for later use. 
 
• Total protein extraction 
This step starts from the frozen cells pellets which were prepared as 
in the cells collection protocol. The extraction was done as follows: 
1. The eppendorfs containing the cells pellets were put on ice and 
between 80-200µl (depending on the size of the pellet) of total 
protein extraction buffer (TGN) was added. The composition of  
TGN buffer is shown in table 2.1. The stock can be distributed 
in 10 ml aliquot and stored in the freezer. 2 tablets of protease 
inhibitor (Roche, UK) were added to 10ml TGN before use. 
 
 
 
 
2. The eppendorfs were mixed and kept on ice for 10 minutes. 
3. The following cycle was repeated 3 times (mixing by 
vortexing, 10 minutes incubation). 
Table 2.1: TGN buffer  stock  (50 ml) 
Substances Volume 
1 M Tris-HCL  PH=6.5     (Sigma, UK) 2,5 ml 
2.5 M NaCl                        (VWR Prolab, UK) 3    ml 
Glyserol (99%)                  (Sigma, UK) 5    ml 
0.5 M β glycerophosphate (Sigma, UK) 5    ml 
Tween 20                           (Sigma, UK) 0.5 ml 
Nonidet P40                       (Fluka, UK) 100µl 
Fill up with  miliQ dH2O  (total volume 50 ml) 
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4. Then the eppendorfs were centrifuged at maximum speed 
(13000-14000 RPM), at 4° C for 10 minutes. 
5. The supernatant containing total proteins was transferred to a 
new eppendorf and the pellet was discarded. 
6. The total proteins eppendorfs were stored in the -20°C freezer 
for further processing. 
 
• Histones extraction 
This protocol was used to extract pure histones from cells to 
investigate post-translational histone modifications. The procedure 
starts from the frozen cells pellets which were prepared in the cells 
collection protocol.  
1. The eppendorfs containing the cells pellets were put on ice (it is 
necessary for histones extraction to be done on ice), and 1 ml of 
lysis buffer (table 2.2) was added to the cells and the mixture 
was homogenized very well. Then the eppendorfs were 
incubated on ice for 15 minutes. The stock of lysis buffer 
should be stored at 4°C. 
2. The eppendorfs were centrifuged at 3500 RPM for 10 minutes 
at 4˚C and the supernatant was removed.  
3. The pellets were washed again with 1 ml of lysis and incubated 
on ice for 15 minutes. 
4. The eppendorfs were centrifuged at 3500 RPM for 10 minutes 
at 4°C and the supernatant was removed.  
5. Then the pellets were washed with 1 ml of ice-cold (1ml) Tris-
EDTA prepared as shown in table 2.3. 
 
95 | P a g e  
 
  
 
6. The eppendorfs were centrifuged at 3500 RPM for10 minutes at 
4°C and the supernatant was removed, the pellets (the nuclei) 
were then suspended in either 50 or 100 µl of ice-cold miliQ 
dH2O depending on the size of the pellet. 
 
 
 
 
7. The eppendorfs were centrifuged at 3500 RPM for10 minutes at 
4°C and the supernatant was removed, the pellets (the nuclei) 
were then suspended in either 50 or 100 µl of ice-cold miliQ 
dH2O depending on the size of the pellet. 
8. Then cold sulphuric acid, H2SO4 (VWR, UK) 0.4 M, was 
added in amounts similar to the water amounts (50 µl of 
H2SO4 if 50 µl of water is added). 
9. The eppendorfs were vortexed and incubated on ice for 1 hour. 
Table 2.2: Histones lysis buffer stock  (500 ml) 
Substances Volume/ amount Final 
concentration 
Tris-HCL PH=6.5  (Sigma, UK) 0.605     g 10 mM 
Sodium bisulphate (Sigma, UK) 3.452     g  50 mM 
MgCl2                    (Sigma, UK) 0.47605 g 10 mM 
Sucrose                  (VWR Prolab, UK) 43          g 8.6% 
Triton X-100          (Sigma, UK) 5           ml 1% 
Fill up with  miliQ dH2O  (total volume 500 ml) 
Table 2.3:  Tris-EDTA buffer stock  (500 ml) 
Substances Volume/ amount Final concentration 
Tris-HCL PH=7.4 (Sigma, UK)  0.605 g 10 mM 
EDTA                   (Sigma, UK)                     2.4 g 13 mM 
Fill up with  miliQ dH2O  (total volume 500 ml) 
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10.The eppendorfs were centrifuged at 15000 RPM for 60 minutes 
at 4°C and the supernatant was transferred to the new tube. 
11. Acetone (VWR, UK) (1 ml) was added to each new 
eppendorf, and brief centrifugation at high speed (15 seconds) 
was applied before overnight incubation at -20°C freezer. 
12. The next day, the eppendorfs were centrifuged at 15000 RPM 
for 10 minutes at 4°C and the supernatant was removed. 
13. The white pellet in each eppendorf was left to air-dry. 
14. Finally, the pellet was dissolved in 50-100 µl miliQ dH2O 
depending on the size of the pellet, and the eppendorfs were 
stored for further processing. 
 
• Bradford protein assay 
This assay is used to measure the concentration of proteins (including 
histones) depending on generating a standard line for serial dilutions 
(from 1 to 5µg/µl) of a known concentration solution of Bovine 
serum albumin (BSA) (Sigma, UK). The reagent for this assay is 
called Coomassie® Brilliant Blue G-250 (Bio-Rad, UK) or 
commonly known Bradford solution. It was diluted 1/5 in miliQ 
dH2O before use, then it was distributed in amount of 200 µl in each 
well of a 96 wells plate. Each unknown sample (1µL) was added to 
one well containing Bradford solution and the absorbance was 
measured at 600 nm wave-length using a GloMax®-Multi Detection 
System (Promega, UK). The measured absorbance values were dealt 
according to the standard line equation (Y= a.X+b) to obtain the 
protein concentration. Y=the protein’s measured absorbance, X= the 
protein’s required concentration, (a, b) are constants obtained from 
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plotting the known concentrations of BSA serial dilutions against 
their corresponding absorbances. 
 
 
• Immunoblotting (western blot) 
An analytical technique allows measuring the level of a specific 
protein in cells using an antibody against that protein. The sequential 
steps of this technique were as follows: 
 
1. Sample preparation 
 Total proteins or histones samples were mixed with Nupage 
lds sample buffer 4X (Invitrogen, UK) and miliQ dH2O 
according to table 2.4: 
 
 
 
 
 
 
 
The mixtures were boiled at 95°C heating block for 3 minutes 
to denature and reduce the protein disulfide bonds, and then the 
samples were centrifuged briefly and used either directly or 
stored in -20°C freezer. In the latter case, the boiling step must 
be applied to the samples before using them again. 
 
 
Table 2.4:   Samples preparation (1X) for immunoblotting 
 Sample 
volume 
Nupage lds 
buffer 
water 
Total proteins Contains 80µg  5 µl Up to 25µl 
Histones Contains 10µg  5 µl Up to 25µl 
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2. Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) 
Mini-PROTEAN Tetra Electrophoresis System (Bio-Rad, UK) 
was used for carrying out this step. Sodium dodecyl sulphate 
polyacrylamide gels were cast in percentage of 12% for total 
proteins and 15% for histones separation, table 2.5. 
PageRuler™ Prestained Protein Ladder (Fermentas, UK) and 
TGS 1X running buffer (Bio-Rad, UK) were used in all SDS-
PAGE. The electrophoresis was performed at 80V until 
separation of the protein ladder marker was visualized and then 
continued at 120V. At the end of the procedure, the gels were 
removed from the glass plates and prepared for the next step by 
removing the stacking gels. Then gels were transferred to a 
solid support for immunodetection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.5:   One gel’s composition   
Materials Total proteins 
 12% 
Histones 
15% 
              Resolving gel  
MiliQ dH2O 3.2      ml 2.45    ml 
40% polyacrylamide 3         ml 3.75    ml 
1,5M tris 8.8 3.75    ml 3.75    ml 
10% SDS 0.1      ml 0.1      ml 
TEMED 0.006  ml 0.006  ml 
10% APS 0.1      ml         0.1      ml 
             Stacking gel 
MiliQ dH2O 1.9     ml 
40% polyacrylamide 0.34   ml 
1,5M tris 6.8 0.75   ml 
10% SDS 0.03   ml 
TEMED 0.005 ml 
10% APS 0.009 ml 
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3. Transfer and immunoblotting 
The proteins on gels were transferred to nitrocellulose 
membranes (GE Healthcare, UK) using Mini Trans-Blot Cell 
(Bio-Rad, UK) filled with 1X transfer buffer (20% methanol in 
1X TGS buffer). The transfer was performed at 400mA for 2 
hours.  The nitrocellulose membranes were then blocked with 
5% powdered milk in PBS-Tween buffer for 30 minutes at 
room temperature. After the blocking step, the membranes were 
washed three times for 5 minutes in 1X PBS-0.1% Tween 
buffer on a rocker shaker machine. After preparing the required 
primary antibodies according to their manufacturer’s directions, 
the nitrocellulose membranes were incubated with them at 4°C 
overnight on a rocker shaker machine. The next day, the 
membranes were washed three times for 5 minutes in 1X PBS-
0.1% Tween buffer and the corresponding species-specific 
horseradish peroxidase-conjugated secondary antibody was 
applied.  The secondary antibodies, either anti-mouse (GE 
Healthcare, UK) or anti-rabbit (Sigma, UK), were prepared in 
5% powdered milk in PBS-Tween buffer in dilution of 1/1000 
(vol/vol). After 1 hour incubation with a secondary antibody at 
room temperature, the membranes were washed three times for 
5 minutes in 1X PBS-0.1% Tween buffer, and they were then 
treated with an enhanced chemi-luminescent reagent (Thermo, 
UK) followed by an incubation in high performance 
chemiluminescence film (GE Healthcare, UK). A Kodak 
machine or a manual developing was used. The densitometry 
analysis of scanned films was done via ImageJ programme. 
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• Real time PCR 
ThermoScript™ RT-PCR System kit (Invitrogen, UK) was used in 
generating cDNA as follows: Total RNA (1µg) and the primer oligo 
(dT)20 (50 pmoles), 2µl of 10 mM dNTP mix, mixed with DEPC-
H2O (up to 12µl), were pre-heated to 65° C for 5 min and then place 
on ice. Then 8µl of the following mastermix (4µl of 5x cDNA 
synthesis buffer, 1µl of 0.1 M DTT, 1µl of RNaseOUT™ (40 U/Yl), 
1µl of DEPC-treated water, and 1µl ThermoScript™ RT) was added. 
The final mix was transferred to a thermal cycler preheated to the 
appropriate cDNA synthesis temperature and incubated as 30-60 min 
at 50° C. Then the cDNA synthesis reaction was terminated by 
incubating at 85° C for 5 min. 
mRNA expression of HDAC2, α-TUBLIN, and PPIA was quantified 
by Platinum® SYBR® Green qPCR SuperMix UDG (Invitrogen, UK) 
with a GeneAmp 7500 Fast System (Applied Biosystems, Carlsbad, 
CA, USA). 2µl of cDNA from each sample was mixed with 5µl 
SYBR green mix, 0.5µl Primer Fwd, 10 µM, 0.5µl Primer REV, 10 
µM, 0.2 µl ROX, and finally the reaction was completed up to 10µl 
with autoclaved distilled water. Real-time PCR reactions were set 
following the manufacture instructions: one initial step at 95ºC for 2 
minutes hold followed by a 40-cycle step, which was 15 seconds at 
95°C for denaturation and 30 seconds at 56°C for annealing and 30 
seconds at 72°C. The dissociation stage was 15 seconds at 95°C, one 
minute at 56°C, and 15 seconds at 95°C. Threshold cycle (Ct) values 
obtained for each gene were normalized to α-TUBLIN and PPIA 
which are housekeeping genes. 
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 Primer pairs used in real time PCR analysis 
 
 
 
 
 
 
• Statistical analysis for in vitro study 
Results were expressed as mean ± SEM of three independent 
experiments measured in triplicate.  Statistical significance was 
assessed by one-way ANOVA with Tukey’s post-hoc test, setting 
statistical significance at p < 0.05 using GraphPad Prism version 5.3 
(GraphPad Software, CA, USA). 
 
 
 
 
 
• List of the antibodies used for immunoblotting 
Table 2.6 lists antibodies used in this study for immunoblotting, their 
manufacturers, sources, and dilutions. 
 
Gene Forward primer 
5'->3' 
Reverse prime 
5'->3' 
HDAC2 GACAGTGGAGATGAAGATGGA TTCTGATTTGGTTCCTTTGG 
PPIA CTGCACTGCCAAGACTGA GCCATTCCTGGACCCAAA 
α-TUBLIN GCCAAGCGTGCCTTTGTTC CACACCAACCTCCTCATAATCC 
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Antigen 
 
Source 
 
Dilution Company 
PARP/ cleaved PARP Rabbit 1/1000 Cell Signaling  Technology® 
Phospho-p53 (Ser15) Mouse 1/1000 Cell Signaling Technology®  
Anit-HDAC1 Mouse 1/1000 Cell Signaling Technology® 
Anit-HDAC2 Mouse 1/1000 Cell Signaling Technology® 
Phospho-p53 (Ser20) Rabbit 1/1000 Cell Signaling Technology® 
Phospho-p53 (Ser37) Rabbit 1/1000 Cell Signaling Technology® 
Acetyl-p53 (Lys382) Rabbit 1/1000 Cell Signaling Technology® 
Anti-total p53 [DO1] Mouse 1/5000 GeneTex 
Anti-MDM2 Mouse 1 μg/ml Merck  Millipore 
Anti-Phospho-Histone H3 (Ser10) Mouse 1 μg/ml Millipore 
Acetyl-Histone H3 (Lys9) Rabbit 1/500 Millipore 
Anti-Histone H3, CT, pan Rabbit 1/25000 Millipore 
Anti-acetyl-Histone H4 (Lys16) Rabbit 0.1 μg/ml Millipore 
Anti-acetyl-Histone H4 (Lys12) Rabbit 1/20000 Millipore 
Anti-Histone H4, pan Rabbit 1/30000 Millipore 
Anti-dimethyl-Histone H3 (Lys9)  Rabbit 1/2000 Millipore 
Anti-acetyl-Histone H3 Rabbit 0.05 μg/ml Millipore 
Survivin  Rabbit 1  μg/ml Novus 
β-Actin mouse 1  μg/ml Sigma 
Secondary antibody: anti-rabbit  mouse 1/1000 Sigma 
Secondary antibody: anti-mouse Rabbit 1/1000 GE Healthcare 
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• List of chemotherapeutic drugs used in this study 
 
1. Doxorubicin (Dox): is a powerful anti-neoplastic and antibiotic 
drug produced by Streptomyces peucetius bacterium species. Dox 
belongs to the anthracycline class, and it is used to treat wide 
spectrum of cancer types. Its mechanism of action depends on 
forming complexes with DNA by intercalation, and inhibiting 
topoisomerase II enzyme activity. Therefore, Dox induces DNA 
damage presented by DNA double-strand breaks (DSB) leading to 
cell death. The major Dox’s side-effect is cardiotoxicity 
(Drugbank, http://www.drugbank.ca/drugs/DB00997). This drug 
was purchased from (Sigma, UK). 
 
2. Camptothecin-11 (CPT-11): is an effective drug mainly used in 
CRC treatment. CPT-11 is one drug from the camptothecin class. 
The mechanism of action for CPT-11 and its active metabolite 
SN-38 relies on topoisomerase I enzyme inhibition. This leads to 
DNA single-strand breaks (SSB) which accumulate, resulting in 
DSB and consequently apoptosis occurs. Toxicity of CPT-11 
manifests in gastrointestinal complications, such as diarrhoea, 
vomiting, nausea, abdominal cramping, and infection (Drugbank, 
http://www.drugbank.ca/drugs/DB00762). This drug was obtained 
from (Sigma, UK). 
 
3. Valproic Acid (VPA): is a short fatty acid used for epilepsy 
treatment. However, its mechanism of action as an anticonvulsant 
and mood-stabilizing drug is not completely understood. It is 
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thought that VPA may increase gamma-aminobutyric acid levels 
in the brain or alter the properties of voltage dependent sodium 
channels (Rosenberg, 2007). Also, it has been noticed that VPA 
has the ability to work as a histone deacetylase inhibitor (HDACI) 
for Class I, IIa of HDACs and is recently under investigation for 
treatment of HIV and other types of cancer (Drugbank, 
http://www.drugbank.ca/drugs/DB00313). This drug was obtained 
from (Sigma, UK). 
 
4. Vorinostat or Suberoylanilide Hydroxamic Acid (SAHA): is a 
well known HDACs inhibitor drug from hydroxamate class. 
SAHA inhibits Class I and Class II of HDACs at nanomolar 
concentrations. As a result, SAHA induces cell cycle arrest and/or 
apoptosis of some transformed cells. SAHA is under pre-
registration stage for the treatment of cutaneous T cell lymphoma 
(CTCL) (Drugbank, http://www.drugbank.ca/drugs/DB02546). 
This drug was purchased from (Sigma, UK). 
 
 
5. Sodium Butyrate (NaB): is a short fatty acid like VPA. The effects 
of NaB on cultured CRC mammalian cells are well known for a 
long time (Davie, 2003). NaB at millimolar concentrations inhibits 
proliferation, induces differentiation and induces or represses gene 
expression (http://www.hdacis.com/Sodium-Butyrate.html). This is 
attributed to its role as HDACI for Class I, IIa of HDACs (Smith 
and Workman, 2009). This drug was purchased from (Sigma, 
UK). 
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6. Cisplatin (Cisp): is a chemotherapeutic drug used to treat diverse 
types of metastatic cancers such as sarcomas, small cell lung 
cancer, ovarian cancer, and lymphomas. Cisp was the first 
member of Platinum-based antineoplastic drugs class which 
includes Oxaliplatin and Carboplatin. Cisp like all alkylating 
agents has three mechanisms of action: 1- Cisp attaches alkyl 
groups to DNA bases. This action is followed by DNA 
fragmentation by repair enzymes which attempt to replace the 
alkylated bases. As a result, DNA synthesis and RNA 
transcription from the affected DNA stop. 2- Cisp forms cross-link 
bonds between atoms in the DNA and this blocks the DNA 
separation for synthesis or transcription, resulting in DNA 
damage. 3- Cisp provokes DNA mutations due to mispairing of 
the nucleotides (Drugbank, http://www.drugbank.ca/drugs/DB00-
515). This drug was purchased from (Sigma, UK). 
 
 
7. Oxaliplatin (Oxa): is in the same family of Cisp. Chemically, Oxa 
differs from Cisp in having a cyclohexyldiamine group replacing 
the two amine groups of Cisp to improve the antitumour activity. 
Oxa is used for the treatment of advanced carcinoma of the colon 
or rectum. Also it is administrated as adjuvant treatment for colon 
cancer patients who have had complete resection of the primary 
tumour. Its mechanism of action is similar to Cisp, but Oxa binds 
preferentially to the guanine and cytosine nucleotides of DNA 
(Drugbank, http://www.drugbank.ca/drugs/DB00526). This drug 
was purchased from (Sigma, UK). 
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8. 5 Fluorouracil (5FU): is a pyrimidine analog which belongs to 
antimetabolites family. 5FU is used as anticancer drug to treat 
different cancers including colon, oesophageal, gastric, rectum, 
and breast. Also, 5FU is used in a cream form for actinic (solar) 
keratoses and superficial basal cell carcinomas of the skin. The 
main 5FU mechanism of action is that it inhibits DNA and RNA 
synthesis by blocking the thymidylate synthetase conversion of 
deoxyuridylic acid to thymidylic acid. This inhibition leads to cell 
suicide and cell death (Drugbank, http://www.drugbank.ca/drugs/- 
DB00544). This drug was purchased from (Sigma, UK). 
 
• The quantification of  synergistic and antagonistic 
effects  of combined drugs used in this study 
The synergistic effect of the combination of two drugs means that 
the effect of using them together is higher than the sum of the 
effect of each drug alone. On the other hand, the antagonistic 
effect of the combination of two drugs together means that they 
produce less effect than the sum of the effect of each drug alone 
(Chou, 2010). The evaluation of effects of combined treatment 
was done using Chou and Talalay method (Chou, 2006). For each 
drug of a combination treatment, dose-effect curves were 
generated and they were used to analyze the results obtained from 
the combination treatment in the same experiment. The data were 
analyzed using CalcuSyn software (Biosoft, Cambridge, UK) to 
calculate the combination index (CI), when CI=1 indicates an 
additive effect, CI<1 indicates a synergistic effect, and when CI>1 
indicates an antagonistic effect. 
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2- In vivo study 
The in vivo work has been done by Prof Jimmy Bell’s group (Ms Leigh 
Brody, PhD student) in collaboration. I prepared and provided 
luciferase-stable cell lines. 
 
• Cells preparation 
The above mentioned luciferase-stable clones from HCT116 P53+/+ 
and HCT116 P53-/- were seeded at 2.5x105 cells per T-25 flask 
(Nunc, USA) and grown as a monolayer in Dulbecco’s Modified 
Eagle Medium (DMEM) (Sigma-Aldrich, UK), supplemented with 
10% foetal calf serum (FCS) (Sigma-Aldrich, UK) and penicillin 
(100U/ml)-streptomycin (100µg/ml) (Sigma, UK) in the presence of 
5% CO2 at 37°C incubator. Cells were passaged every 3-5 days 
while never exceeding 15 passages. Once the cells were 
approximately 80% confluent, they were harvested by removal of 
the medium, washing with PBS 1X, and followed by the addition of 
trypsin (Sigma-Aldrich, UK) for approximately 5 minutes. The cells 
were transferred to a tube, washed with PBS three times and re-
suspended in serum-free DMEM and centrifuged at 1,000 RPM for 5 
minutes. After the cells were counted on a haemocytometer, the 
medium was removed and the cells were finally re-suspended at 
1x107 cells per ml of serum-free DMEM for injections into the mice.  
 
• Liposomes’ preparation  
Liposomes were prepared from stock solutions in organic solvent of 
N1-cholesteryloxycarbonyl-3,7-diazanonane-1,9-diamine (CDAN), 
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1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), cholesterol, and 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy (poly-
ethylene glycol)-2000 (DSPE-PEG2000) using a spontaneous 
vesicle formation procedure. The solvent was then removed in vacuo 
to ensure production of an even lipid. The film was re-hydrated and 
remotely loaded with a defined volume of either 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid (HEPES) (4mM, NaCl 135mM, pH 
6.5) or with the combination of Doxorubicin and SAHA , giving 
lipid suspensions in either case with predetermined total lipid 
concentration of 2.88mg/mL. The concentration of doxorubicin and 
SAHA was selected to approximate a 20g mouse receiving 
liposomal doxorubicin at a dosage of 10 mg/kg and a liposomal 
dosage of SAHA to be 50mg/kg. After the thin-film rehydration, the 
nanoparticle solution was sonicated for 1hr at 30oC, in order to form 
the required uniform PEGylated liposome, and buffered to a pH of 
7.0. The liposomal solution was dialyzed for 18 h using the Float-A-
Lyzer G2 device to remove any unencapsulated materials. The 
particles had a component molar ratio of 32/24/8/30 (CDAN/DOPC 
/DSPE-PEG PEG2000/cholesterol). Particle size and zeta potential 
were determined using a Malvern Zetasizer. The size of the vesicles 
was typically 100nm.   
 
• In vivo tumour model development 
All experiments were carried out in compliance with Animals 
(Scientific Procedure) Act 1986 under the project licence 70/6656. 
Cells from the previous step were injected into male Balb-c 
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nude/nude mice subcutaneously into the right flank in concentration 
of 1x106 cells in 100 µl of serum-free media, using a 25 gauge 
needle. Mice were divided into groups bearing tumours from two 
cell lines of the colon cancer origin which contain p53 in varying 
states of activity: Group 1 (n=8) consisted of mice bearing tumours 
from HCT116 p53 +/+; Group 2 (n=8) consisted of mice bearing 
tumours from HCT116 p53 -/-. Identification of subcutaneous nude 
mouse xenograft tumours took 14 to 20 days. Once tumours were 
palpable, they were measured by a pair of callipers and the volume 
estimated using the modified ellipsoidal shape equation (Jensen et 
al., 2008):    
Tumor volume = 1/2(length × width2) 
 
 
• Tumour regression assessment by size and by 
bioluminescent imaging luciferase 
For an assessment of tumour growth, a bioluminescence imaging 
approach was employed using IVIS Spectrum pre-clinical optical in 
vivo imaging system (PerkinElmer, Massachusetts, USA). At the 
initial identification of the xenograft tumour, a baseline 
measurement was obtained using callipers and IVIS Spectrum. After 
baseline measurements, mice were divided into 2 groups (n=4 per 
group). In the first group, mice were treated intraperitoneally with a 
dose of 40mmol/day of Doxorubicin/SAHA combination liposome 
(200 µL). In the second group, mice were treated intraperitoneally 
with the control HEPES liposome (200 µL) in parallel. For the 
duration of the study, intraperitoneally injections were administered 
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three times a week with parallel callipers and IVIS measurements 
taken weekly. For visualization by luminescence, the Xeogen IVIS-
200 (PerkinElmer, Massachusetts, USA) optical imaging system was 
used. Briefly, an IVIS 200 cooled CCD camera system was used for 
emitted light acquisition and Living Image software (PerkinElmer, 
Massachusetts, USA) for data analysis as an overlay on IGOR 
software (Wavemetrics Corporation, USA). Animals were given a 
100 µl subcutaneous injections in the scruff of the neck of D-
luciferin (Gold Biotechnology, USA) at a concentration of 15 mg/ml 
under 1-2% inhaled Isoflurane anaesthesia. An average of 10 kinetic 
bioluminescent acquisitions were collected between 0 and 30 
minutes after substrate injection to confirm a peak photon emission 
recorded as maximum photon efflux per second. Data analyses and 
background correction were carried out by using total photon flux 
emission (photons/s) in a region of interest (ROI) covering the entire 
xenograft tumour region.  
 
 
• Tumour histological study 
The total immunohistochemistry (IHC) work was done by Dr Mona 
A El-Bahrawy’s group in collaboration. Animals were killed and the 
tumours were carefully excised to make sure that the samples did not 
include any surrounding normal tissue. Tumours were weighed and 
portioned to formalin solution (Sigma-Aldrich, UK) for histological 
evaluation by immunohistochemistry (IHC) studies as follows: After 
mounting the tumours’ sections on slides, they were de-waxed and 
rehydrated by passing them through xylene and descending grades 
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of alcohol then rinsed in water. Then the slides were incubated for 
15 minutes with 0.6% hydrogen peroxide solution. The slides were 
rinsed and immersed in 0.1M citrate buffer pH 6.0 and microwaved 
for 15 minutes in a microwave oven (750 watts) for antigen 
retrieval. They were then immediately cooled under running water 
and rinsed in phosphate buffered solution (PBS). 100µl of Protein 
block was added to each slide for 5 minutes. After rinsing with 
0.05% PBS/Tween 20 solution for 5 minutes, the slides were 
incubated with 100µl of the primary antibody at 4ºC overnight. The 
survivin (Novus biological, Cambridge), P53 (Dako, CA), and 
HDAC2 (Cell Signaling Technology, MA) antibodies were used at 
the following dilutions 1/400, 1/200, and 1/200 respectively. 
Following overnight incubation, slides were washed with 0.05% 
PBS/ Tween 20 solution. The slides were then incubated with 
secondary antibody (rabbit anti-mouse, Vector laboratories) for 30 
minutes at room temperature. The slides were stained using the ABC 
kit (Vector laboratories), and counterstained by haematoxylin for 2 
minutes then rinsed in tap water for 5 minutes. Slides were then 
dehydrated in ascending grades of alcohol and cleared in 3 changes 
of xylene. Finally, the slides were mounted using Di-N-Butyl 
Phthalate in Xylene (DPX) mountant and covered with a glass 
coverslip. For negative controls, duplicate slides from each case 
were used. These slides were incubated with 100μl antibody diluent 
instead of primary antibody. 
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•  Human samples used in this study 
In collaboration with Dr Mona El-Bahrawy (Department of 
Histopathology, Imperial College London), 10 human normal liver 
samples and 10 human CRC hepatic metastases were obtained from 
the archived material of the Department of Histopathology, 
Hammersmith Hospital, London, United Kingdom. Ethics approval 
for the use of human tissue for research was obtained from the 
Institutional Board of the Tissue Bank of Imperial College 
Healthcare NHS Trust. 
 
 
• Statistical analysis for in vivo study 
Results were expressed as mean ± SEM of three independent 
experiments.  Statistical significance was assessed by one-way 
ANOVA with Tukey’s post-hoc test, setting statistical significance 
at p < 0.05 using GraphPad Prism version 5.3 (GraphPad Software, 
CA, USA).   
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Results
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1-Characterization of response of wild-type, null, and 
mutated p53 mCRC cell lines to DNA damaging agents. 
Summary: 
Mutations in TP53 suppressor gene are a notable event which takes place 
in the late stages of the complex tumourigenesis of colorectal cancer 
(Iacopetta et al., 2006), whereas the early stages maintain a wild-
type TP53 gene but acquire other genetic (APC and RAS) or epigenetic 
alterations (e.g. DNA methylation promoter silencing) that compromise 
the p53 response (Worthley et al., 2007). However, the alteration of p53 
protein function followed by increased aggressiveness of tumour growth is 
controversial (Kern et al., 2002). In this section, I investigated the 
importance of p53 protein in the induction of metastatic colorectal cancer 
(mCRC) cell death by DNA damaging agents. I found that in the four 
mCRC cell lines used in this study, wild-type p53 protein is a key element 
in the sensitivity to DNA damaging agents. However, p53 mutations alone 
do not play an important role in resistance to DNA damaging agents. 
SW480 cells have two p53 mutations (one of them is similar to the only 
p53 mutation in HT-29 cells) yet these cells are more sensitive than 
HCT116 p53-/- (lack TP53 gene) and HT-29 cells (have one p53 
mutation). Moreover, HCT116 p53-/- cells lack p53 proteins but they 
showed better response than HT-29 cells to DNA damaging agents. 
Laboratory work and results:  
Wild-type p53 HCT116 cell line (HCT116 p53+/+) was treated with an 
increasing concentration (0.1-3 µM) of Doxorubicin (Dox). In p53 positive 
cells the use of 0.5µM of Dox was sufficient to phosphorylate the p53’s 
serine residues (Ser15, Ser37, and Ser20) in sequence, and to stabilize p53 
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as a result. Also 0.5µM of Dox induced PARP cleavage (a hallmark of 
apoptotic cell death). Acetylated K382 residue in p53 and substantial 
PARP cleavage (PARPc) appear with 1 µM Dox, figure 3.1A. To check 
the role of p53 in controlling the sensitivity to doxorubicin, p53 wild-type 
(HCT116 p53+/+) and null isogenic TP53 (HCT116 p53-/-) were treated 
with 1µM Dox and PARP cleavage was checked by immunoblotting. As 
expected, HCT116 p53-/- cells were less sensitive to 1µM Dox treatment 
and showed less cell death in comparison with HCT116 p53+/+, figure 
3.1B. 
 
 
Figure 3.1: Characterization of HCT116 p53+/+ and HCT116 p53-/- response to 
Dox.  
A) HCT116 p53+/+ cells were treated with dose-increase of Dox for 24 hours, cell 
death was confirmed by PARP cleavage (PARPc) expression, also activation and 
stabilization of p53 were assessed. B) Comparison of cell death upon Dox 1μM 
between HCT116 p53+/+ and HCT116 p53-/-. β-actin was used as a loading control. 
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In order to substantiate once more the importance of intact TP53 gene in 
regulating DNA damaging response, HT-29 and SW480 cells (both have a 
mutated TP53 gene, see cell lines used in this study paragraph for more 
details) were also treated with a dose-increase of Dox for 24 hours 
followed by cell death measured by Poly (ADP-ribose) polymerase 
(PARP) and its cleaved form (PARP cleavage which is a hallmark of 
apoptosis) expression. I found that HT-29 cells (which have one mutation 
in the DNA binding domain of TP53 gene) are the most resistant to Dox 
among the tested cell lines as this treatment failed to induce PARPc in HT-
29 even at high concentration (2 µM), whereas SW480 cells (which have 
two mutations in TP53 gene, one of them similar to HT-29 P53 mutation 
and the other mutation is in oligomerization domain) responded to Dox, 
and they were even more sensitive than HCT116 p53-/- cells, figure 3.2. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Characterization of SW480 and HT-29 response to Dox. 
A) Cell death in SW480 upon an increasing dose of Dox. B) Checking cell death by 
measuring PARPc expression and p53 level in HT-29 cells after 24 hour treatment 
for Dox 0.5, 1μM, and 2µM. β-actin was used as a loading control. 
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To show the treatment response of Dox among the four tested cell lines in 
a clear and unified way, quantification of PARPc bands upon Dox 1µM in 
each cell line was presented in figure 3.3. The graph shows that wild type 
p53 cells (HCT116 p53+/+) are the most sensitive cells followed by 
SW480 cells (which have two p53 mutations). In addition, null p53 cells 
(HCT116 p53-/-) is less sensitive than SW480, and HT-29 cells (which 
have one p53 mutation) is the most resistant cells in this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Quantification of PARPc upon 1μM Dox treatment in HCT116 
P53+/+, HCT116 P53-/-, SW480, and HT-29. 
The band of PARPc corresponding to Dox 1µM for each cell line was quantified 
relative to the control cells of each cell line using ImageJ program. Data was 
presented as mean ± S.E.M.; n=3. One-way ANOVA, Tukey’s post-hoc test, statistical 
level 95%. *** denotes statistical significance (p<0.0001).  
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To investigate whether or not the difference in sensitivity of analysed cell 
lines is Dox-specific, several more drugs were tested. Therefore, the first-
line chemotherapy to treat mCRC: 5-fluorouracil (5FU) and Oxaliplatin 
(Oxa), and the most widely used chemotherapeutic agents in cancer 
treatment, Cisplatin (Cisp) and Irinotecan or Camptothecin-11 (CPT-11) 
were applied to HCT116 p53+/+ cells (as the most sensitive among the 
tested cells) and HT-29 cells (as the most resistant cells among the tested 
cells). Selected low and high concentrations were used of each drug for 
HCT116 p53+/+ cells, whereas the high concentrations of selected drugs 
were used for HT-29 cells, figure 3.4A. The cell death checked by PARPc 
showed that HCT116 p53+/+ cells responded in a dose-dependent manner 
with applied treatment. However, HT-29 cells were resistant to all drugs as 
they did not show any cell death measured by PARPc and flow cytometry, 
figure 3.4B. These results revealed that difference in response to treatment 
is not Dox-specific, and it is general characterizations of each cell type. 
ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ 
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Figure 3.4: Characterization of HCT116 P53+/+ and HT-29 response to CPT-11, 
Cisp, 5FU, and Oxa. 
A) Cell death investigated by measuring PARPc expression upon low and high dose 
treatment of Irinotecan or Camptothecin-11 (CPT-11), Cisplatin (Cisp), 5-
fluorouracil (5FU) and Oxaliplatin (Oxa) in HCT116 P53 and HT-29 cells. As HT-29 
showed a strong resistance to Dox, just high concentrations of CPT-11, Cisp, 5FU, 
and Oxa were applied to these cells. B) HT-29 cell death investigated by flow 
cytometry using Propidium iodide (PI) staining. The flow cytometry analyses were 
represented by mean ± S.E.M.; n=3. The cell death upon the treatments (CPT-11, 
Cisp, 5FU, and Oxa) were not significant in comparison with the control (P=0.55), 
and this supports the immunoblotting for these treatments in HT-29 as no PARPc 
bands were detected. 
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2-Selective combined treatment with HDAC inhibitors 
and DNA damaging agents induces different levels of 
sensitivity in mCRC cells. 
Summary: 
HDACIs modulate cellular responses to DNA damaging agents including 
chemotherapeutic drugs (Chen et al., 2007). Although many combinatorial 
strategies showed both effective and synergistic effects (Frew et al., 2009, 
Bruzzese et al., 2009), the exact mechanisms for this synergy are not 
clearly understood and they seem different according to the employed 
combination regimen (Dokmanovic and Marks, 2005b). Despite the fact 
that several HDACs inhibitors are potential drugs for CRC treatment, 
including Vorinostat (SAHA), Valproic acid (VPA), and sodium butyrate 
(NaB), few have shown promising preclinical results (Sakajiri S et al., 
2005). In this section, I investigated the effects of combinations of low 
doses of HDACIs (VPA, SAHA, and NaB) and low doses of DNA 
damaging agents (Dox, CPT-11, 5FU, and Oxa) in HCT116 p53+/+, 
HCT116 p53-/-, and HT-29 (the combinations of 5FU and Oxa were just 
used for HT-29 cells as these cells showed high resistance to Dox in the 
previous section). The concentrations of the 5FU and Oxa were chosen 
from the literature, whereas the concentrations of the other drugs were 
from dose-increasing experiments. I found that the synergistic effects of 
combinations of HDACIs and DNA damaging agents are obtained in the 
early stages of colorectal cancer represented by HCT116 p53+/+ cells, 
regardless of the identity of the HDACIs and DNA damaging agents. 
However, in the late stages of colorectal cancer (where P53 is mutated) 
represented by HT-29 cells; Just SAHA (as a HDAC inhibitor) combined 
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with specific DNA damaging agents (5FU and Oxa) can induce the 
synergistic effects. 
 
Laboratory work and results: 
HCT116 p53+/+ and HCT116 p53-/- were treated with a low 
concentration of either a DNA damaging agent alone, Dox (0.5µM) and 
Camptothecin-11(CPT-11) (5µM) or combined with a HDAC inhibitor, 
VPA (1mM), SAHA (0.5µM), and sodium butyrate (1mM) for 24h. Cells 
were incubated with propidium iodide (PI) and then analysed for cell death 
by flow cytometry. Significant cell death was observed upon SAHA and 
NaB as a single treatment in HCT116 P53+/+ but only a slight increase in 
HCT116 p53-/-, figure 3.5 A. In addition, all combined treatments in 
HCT116 p53+/+ induced a synergistic effect on cell death in comparison 
with the single treatment, whereas HCT116 p53-/- showed a synergistic 
effect only with Dox/SAHA. Moreover, an antagonistic effect on cell 
death was observed with the combinations Dox/VPA, Dox/NaB, 
CPT/SAHA, and CPT/NaB in the HCT116 p53-/-, figure 3.5 A.  As HT-29 
cells were more resistant to Dox treatment than the other two cell lines 
(HCT p53+/+ and HCT p53-/-), more drugs were tested with this cell line. 
Therefore, in addition to Dox (0.5 and 2 µM) and CPT-11(5 µM), 5-
fluorouracil (5FU) and Oxaliplatin (Oxa) were used as a single treatment 
or combined with SAHA (0.5 µM). The combined treatments, SAHA/5-
FU (5 µg/ml) and SAHA/Oxa (10 µM) analysed by flow cytometry 
showed synergistic effects on cell death in comparison with the single 
treatment. However, Dox 0.5 µM or 2 µM combined with SAHA and 
CPT/SAHA exhibit antagonistic effects, figure 3.5 B. 
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 Figure 3.5: Selective combined treatment of HDAC inhibitors and DNA 
damaging agents induces different levels of sensitivity to cell death in HCT116 
p53+/+, HCT116 p53-/-, and HT-29. 
Cell death was analysed by flow cytometry using Propidium iodide (PI) staining after 
different treatment combinations of Dox, CPT, 5FU and SAHA for 24 hours. A) 
HCT116 p53+/+, HCT116 p53-/-. B) HT-29 cells. S denotes a synergistic effect and 
A denotes an antagonistic effect. Error bars were represented by the mean ± S.E.M.; 
n=3. ***P<0.001. 
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3-Doxorubicin combined with SAHA or VPA triggers 
decrease in histone acetylation correlating with the 
degree of response to applied treatments. 
Summary: 
Modifications of histones taking place in several histone lysine residues 
play a role in gene activity (Jenuwein, 2006). For example, the 
modifications (methylation and acetylation) of specific lysines in histone 
H3 or H4 is associated with gene silencing and cancer development 
(Kondo et al., 2008, Fraga et al., 2005). In addition, histone lysine residues 
modifications are considered to be informative of tumour stage in different 
types of cancer (Stirzaker et al., 2004). Moreover, it has been found that 
elevated acetylation level in specific lysine 9 residues in H3 participates in 
the development of multidrug resistance in breast cancer cells (Toth et al., 
2012). In this section, I investigated the acetylation levels in lysine 9 in H3 
(H3K9ac) and lysine 12 (H4K12ac) and 16 in H4 (H4K16ac) upon a 
combinatorial treatment with Dox (DNA damaging agent) and VPA or 
SAHA (HDACIs) in HCT116 p53+/+, HCT116 p53-/-, SW480, and HT-
29 cell lines. I found that in HT-29 cells which were very resistant to the 
applied treatment, both combination treatments (Dox/VPA or Dox/SAHA) 
induced elevated levels of acetylation in the three tested lysine residues. In 
contrast a sharp decrease in acetylation levels in those residues occurred in 
HCT116 p53+/+ cells which were highly sensitive to the applied 
treatment. However, moderate decrease in acetylation levels in lysine 9 in 
H3 and lysine 12 in H4 and no change  in lysine 16 in H4 took place in 
HCT116 p53-/- and SW480 cells which were moderately sensitive upon 
both combined treatments. It seems that the effect of combined treatment 
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on histone acetylation is p53-independent. This correlation between 
response to treatment and acetylation levels in the tested lysine residues 
was an indication for HDAC investigation which I did in the next section. 
 
Laboratory work and results: 
HCT116 p53+/+, HCT116 p53-/-, SW480, and HT-29 cell lines were 
treated with low concentrations of Dox (0.5µM), VPA (1mM), and SAHA 
(0.5µM) and their combinations Dox/VPA and Dox/SAHA for 24 hours. 
Cells were collected and total proteins and histones were then extracted 
and exposed to SDS-PAGE on 12% for total proteins and 15% gels for 
histones. After the transfer and blocking steps, antibodies against PARPc, 
β-actin, H3K9ac, total histone 3 (H3), H4K12ac, H4K16ac, and total 
histone 4 (H4) were used. HCT116 p53+/+ cells which responded 
positively to the applied treatment (figure 3.6A) showed noticeable 
decrease in acetylation levels in H3K9ac, H4K12ac, and H4K16ac upon 
combined treatments Dox/VPA and Dox/SAHA, as appeared in 
immunoblotting images and their quantifications (figure 3.6 A and B). 
However, HT-29 cells which were very resistant to high concentrations of 
Dox or its combinations (figure 3.2, 3.6A) exhibited very high levels of 
acetylation in the three lysine residues upon all single or combined 
treatments Dox/VPA and Dox/SAHA, figure 3.6 A and B. HCT116 P53-/- 
and SW480 cell lines which were between HT-29 and HCT116 p53+/+ in 
their sensitivity to Dox and its combinations (figure 3.2 and 3.6A) 
displayed moderate decrease in acetylation levels in H3K9ac and 
H4K12ac with no change in H4K16ac residues, figure 3.6 A and B. These 
results reveal a correlation between the acetylation levels in the tested 
lysine residues and sensitivity to chemotherapeutic drugs, and they 
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indicate the involvement of HDAC members in this relationship. This 
indication was investigated and established in the next section. 
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  Figure 3.6 A
: D
oxorubicin com
bined w
ith SA
H
A
 or V
PA
 triggers decrease in histone acetylation correlating w
ith the degree of 
cell death upon applied treatm
ents. 
H
C
T116 p53+
/+
, H
C
T116 p53-/-, SW
480, and H
T-29 cell lines w
ere treated w
ith D
ox (0.5µ
M
 and 1µ
M
 ), V
P
A
 (1m
M
), SA
H
A
 (0.5µ
M
) 
and their com
binations (D
ox/VPA and D
ox/SAH
A) for 24 hours. C
ell death w
as investigated by m
easuring PARPc expression in parallel 
w
ith the acetylation status in the follow
ing histone lysine residues: H
3K
9, H
4K
12, and H
4K
16. TH
3, TH
4=
total histone 3 and 4, 
respectively.                                              
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    Figure 3.6 B: Q
uantifications of acetylation alteration in histone H
3K
9, H
4K
12, and H
4K
16 residues upon D
ox, V
PA
, SA
H
A
 and 
their com
bination treatm
ent in H
C
T116 P53+/+, H
C
T116 P53-/-, SW
480, and H
T-29.  
The bands of acetylated histones in H
3K
9, H
4K
12, and H
4K
16 upon the applied treatm
ent for each cell line in figure 3.6 w
ere 
quantified by densitom
etric scanning using Im
ageJ program
. D
ata w
as presented as m
ean ± S.E.M
.; n=
3. **P betw
een 0.001-0.01, 
***P<
0.001.
4-Increased HDAC2 expression linked with p53 status 
represents a key factor in drug resistance when Dox is 
combined with VPA or SAHA in the mCRC cell lines 
used in this study.  
Summary: 
HDAC2 over-expression and p53 mutations are significantly associated 
with advanced stages and poor prognosis in CRC patients (Hanigan et al., 
2008). However, the relationship between HDAC2 and p53 status is not 
completely understood (Ito et al., 2002) nor the role and regulation of 
HDAC2 expression level upon CRC drug treatments. In this section, I 
checked the levels of HDAC1 and 2 and their relationship with p53 status 
in untreated mCRC cell lines. In addition, I examined the HDAC2 
alterations in response to Dox and its combined treatment with HDACIs, 
VPA and SAHA. I found that there is no correlation between HDAC1 and 
the response to the applied treatment. However, I found that the 
relationship between HDAC2 levels and p53 status depends on the 
functionality of p53 per se in normal conditions (without treatment) as the 
untreated HCT116 p53+/+ cell line (which has intact and functional p53, 
wild-type p53) expresses high level of HDAC2, whereas the level of 
HDAC2 is very low in the cell line which either lacks p53 totally 
(HCT116 p53-/-) or has mutated p53 (SW480 and HT-29). Moreover, the 
high level of HDAC2 in HCT116 p53+/+ decreases along-side the 
response to Dox combined with VPA or SAHA treatment while the low 
level of HDAC2 in HCT116 p53-/-, SW480, and HT-29 increases 
alongside the resistance to the applied treatment, and the highest HDAC2 
increase is in HT-29. These findings are consistent with the results found 
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in the previous section. In addition, these results show that HDAC2 is a 
crucial player in chemotherapy resistance in the tested cell lines. 
 
Laboratory work and results: 
In the previous section, I found that elevated levels of acetylation 
developed alongside the resistance to Dox as single treatment or combined 
with VPA and SAHA in HT-29 cell line, whereas the acetylation levels 
decreased alongside the response to the same treatment in HCT116 
p53+/+, HCT116 p53-/-, and SW480 cell lines, figure 3.6 A and B. This 
was an indicator to check the main HDAC enzymes, HDAC2 which is 
over-expressed in mCRC (Song J et al., 2005) and HDAC1 which usually 
forms a complex with HDAC2 (Hayakawa and Nakayama, 2011). 
Therefore, I applied Dox and its combination with VPA and SAHA 
treatment which was used for checking the acetylation status in the 
previous section. HCT116 p53+/+, HCT116 p53-/-, SW480, and HT-29 
cell lines were treated for 6 and 24 hours to check respectively for the 
early and late effects of the treatment. Expression of HDAC1 and 2 were 
investigated alongside PARPc (cell death indicator) for each treatment. At 
6 hours treatment the HCT116 p53+/+ cell line exhibited noticeable 
sensitivity to both combination VPA/Dox and SAHA/Dox but not to the 
single treatment as measured by PARPc, figure 3.7 A. This sensitivity 
correlated with marked decrease in HDAC2 expression figure 3.7 A and B. 
However, HCT116 p53-/-, SW480 and HT-29 showed pronounced 
increase of HDAC2 upon single or combined treatments which correlated 
with resistance to the treatment, figure 3.7 A and B. To check whether the 
protein changes of HDAC2 levels are transcriptional or not, a preliminary 
real time PCR analysis was done in HCT116 p53+/+ and HT-29 upon 6 
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hours treatment of Dox, VPA and VPA/Dox. Interestingly, I found that 
changes in HDAC2 levels are on transcriptional levels, figure 3.8. At 24 
hours treatments all cell lines showed different cell death responses to the 
applied treatment and they can be classified in their sensitivity as follows: 
HCT116 p53+/+ being the most sensitive, then SW480, HCT116 p53-/-, 
and finally HT-29 as shown in figure 3.9 A. The sensitivity response was 
in parallel with the decrease in HDAC2 in HCT116 p53+/+ and SW480 
cell lines, but the resistance response was in parallel with increase in 
HDAC2 in HCT116 p53-/- and HT-29 cell lines, figure 3.9 A and B. No 
response to the applied treatment has been shown in HT-29 cell line and 
this correlated with increasing levels of HDAC2. While HDAC2 
expression level increased significantly with treatment and this correlated 
with drug resistance, HDAC 1 showed no clear correlation in all cell lines 
at 6 and 24 hours, figure 3.7 and 3.9.  
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Figure 3.7 B: Q
uantification of alterations in H
D
A
C
2 levels upon 6 hours treatm
ent w
ith D
ox, V
PA
, SA
H
A
 and their 
com
bination in H
C
T116 p53+/+, H
C
T
116 p53-/-, SW
480, and H
T-29 cells. 
The bands of H
D
AC
2 levels in figure 3.7 A upon the applied treatm
ent for each cell line w
ere quantified follow
ing scanning 
densitom
etry using Im
ageJ program
. D
ata w
as presented as m
ean ± S.E.M
.; n=
3. **P betw
een 0.001-0.01, ***P<
0.001. 
  
 
 
Figure 3.8: Real time PCR analysis for HDAC2 mRNA levels in HCT116 p53+/+ 
and HT-29 upon 6 hours treatment of Dox, VPA, and VPA/Dox. 
Both cell lines were treated for 6 hours treatment with Dox (0.5µM), VPA (1mM), 
and their combinations (Dox/VPA). mRNA was extracted and quantified by real time 
PCR for HDAC2, α-TUBLIN, and PPIA genes. mRNA of HDAC2 levels were 
normalized against α-TUBLIN and PPIA  mRNA levels. Data was presented as mean 
± S.E.M.; n=3. **P between 0.001-0.01. 
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              Figure 3.9 B: Q
uantification of H
D
A
C
2 levels alterations upon 24 hours treatm
ent w
ith D
ox, V
PA
, SA
H
A
 and their com
bination 
treatm
ent in H
C
T116 pP53+/+, H
C
T116  p53-/-, SW
480, and H
T-29 cells.  
The bands of H
D
AC
2 levels in figure 3.9 A upon the applied treatm
ent for each cell line w
ere quantified follow
ing scanning 
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etry using Im
ageJ program
. D
ata w
as presented as m
ean ± S.E.M
.; n=
3. **P betw
een 0.001-0.01, ***P<
0.001. 
5-Correlation between survivin and HDAC2 levels 
determines cell death on treatment with Dox combined 
with VPA or SAHA in the mCRC cell lines used in this 
study. 
Summary: 
Survivin is a bifunctional protein encoded by BIRC5 gene. It prevents 
apoptosis by inhibiting caspase 3 and 7 activation. Also survivin regulates 
mitosis (Knauer et al., 2007), hence survivin is over-expressed in the 
majority of cancer types (Kennedy et al., 2003). However, the relationship 
between its expression and either status of P53 or HDAC2 in mCRC is 
unclear. I found in the previous section that HDCA2 levels increased 
alongside the resistance to applied treatment. Therefore, in this section, I 
checked the survivin levels (an inhibitor of apoptosis) in untreated and 
Dox/VPA and Dox/SAHA treated mCRC cell lines displaying different 
p53 status: wild-type p53 (HCT116 p53+/+), mutated p53 (SW480 and 
HT-29), and null p53 (HCT116 p53-/-) mCRC cell lines. I found that 
survivin expression levels correlate with their HDAC2 counterparts. In 
untreated wild-type p53 cell line (HCT116 p53+/+), Survivin is over-
expressed, whereas in the untreated and mutated or null p53 (SW480, HT-
29, and HCT116 p53-/-) survivin is expressed at low levels. (Also HDAC2 
has the same status, see the previous section). In addition, I found that the 
high level of survivin in HCT116 p53+/+ decreases alongside the response 
to Dox combined with VPA or SAHA treatment while the low level of 
survivin in SW480, HT-29  and HCT116 p53-/- increases alongside the 
resistance to the applied treatment. The changes in survivin protein level 
following the applied treatment are similar to the alterations of HDAC2 
expression level upon the same treatments (see the previous section). This 
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correlation between HDAC2 and survivin explains the relationship 
between HDAC2 levels and the response to Dox as a single treatment or 
combined with VPA and SAHA in mCRC. 
Laboratory work and results: 
In the previous section, I found that HDAC2 levels increase alongside the 
absence or reduction of apoptosis response upon Dox and its combination 
with VPA and SAHA treatment in HCT116 p53+/+, SW480, HCT116 
p53-/-, and HT-29. As survivin is an inhibitor of apoptosis and is over-
expressed in mCRC, I checked, therefore, the status of its level and the 
occurred change upon Dox and its combination with VPA and SAHA 
treatment. The four cell lines were treated with Dox (0.5µM), VPA 
(1mM), and SAHA (0.5µM) and their combinations Dox/VPA and 
Dox/SAHA for 24 hours. Total proteins were extracted and immunobloted 
in nitrocellulose membranes (see materials and methods for more details). 
p53, HDAC2, and survivin were investigated, figure 3.10 A. Untreated 
(control) wild-type P53 cells (HCT116 p53+/+) showed high level of 
survivin and HDAC2, whereas untreated and mutated p53 cells (SW480 
and HT-29) and untreated null p53 cells (HCT116 p53-/-) displayed low 
level of survivin and HDAC2 compared to their counterparts in HCT116 
p53+/+, figure 3.10 A. Moreover, the alterations of survivin levels towards 
the sensitivity or resistance to the applied treatment were the same as 
HDAC2 levels alterations. In HCT116 p53+/+, SW480, and HCT116 p53-
/-, the survivin level reduced with sensitivity and response to the treatment, 
figure 3.10 B. However, in HT-29 cells, the survivin levels significantly 
increased with the strength of resistance to the applied drug, figure 3.10 B. 
The correlation between the increase of HDAC2 level and the resistance to 
the treatment was reflected by corresponding increase of survivin level.
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   Figure 3.10 A
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een H
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Figure 3.10 B: Q
uantification of survivin level alterations upon 24 hours treatm
ent w
ith D
ox, V
PA
, SA
H
A
 and their 
com
bination treatm
ent in H
C
T116 P53+/+, H
C
T
116 P53-/-, SW
480, and H
T-29 cells. 
The bands of survivin levels in figure 3.10 A upon the applied treatm
ent for each cell line w
ere quantified follow
ing densitom
etric 
scanning using Im
ageJ program
. D
ata w
as presented as m
ean ± S.E.M
.; n=
3. *P betw
een 0.01-0.05, **P betw
een 0.001-0.01, 
***P<
0.001. 
6-HDAC2 depletion sensitizes HCT 116 p53-/- to Dox/ 
VPA treatment, whereas its over-expression erases 
SW480 sensitivity to the same treatment. 
Summary: 
Throughout the previous sections, I showed the correlation between 
HDAC2 level and the response to the applied treatment. While the 
sensitivity to treatment is accompanied by a reduction in HDAC2 level, the 
resistance to treatment is accompanied by an increase of HDAC2 level in 
the tested mCRC. However, until this point there is still an urgent question 
to be addressed which is: ‘does HDAC2 play a direct role in conferring 
resistance or sensitivity to treatment’ or in other words, ‘If HDAC2 has 
been knocked down in the resistant cells, would this sensitize these cells to 
the treatment?’ and vice versa, ‘if HDAC2 has been over-expressed in the 
sensitive cells, would this confer resistance to these cells’. In this section, I 
answered these questions and I proved that HDAC2 play a direct role in 
conferring resistance or sensitivity to treatment. HCT116 p53-/- cells 
showed resistance against Dox (0.5µM), VPA (1mM), and their 
combination Dox/VPA treatment. This resistance is accompanied by 
HDAC2 level increase, section 4- figure 3.9A. However, shRNA- HDAC2 
HCT116 p53-/- stable clone cells (HDAC2 knocked-down by shRNA) 
showed clear response and cell death measured by PARP cleavage 
expression. On the other hand, SW480 cells are sensitive to Dox (0.5µM), 
VPA (1mM), and their combination Dox/VPA treatment. This sensitivity 
is accompanied by HDAC2 level decrease, section 4- figure 3.9A. 
However, over-expressed HDAC2 SW480 cells become resistant to the 
same treatment and PARP cleavage bands disappeared. These results 
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prove that HDAC2 expression levels play a direct and crucial role in 
conferring resistance or sensitivity to treatment. 
 
Laboratory work and results: 
ShRNA-HDAC2 HCT116 p53-/- stable clone and transient over-expressed 
HDAC2 SW480 were generated as described in materials and methods. 
The efficiency of Knock-down HDAC2 in HCT116 p53-/- was about 85% 
measured by the quantification of HDAC2 levels in untreated parental 
HCT116 p53-/-  and shRNA-HDAC2 HCT116 p53-/- stable clone, figure 
3.11 A and B. To compare the sensitivity between parental HCT116 p53-/- 
(which showed resistance against the treatment used, section 4- figure 
3.9A) and shRNA-HDAC2 HCT116 p53-/-, Dox (0.5µM), VPA (1mM), 
and their combination Dox/VPA treatment was used for 24 hours. Cell 
death was measured by PARPc expression. Figure 3.11 C shows that 
HDAC2 depletion renders HCT116 p53-/- responsive and sensitive to the 
treatment to which the parental cells HCT116 p53-/- cells were resistant. 
This increase in sensitivity to the treatment upon knocking down HDAC2   
was also confirmed by flow cytometry analysis using PI dye, figure 3.11 
D. On the other hand, over-expression of HDAC2 (about 1.5 fold, figure 
3.12 A and B) in SW480 cells renders these cells completely resistant to 
24 hours treatment of Dox (0.5µM), VPA (1mM), and SAHA (0.5µM) and 
their combinations Dox/VPA, Dox/SAHA. Moreover, over-expression of 
HDAC2 in SW480 cells erased the PARPc cleavage bands which were 
developed upon this treatment in the parental SW480 cells, and made 
SW480+HDAC2 cells resistant to the applied treatment comparing with 
their parental SW480 cells, figure 3.12 C. This resistance was also 
confirmed by flow cytometry analysis using PI dye, figure 3.12 D. 
144 | P a g e  
 
 Figure 3.11: HDAC2 depletion sensitizes HCT 116 p53-/- cells to Dox/VPA 
treatment alone and in combination. 
A: Immunoblotting for HDAC2 in HDAC2-knocked down HCT 116 p53-/- cells. 
Parental HCT 116 p53-/- cells were transfected with scrambled shRNA or HDAC2-
specific shRNA. B: Quantification of HDAC2 bands in panel A by densitometric 
scanning shows that the efficiency of HDAC2 knock-down is about 85%. C: Parental 
HCT116 p53-/- and shRNA-HDAC2 HCT116 p53-/- cells were treated with Dox 
(0.5µM), VPA (1mM), and Dox/VPA for 24 hours. Cell death was investigated by 
PAPRc expression (a hallmark of apoptosis). D: Sensitivity to the treatment upon 
knocking down HDAC2 was confirmed by flow cytometry analysis using PI dye to 
measure cell death. Data was presented as mean ± S.E.M.; n=3.*P between 0.01-
0.05, **P between 0.001-0.01, ***P<0.0001. 
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Figure 3.12: HDAC2 over-expression renders SW480 cells resistant to 
Dox/SAHA treatment. 
A: Immunoblotting for HDAC2 in HDAC2-overexpressed SW480 cells. Parental 
SW480 cells were transiently transfected with mock vector or HDAC2-expression 
vector. B: Quantification of HDAC2 bands in panel A by densitometric scanning 
shows that the efficiency of HDAC2 overexpression is about 1.5 fold. C: Parental 
SW480 and SW480+HDAC2 cells were treated with Dox (0.5µM), VPA (1mM), 
SAHA (0.5µM) and their combination for 24 hours. Apoptosis was investigated by 
PAPRc expression levels. D: Resistance to the treatment was confirmed by flow 
cytometry analysis using PI dye to measure cell death. Data was presented as mean ± 
S.E.M.; n=3.*P between 0.01-0.05, **P between 0.001-0.01, ***P<0.0001. 
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7-HDAC2 controls chromatin plasticity and its 
depletion enhances mitotic cell death in drug resistant 
HT-29 cells upon 5FU and Oxa treatments. 
 
Summary: 
HT-29 cells were the most resistant cells in this study and they expressed 
high levels of HDAC2 alongside their resistance to treatment. In this 
section, I experimentally answered the question “If HDAC2 was knocked 
down in these resistant cells, would this sensitize the cells to treatment”. I 
found that HT-29 cells undergo caspase-independent cell death, 
specifically mitotic cell death (MCD) by chromosome fragmentation 
(Stevens JB et al., 2007), upon 5FU/SAHA and Oxa/SAHA combined 
treatment. This MCD explains the absence of PARPc after 5FU/SAHA 
and Oxa/SAHA combined treatment, although there was cell death as 
investigated by flow cytometry. In addition, I found that HDAC2 depletion 
via shRNA was sufficient to sensitize HT-29 cells to 5FU or Oxa as a 
single treatment. Moreover, HDAC2 depletion significantly increased 
MCD in shRNA-HT-29 cells compared to parental HT-29 cells after 
exposing both cell lines to the same treatment with 5FU or Oxa. These 
results again confirm the crucial role of HDAC2 in determining response 
to chemotherapy. 
 
Laboratory work and results: 
HT-29 cells have shown resistance to 5FU (5µg/ml) or Oxa (10µM) as a 
single treatment, figure 3.13 A. However, 5FU/SAHA (0.5µM) or 
Oxa/SAHA (0.5µM) combined treatment sensitized HT-29 cells and 
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induced significant cell death as investigated by flow cytometry and 
microscopy analysis, figure 3.13 B and C. Nevertheless, this significant 
cell death was not accompanied by PARPc induction, figure 3.13 D. This 
indicates that the cell death induced by both combinations in HT-29 cells 
is caspase-independent and does not involve PARPc. To investigate 
further, HT-29 were exposed to the same treatment above and cell death 
was investigated by confocal microscopy, with immunofluorescence using 
phosphorylated serine 10 histone H3 antibody (Mitotic Marker, Abcam, 
UK) and 4',6-diamidino-2-phenylindole (DAPI) dye (a nuclear and 
chromosome counterstain, Invitrogen, UK). Interestingly, the confocal 
microscope images showed that the cell death induced upon 5FU/SAHA 
and Oxa/SAHA combined treatment is mainly mitotic cell death (MCD), 
figure 3.14 A, B. This type of cell death occurs during metaphase and 
involves the degradation of condensed chromosomes (Stevens JB et al., 
2007). However, MCD does not lead to PARPc because it is caspase-
independent form of cell death. This explains why there is no PARPc in 
HT-29 cells upon 5FU/SAHA and Oxa/SAHA combined treatment even 
though there is cell death shown by flow cytometry and microscopy 
analysis. To check if HDAC2 depletion in HT-29 can sensitize the cells to 
treatment with 5FU or Oxa as a single treatment, to which HT-29 cells 
were resistant, shRNA-HDAC2 HT-29 stable clone was generated as 
described in materials and methods, and shRNA HT-29 and parental HT-
29 cells were treated with SAHA (0.5 µM), 5FU (5 µg/ml), and Oxa (10 
µM) for 24 hours. Mitotic cell death was investigated by 
immunofluorescence as there was no PARPc induced after treatment (as 
mentioned above these cells undergo caspase-independent cell death). 
Interestingly, shRNA-HDAC2 HT-29 cells showed significant increase in 
MCD compared to parental HT-29 cells, figure 3.15 A, B. Therefore, 
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HDAC2 depletion was sufficient to sensitize HT-29 cells to 5FU or Oxa as 
a single treatment.  Moreover, HDAC2 depletion disturbs the higher order 
chromatin structure in a similar manner to SAHA combined with 5FU or 
Oxa, figure 3.15 C and figure 3.16.  
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Figure 3.13: HT-29 cells undergo a caspase-independent cell death upon 
SAHA/5FU and SAHA/Oxa combined treatments. 
Checking cell death by PARP cleavage (PARPc) in HT-29 upon treatment by 5FU 
(5µg/ml) and Oxa (10µM) as a single treatment for 24 hours (A). HT-29 cells were 
treated with SAHA (0.5µM), 5FU (5µg/ml), Oxa (10µM), and their combined 
treatment SAHA+5FU and SAHA+SAHA for 24 hours, then cell death was 
investigated by: flow cytometry (B) using Propidium iodide (PI) staining, by 
microscopic observations (C), and by PARPc (D). S denotes a synergistic effect. 
Error bars represent the mean ± S.E.M.; n=3. *P between 0.01-0.05.  
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Figure 3.14: HT-29 mitotic cell death (MCD) by chromosome fragmentation 
upon SAHA/5FU and SAHA/Oxa combined treatments. 
A: Mitotic cell death (MCD) in HT-29 upon SAHA+Oxa combined treatment 
observed under a confocal microscope after immunostaining with DAPI and 
phosphorylated H3. B: Quantifications of mitotic cell death (MCD) in HT-29 upon 
5FU, Oxa combined with SAHA. Error bars represent the mean ± S.E.M.; n=3. *P 
between 0.01-0.05, **P between 0.001-0.01. 
 
 
151 | P a g e  
 
  
Figure 3.15: HDAC2 controls the chromatin plasticity and its depletion enhances 
mitotic cell death in drug resistant HT-29 cells upon 5FU and Oxa treatments. 
A: Checking cell death by PARP cleavage (PARPc) in parental and shRNA-HDAC2 
HT-29 cells and upon 5FU, Oxa combined with SAHA. B: Quantifications of MCD in 
parental and shRNA-HDAC2 HT-29 cells upon treatment by 5FU, Oxa combined 
with SAHA. The observations of cell death were done under a confocal microscope 
after immunostaining. C: Zeta stack images for parental and shRNA-HDAC2 HT-29 
cells upon Oxa+SAHA (in parental HT-29 cells) and Oxa (in shRNA-HDAC2 HT-29, 
which mimics the effect of SAHA). Both cell lines were stained with DAPI and 
incubated with HDAC2 and Survivin primary antibodies. Error bars represent the 
mean ± S.E.M.; n=3. *P between 0.01-0.05.   
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Figure 3.16: Oxa combined with SAHA or ShRNA-HDAC2 has similar effects 
on HT-29 mitotic cell death. 
Confocal microscope images after immunostaining for parental and shRNA-HDAC2 
HT-29 cells upon Oxa+SAHA (in parental HT-29 cells) and Oxa (in shRNA-HDAC2 
HT-29). HDAC2-knock down mimics the effect of SAHA in combined treatment with 
Oxa. Both cell lines were stained with DAPI and incubated with HDAC2 and 
Survivin primary antibodies.  
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8-In vivo imaging and immunohistochemical 
confirmation of Dox/SAHA combined treatment effects 
and the related role of HDAC2 in obtained response. 
 
Summary: 
In vivo studies are complementary to their counterparts in vitro, and both 
are crucial for modern cancer research and clinical care. A key advantage 
of in vivo imaging (as a part of in vivo studies) is that it provides 
information about treatment efficacy in the real or similar milieu or 
microenvironment of a tumour (Condeelis and Weissleder, 2010). In this 
section, I managed to confirm the synergistic effect of the combined 
treatment Dox/SAHA in HCT116 p53+/+ and HCT116 p53-/- in a murine 
xenograft model. Dox/SAHA combined treatment induced cell death in 
both HCT116 p53+/+ and HCT116 p53-/-, also decreased HDAC2 and 
survivin expression levels in vitro (see result section 2). In this preliminary 
in vivo study I showed by immunohistochemistry (IHC) analyses as proof 
of concept that Dox/SAHA treated tumours isolated from HCT116 p53+/+ 
xenograft mice dramatically decreased their cellular HDAC2 and survivin 
levels (tumours isolated from HCT116 p53-/- xenograft mice showed 
necrosis, so IHC for them was not successful).The decrease in HDAC2 
and survivin levels is consistent with the in vitro results (result section 4 
and 5). In this section, I also had the chance to compare the HDAC2, 
survivin, and p53 levels between normal human liver tissues and human 
CRC metastases in liver tissues using IHC analyses. All CRC metastases 
in liver tissues showed high increase of HDAC2, survivin, and p53 levels. 
This increase is consistent with the metastatic status.  
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Laboratory work and results: 
In order to substantiate the association between HDAC2 expression level 
and cell death in vivo, non-invasive spatiotemporal visualization was used 
based on bioluminescent molecular imaging system of a murine xenograft 
model. Luciferase stable cell lines HCT116 p53 +/+ and HCT116 p53-/- 
were generated and subcutaneously transplanted into nude mice. Since the 
combined treatment Dox/SAHA produces significant cell death in both 
HCT116 p53+/+ and HCT116 p53-/- cell lines in vitro, the in vivo 
validation of this effect was explored. Therefore, liposomal-encapsulated 
SAHA/Dox was prepared and intraperitoneally delivered to the mice 
bearing human mCRC xenografts. This innovative delivery strategy 
allowed for easier delivery and increased toxicity reduction. Eight nude 
mice were transplanted subcutaneously with each luciferase stable clone 
cell line. After the tumour growth arose in the mice (2-3 weeks), the 
control group (n=4 mice per cell line) was separated from the treated 
group. The size of the tumour was measured using callipers and recorded 
before treatment in parallel with luciferase activity measurement to ensure 
the presence and viability of the transplanted cells, figure 3.17. The results 
showed noticeable decrease in the size of tumour together with luciferase 
activity upon the combined treatment in HCT116 p53+/+ (figure 3.18 A 
and B), and in HCT116 p53-/- (figure 3.19 A and B). Moreover, the IHC 
analyses for HDAC2 level on the tumour isolated from HCT116 p53+/+ 
xenograft mice showed that HDAC2 level decreased by more than 50% 
after Dox/SAHA combined treatment, figure 3.18 C (tumours isolated 
from HCT116 p53-/- xenograft mice showed necrosis, so IHC for them 
was not successful). This clearly supports the relationship between 
HDAC2 expression level and sensitivity to the combined treatment. In 
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addition, the IHC analyses for survivin showed a decrease in survivin level 
in tumours isolated form Dox/SAHA treated HCT116 p53+/+ xenograft 
mice, figure 3.18 C. The decrease in HDAC2 and survivin levels in 
Dox/SAHA treated HCT116 p53+/+ xenograft mice was in parallel with 
cell death and tumour shrinkage. These results confirm again the 
relationship between HDAC2 levels and resistance or response to 
Dox/SAHA treatment. Also, IHC analyses for 10 samples from normal 
human liver tissues and 10 samples from human CRC metastases in liver 
showed high levels of HDAC2, p53, and survivin compared with the 
normal tissues. Figure 3.20 shows the IHC analyses for HDAC2, survivin, 
and p53 in representative samples. Table 3.1 (below the figure 3.20) 
summaries the immunohistochemistry observations for the 10 samples of 
human CRC metastases in liver. 
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Figure 3.17: Monitoring the establishment of HCT116 p53+/+ and HCT116 p53-
/- in mice by size and luciferase activity. 
The correlation between calipers and luciferase activity  measurements confirms the 
establishment and viability of HCT116 p53+/+ and HCT116 p53-/- xenograft in 
mice. 
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Figure 3.18 A-B: In vivo imaging of liposome-encapsulated Dox/SAHA 
treatment effects in HCT116 p53+/+ xenograft mice. 
A: The tumour size and luciferase activity in control and liposomal Dox/SAHA 
treated HCT116 p53+/+ xenograft groups. Error bars represent by the mean ± 
S.E.M.; n=3. Statistical significance at p < 0.05. B: Bioluminescence imaging for 
control and Dox/SAHA treated HCT116 p53+/+ xenograft mice throughout three 
weeks shows sharp decrease in tumour size. 
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Figure 3.18 C: Immunohistochemistery analyses for HCT116 p53+/+ xenograft 
in mice. 
Immunohistochemistery analyses for HDAC2 and survivin on the control and the 
treated tumour extracted from HCT116 P53+/+ xenograft mice. HDAC2 and 
survivin levels have decreased by more than 50% after Dox/SAHA combined 
treatment. 
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Figure 3.19: In vivo imaging of liposome-encapsulated Dox/SAHA treatment 
effects in HCT116 p53-/- xenograft mice. 
A: The tumour size and luciferase activity in control and liposomal Dox/SAHA 
treated HCT116 p53-/- xenograft groups. Error bars represent by the mean ± S.E.M.; 
n=3. Statistical significance at p < 0.05. B: Bioluminescence imaging for control and 
Dox/SAHA treated HCT116 p53-/- xenograft mice throughout three weeks shows a 
decrease in tumour size. 
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Figure 3.20: Immunohistochemical analyses for HDAC2, survivin, and p53 
expression levels in 3 samples of normal human liver and CRC hepatic 
metastases.  
Metastatic CRC tissues have shown high levels of HDAC2, survivin, and p53 in 
comparison with their human normal tissues. This confirms in vitro results found in 
this project. 
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able 3.1: Im
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unohistochem
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ples of hum
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C
 m
etastases in liver. 
 
Sam
ple ID
 
P53 levels 
(intact and m
utated) 
H
D
A
C
2 levels 
Survivin levels 
H
S08-11131 
negative 
m
oderate nuclear in 100%
 of cells 
w
eak cytoplasm
ic in all cells and m
oderate nuclear in < 
50%
 of cells 
H
S09-5038 
m
oderate to strong nuclear staining in 90%
 
of cells 
m
oderate nuclear in 100%
 of cells 
w
eak cytoplasm
ic in all cells and m
oderate to strong 
nuclear in > 50%
 of cells 
H
S09-8283 
w
eak nuclear staining in 1%
 of cells 
m
oderate to strong nuclear in 100%
 of 
cells 
w
eak cytoplasm
ic in all cells and m
oderate nuclear in < 
50%
 of cells 
H
S10-313 
negative 
m
oderate to strong nuclear in 100%
 of 
cells 
w
eak cytoplasm
ic in all cells and m
oderate to strong 
nuclear in > 50%
 of cells 
H
S08-12482 
strong nuclear in 75%
 of cells 
m
oderate to strong nuclear in 100%
 of 
cells 
w
eak cytoplasm
ic in all cells and m
oderate nuclear in < 
50%
 of cells 
H
S08-2468 
strong nuclear in 95%
 of cells 
w
eak to m
oderate nuclear in 100%
 of 
cells 
w
eak cytoplasm
ic in all cells and strong nuclear in < 50%
 
H
S09-8935 
negative 
m
oderate to strong nuclear in 100%
 of 
cells 
w
eak cytoplasm
ic in all cells and m
oderate to strong 
nuclear in > 50%
 of cells 
H
S10-8435 
m
oderate nuclear in 45%
 of cells 
m
oderate to strong nuclear in 100%
 of 
cells 
w
eak cytoplasm
ic in all cells and m
oderate to strong 
nuclear in < 50%
 of cells 
H
S09-4289 
m
oderate nuclear in 15%
 of cells 
strong nuclear in 100%
 of cells 
w
eak cytoplasm
ic in all cells and m
oderate to strong 
nuclear in > 50%
 of cells 
H
S08-11129 
m
oderate nuclear in 95%
 of cells 
m
oderate nuclear in 100%
 of cells 
w
eak cytoplasm
ic in all cells and m
oderate to strong 
nuclear in > 50%
 of cells 
G
eneral 
com
m
ent 
 
N
o nuclear staining in norm
al tissue 
 
N
o nuclear staining in norm
al tissue 
 
N
o nuclear staining in norm
al tissue 
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1. Discussion 
The ultimate role of p53 protein is to maintain the integrity of the genome 
in the cell; hence it is dubbed “the guardian of the genome” (Efeyan and 
Serrano, 2007). To accomplish this role, p53 is involved in several 
pathways forming a functional circuit called the p53 functional circuit (Jin 
and Levine, 2001) which opt for DNA repair, cell cycle arrest,  or 
apoptosis when the cell has stress signals, as shown in figure 4.1. Giving 
this importance of p53, more than 50% of human cancers have mutated 
p53 (Miller et al., 2005). The great bulk of the studies in cancer research 
field have shown that mutated p53 induces resistance to chemotherapy 
treatment in cancer cells (Mogi and Kuwano, 2011, Crea et al., 2011).  
Consistent with these studies, however, in this research project, I have 
shown that reduction in HDAC2 expression level plays an essential role in 
mCRC response to DNA damaging agents as single treatment or combined 
with HDACIs, whereas TP53 mutation status was found to be a less 
significant drug resistance factor in mCRC. While, mutated TP53 HT-29 
cells exhibited extreme resistance to drugs, mutated TP53 SW480 cells 
showed drug sensitivity comparable to that of wild-type p53 HCT116 cells 
(HCT116 p53+/+). Although, all tested combined-treatments were found 
to exert a synergistic effect on the induction of cell death in mCRC 
HCT116 p53+/+ cells, cell death induced in HCT116 p53-/- (null p53 
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cells) was shifted from synergistic with Dox/SAHA combinations to 
antagonistic with Dox/VPA, Dox/NaB, and all CPT-11 combinations. 
These results point to the nonessential role of TP53 in the effects of 
Dox/SAHA combinations since this treatment induces a synergistic effect 
on cell death in wild type and null p53 cells. Also, this is supported by 
previous finding where in the absence of functional p53, SIRT1 (HDAC 
class III) expression level is a critical parameter in trichostatin A or VPA-
mediated sensitization of several multidrug-resistant cancer cells to 
topoisomerase II inhibitor etoposide (Hajji et al., 2010). Additionally, the 
introduction of wild-type p53 alone is not sufficient to substantially alter 
the sensitivity of cancer cells to a given chemotherapeutic agent (Breen et 
al., 2007). Mutated p53 expression in different cell backgrounds causes 
distinct patterns of drug resistance, indicating that cell context can 
influence this phenotype (Sampath J et al., 2001). These differences in 
drug resistance might be explained by epigenetic regulation of certain 
genes which are influenced by mutated p53 (Sampath J et al., 2001). In 
fact, reconstitution of p53 protein in HT-29 was not able to increase 
sensitivity to drug treatment in these cells (work was done by my 
colleague who continues this research).  
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Figure 4.1: The p53 functional circuit. 
P53 is maintained at a low level in cells under normal conditions. However, upon 
many stress signals p53 is activated and stabilized to transcriptionally regulate or 
directly activate proteins involved in DNA repair process, Apoptosis, inhibition of 
transformation, and cell cycle arrest. Through its pathways, p53 retains intact 
genome in cells and suppresses tumour formation.  The figure was re-shaped from 
(Jin and Levine, 2001). 
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In wild type p53, null p53 and mutated p53 (SW480) cell lines which were 
treated with SAHA or VPA combined with Dox, significant decrease in 
the expression level of HDAC2 is observed when apoptosis is induced, as 
shown by PARP cleavage as a hallmark of apoptosis. In contrast upon the 
same combinations, mutated p53 (HT-29) cell line shows an increase in 
HDAC2 expression with resistance to cell death. Remarkably HDAC2 
overexpression renders mutated p53 SW480 cells resistant to the combined 
treatment. These results suggest that p53 mutation in mCRC does not 
confer protection against the effect of HDACIs (SAHA or VPA) combined 
with Dox, and provide evidence for the importance of HDAC2 level in 
drug combination response. Like HDAC2 expression, HDAC1 also seems 
to be upregulated in colorectal cancer (Lucio-Eterovic et al., 2008). Here I 
have shown, while HDAC2 expression level increased significantly with 
resistance to the treatment, HDAC 1 had no clear correlation in all tested 
cell lines. The change in HDAC2 expression levels does not associate with 
change in HDAC2 activity upon SAHA/Dox treatment in the cell lines 
used in this study. This was investigated by HDAC2 activity assay which 
was kindly done by Dr Nicolas Mercado as he has the facility in his 
laboratory (Airway Disease Section, National Heart and Lung Institute, 
Imperial College). After I treated the four cell lines (HCT116 p53+/+, 
SW480, HCT116 p53-/-, and HT-29) with SAHA/Dox combination. The 
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cells were collected and sent out for measuring HDAC2 activity. 
Interestingly, the four cell lines have shown no significant change in 
HDAC2 activity upon the treatment, as shown in figure 4.2. However, 
measuring HDAC2 activity supported that wild-type p53 cells have high 
expression levels and more activity of HDAC2 than mutated p53 cell lines.  
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Figure 4.2: HDAC2 activity measurment upon SAHA/Dox treatment. 
The four cell lines (HCT116 p53+/+, HCT116 p53-/-, SW480, and HT-29) were 
treated for 24 hours with Dox and SAHA as single or combined. The cells were then 
collected and sent out for measrungi HDAC2 activity. Interestingly, each cell line has 
shown no clear change in HDAC2 activity. However, this measurment support what I 
found about high expression level of HDAC2 in wild-type p53, whereas low 
expression level in mutated p53 cell line. Data was presented as mean ± S.E.M.; n=3. 
*P between 0.01-0.05, **P between 0.001-0.01. 
 
  
170 | P a g e  
 
Also, I have established an in vivo model for verification of HDAC2 level 
and the response to combined treatment, where liposomal-encapsulated 
SAHA/Dox was used to treat human mCRC xenografts mice as an 
innovative delivery strategy for toxicity reduction. According to data 
available on the internet web, this is the first time that a nanoparticle 
(liposomal) approach has been applied to deliver a HDACI/DNA 
damaging agent (SAHA/Dox in this project) combined therapy directed to 
the site of action for mCRC treatment. I have found that the combined 
treatment induces a proportional and significant decrease in HDAC2 
expression level associated with tumour shrinkage as measured by tumour 
size and luciferase activity. The combined treatment induces similar 
reduction in both wild type p53 and null p53 tumour. Therefore, this 
verifies the nonessential role of p53 against the level of HDAC2 as 
potential marker for positive response to this combined treatment. 
Interestingly, I have found that mutated p53 (SW480 and HT-29) and null 
p53 cell lines express a low level of HDAC2 in comparison with wild-type 
p53 cell line which expresses a high level of HDAC2 in untreated cells. 
The mechanism of HDAC2 inactivation and drug treatment inducing cell 
death remains largely unknown. In HT-29 cell line, I found that HDAC2 
depletion disturbs the higher order chromatin structure in a similar manner 
as HDACIs and increases HT-29 sensitivity to 5FU or Oxa treatment 
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resulting in mitotic cell death (MCD). Recently, whole genome expression 
microarray analyses performed on HDAC2 knockdown human 
hepatocellular carcinoma (HCC) cells has identified up-regulation of many 
of cell cycle inhibitors genes and down-regulation of cyclins genes (Noh et 
al., 2011). Therefore, I investigated the mechanism of HDAC2 depletion 
on cell death in mCRC. The results in my research support what has been 
found in the above mentioned studies, and they further elucidate the 
underlying mechanism of the HDAC inhibitor SAHA combined with 5FU 
or Oxa and the role of HDAC2 in inducing mitotic cell death in HT-29 cell 
line. The increased HDAC2 expression has been found in colorectal cancer 
patients at mRNA and protein level indicating that HDAC2 overexpression 
is due to transcriptional activation (Zhu P et al., 2004). This 
overexpression of HDAC2 appears to be implicated in cancer through its 
aberrant recruitment and consequent silencing of tumour suppressor genes. 
For example, β-catenin/T-cell factor (TCF) signalling pathway which is 
deregulated in colon cancer regulates HDAC2 transcription . Also, histone 
acetyltransferase p300/CREB-binding protein (CBP) is found to be a 
critical coactivator for β-catenin-TCF-mediated survivin transcription (Ma, 
2005, Ma et al., 2005) which is enhanced by β-catenin and repressed by 
p53 [32]. However, the relationship among survivin, mutated TP53, and 
HDAC2 on cell death has not been explored upon the combined treatment 
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in mCRC. Here I have shown that combined treatment VPA/Dox or 
SAHA/Dox induced dramatic reduction in survivin and HDAC2 
expression level in wild-type p53 and SW480 but not in HT-29 cells. The 
overexpression of survivin in HT-29 appears to correlate with increased 
HDAC2 and the resistance to the combined treatments.  Therefore, p53 
appears not to be involved in survivin and HDAC2 regulation of cell death 
upon these combined treatments. Moreover, the results in this research 
show that SAHA/Oxa or shRNA-HDAC2/Oxa triggered clear increase in 
survivin level with dramatic decrease in the HDAC2 expression in HT-29 
cells. This unexpected increase in survivin level upon cell death supports 
the special cell death (mitotic cell death) induced after SAHA/Oxa or 
shRNA-HDAC2/Oxa in HT-29. A body of evidence indicates that compact 
chromatin is crucial for the protection against agents causing DNA breaks 
and oxidative DNA damage. This protection disappears via chromatin 
relaxation (Ljungman and Hanawalt, 1992). HDACIs increase histone 
acetylation and the subsequent chromatin relaxation renders DNA more 
susceptible to a number of DNA-damaging agents (Rajendran P et al., 
2011). It may also allow for the increased binding of transcription factors 
that regulate genes involved in cell death. Interestingly, it has been 
suggested that p53 has the biochemical potential for inducing chromatin 
relaxation, as it can employ the histone acetyltransferase (HAT) p300 to 
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chromatin and thus initiate histone acetylation (Espinosa and Emerson, 
2001) and subsequently enhance chromatin accessibility to enable efficient 
lesion detection (Green and Almouzni, 2002, Friedberg, 2001, Rubbi and 
Milner, 2003). On the contrary, recent studies showed that the elevated 
acetylation levels in H3 correlate with cancer proliferation and drug 
resistance (Toth et al., 2012, Simpson NE et al., 2010). However, it is not 
clear whether such differences in acetylation steady state levels form a 
marker for resistance to drugs as single therapy or combined with HDACIs 
in cancer cells. With this perspective in mind, I have demonstrated that 
doxorubicin combined with SAHA or VPA triggers a decrease in histone 
acetylation in sensitive mCRC cells (wild-type p53 and SW480 cells) but 
not in highly resistant HT-29 cells. Therefore, in HT-29 the H3K9ac, 
H4K12ac and H4K16ac levels remain elevated after the combined 
treatments compared to the other cells. These results are in agreement with 
the elevated levels of lysine 9-acetylated histone H3 that occur at the 
multidrug-resistance protein 1 (MDR1) promoter in multidrug-resistant 
cells (To KK et al., 2008). Hence, the association between histone 
acetylation levels and mCRC sensitivity could have particular importance, 
since the level of acetylation may predict the combination therapy 
outcomes. However, the level of histone acetylation appears to be 
independent on HDAC2 regulation in drug resistance, and possibly 
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HDAC2 expression represses activation of transcription factors which 
control cancer cell death. For example, it has been found that 
overexpression of HDAC2, but not HDAC1, represses NOXA gene 
expression and induces resistance towards  VPA and etoposide combined 
treatment in pancreatic cancer cells, while HDAC2 depletion upregulates 
NOXA protein level and sensitizes theses cells to the VPA and etoposide 
combined treatment (Fritsche et al., 2009). In summary, HDAC2, in a 
given tumour entity, might not only be of prognostic value, but may also 
predict the response to combined (HDACIs/DNA damaging drug) therapy. 
I think that identification of HDAC2 expression as a possible sensitive 
“epigenetic biomarker” associated with HDACIs/ DNA damaging drug 
resistance may lead to a new molecular target for mCRC therapy, help to 
improve treatment of CRC and provide a more robust mechanistic 
rationale for the use of HDACIs. It is, therefore, highly probable that the 
overall response to conventional treatment may be less effective in patients 
that strongly express HDAC2 in their cancer cells. Also, it may be rational 
to recommend that translational protocols for future clinical trials should 
include HDACIs as adjuvant therapeutic agents with conventional mCRC 
drugs. 
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2. Study limitation 
I would like to mention that the time was a major limitation. Also, lack of 
specific HDAC2 inhibitors until now is a potential limitation in my 
research. All HDAC inhibitors (SAHA, VPA, and NaB) used in this 
project are not specific for HDAC2. 
 
3. Future works emerging from this study 
• The in vivo experiment done in this project was a preliminary and 
proof of concept for Dox/SAHA combined treatment effect. In the 
future, therefore, the in vivo work will be expanded to include Dox 
and SAHA as single treatment.   
• Also, xenograft mice bearing ShRNA-HDAC2 HCT116 p53-/- or 
ShRNA-HDAC2 HT-29 tumours will be established. 
• Testing more mCRC cell lines for HDAC2 role found in this project. 
•  Introduction of wild-type p53 into the mutated p53 cells line 
(SW480 and HT-29) and investigation into effects on cell death 
would be encouraging (My colleague who continues this project did 
some preliminary work on HT-29 as mentioned in the discussion). 
•  In addition, examination of the lysine residues in histones tails and 
other proteins controlled via HDAC2 expression level and 
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identification of histone or non-histone cell death code will be 
investigated in future work. Also, exploration of HATS enzymes 
which counteract HDAC2 action and their balance in mCRC cell 
lines will support this study.  
• Using Micrococcal Nuclease enzyme (MNase) digestion for 
chromatin extracted from mCRC cell lines established in this project 
will be done. MNase digestion is a good and simple assay to map 
nucleosome positions in chromatin. Applying quantitative real-time 
PCR (qPCR) technique after extensive MNase digestion up to 
mononucleosome-sized fragments of DNA will give an idea about 
DNA sequence that was protected from digestion (i.e. 
transcriptionally inactive DNA sequence).  
• Finally, assessment of HDAC2 recruitment into DNA and its control 
of the pro-survival genes in mCRC will be in the future work. 
Therefore, my colleague started generating a reporter gene using 
luciferase gene within pGL4.20 plasmid and different parts of 
HDAC2 promoter as shown below. The idea is to check which part 
of HDAC2 promoter plays a role in transcription process, and then 
transcription factors and proteins which bind to the effective part of 
HDAC2 promoter will be investigated.  
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4. A schematic summary of the results obtained in this 
project  
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179 | P a g e  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
180 | P a g e  
 
References 
5FU [Online]. Available: http://www.drugbank.ca/drugs/DB00544. 
 
Cisplatin [Online]. Available: http://www.drugbank.ca/drugs/DB00515. 
 
CPT-11 [Online]. Available: http://www.drugbank.ca/drugs/DB00762. 
 
Doxorubicin [Online]. Available: http://www.drugbank.ca/drugs/DB00997. 
 
HT-29 cell line [Online]. Available: 
http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452
/Default.aspx?ATCCNum=HTB-38&Template=cellBiology. 
 
OMIM-Survivin gene [Online]. Available: http://omim.org/entry/603352. 
 
Oxaliplatin [Online]. Available: http://www.drugbank.ca/drugs/DB00526. 
 
p53 discovery [Online]. Available: http://p53.free.fr/p53_info/p53_disco.html. 
 
p53 domains [Online]. Available: http://p53.free.fr/p53_info/p53_Protein.html. 
 
SAHA [Online]. Available: http://www.drugbank.ca/drugs/DB02546. 
 
Sodium butyrate [Online]. Available: http://www.hdacis.com/Sodium-Butyrate.html. 
 
Survivin-Genecards [Online]. Available: 
http://www.genecards.org/cgibin/carddisp.pl?gene=BIRC5&search=survivin. 
 
SW480 cell line [Online]. Available: 
http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452
/Default.aspx?ATCCNum=CCL-228&Template=cellBiology. 
 
TP53 gene, OMIM [Online]. Available: http://omim.org/entry/191170. 
 
TP53 mutations in CRC [Online]. Available: 
http://p53.iarc.fr/TP53SomaticMutations.aspx. 
 
VPA [Online]. Available: http://www.drugbank.ca/drugs/DB00313. 
 
WHO [Online]. Available: 
http://www.who.int/gho/ncd/mortality_morbidity/cancer_text/en/. 
181 | P a g e  
 
AGUIRRE, A., BARDEESY, SINHA, M., LOPEZ, L., TUVESON, D., HORNER, J., REDSTON, 
M. & DEPINHO, R. A. 2003. Activated Kras and Ink4a/Arf deficiency cooperate 
to produce metastatic pancreatic ductal adenocarcinoma. 
 
ALTIERI, D. C. 2003. Validating survivin as a cancer therapeutic target. 
 
ALTIERI, D. C. 2006. The case for survivin as a regulator of microtubule dynamics and 
cell-death decisions. 
 
AMARAVADI, R. K., YU, D., LUM, J. J., BUI, T., CHRISTOPHOROU, M. A., EVAN, G. I., 
THOMAS-TIKHONENKO, A. & THOMPSON, C. B. 2007. Autophagy inhibition 
enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. 
The Journal of Clinical Investigation, 117, 326-336. 
 
AN, W., KIM, J. & ROEDER, R. G. 2004. Ordered cooperative functions of PRMT1, 
p300, and CARM1 in transcriptional activation by p53. 
 
ARAÚJO, J. R., GONÇALVES, P. & MARTEL, F. 2011. Chemopreventive effect of 
dietary polyphenols in colorectal cancer cell lines. Nutrition Research, 31, 77-
87. 
 
ARD, P., CHATTERJEE, KUNJIBETTU, S., ADSIDE, L., GRALINSKI, L. & MCMAHON, S. B. 
2002. Transcriptional regulation of the mdm2 oncogene by p53 requires 
TRRAP acetyltransferase complexes. 
 
ARMAGHANY, T., WILSON, J. D., CHU, Q. & MILLS, G. 2012. Genetic alterations in 
colorectal cancer. Gastrointest Cancer Res, 5, 19-27. 
 
BACHER JW, FLANAGAN LA, SMALLEY RL, NASSIF NA, BURGART LJ, HALBERG RB, 
MEGID WM & SN, T. 2004. Development of a fluorescent multiplex assay for 
detection of MSI-High tumors. Disease Markers, 20, 237-250. 
 
BALASUBRAMANIAN, RAMOS, LUO, Z., SIRISAWAD, M., VERNER, E. & BUGGY, J. J. 
2008. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 
induces apoptosis in T-cell lymphomas. 
 
BALASUBRAMANIAN, S., VERNER, E. & BUGGY, J. J. 2009. Isoform-specific histone 
deacetylase inhibitors: the next step? Cancer Lett, 280, 211-21. 
 
BALLINGER, A. B. & ANGGIANSAH, C. 2007. Colorectal cancer. BMJ, 335, 715-8. 
 
BANDYOPADHYAY, D., MISHRA, A. & MEDRANO, E. E. 2004. Overexpression of 
histone deacetylase 1 confers resistance to sodium butyrate-mediated 
apoptosis in melanoma cells through a p53-mediated pathway. 
182 | P a g e  
 
BAYLIN, S. B., ESTELLER, M., ROUNTREE, M. R., BACHMAN, K. E., SCHUEBEL, K. & 
HERMAN, J. G. 2001. Aberrant patterns of DNA methylation, chromatin 
formation and gene expression in cancer. Hum Mol Genet, 10, 687-92. 
 
BAYLIN, S. B. & HERMAN, J. G. 2000. DNA hypermethylation in tumorigenesis: 
epigenetics joins genetics. Trends Genet, 16, 168-74. 
 
BECKERMAN, R. & PRIVES, C. 2010. Transcriptional regulation by p53. 
 
BERG, M., DANIELSEN, S. A., AHLQUIST, T., MEROK, M. A., ÅGESEN, T. H., VATN, M. 
H., MALA, T., SJO, O. H., BAKKA, A., MOBERG, I., FETVEIT, T., MATHISEN, Ø., 
HUSBY, A., SANDVIK, O., NESBAKKEN, A., THIIS-EVENSEN, E. & LOTHE, R. A. 
2010. DNA Sequence Profiles of the Colorectal Cancer Critical Gene Set KRAS-
BRAF-PIK3CA-PTEN-TP53 Related to Age at Disease Onset. PLoS ONE, 5, 
e13978. 
 
BERGAMASCHI D, SAMUELS Y, O'NEIL NJ, TRIGIANTE G, CROOK T, HSIEH JK, 
O'CONNOR DJ, ZHONG S, CAMPARGUE I, TOMLINSON ML, KUWABARA PE , LU 
X. 2003. iASPP oncoprotein is a key inhibitor of p53 conserved from worm to 
human. Nat Genet. Feb; 33(2):162-7. 
 
BERGAMASCHI, D., SAMUELS, Y., SULLIVAN, A., ZVELEBIL, M., BREYSSENS, H., BISSO, 
A., G, D. S., SYED, N., SMITH, P., GASCO, M., CROOK, T. & LU, X. 2006. iASPP 
preferentially binds p53 proline-rich region and modulates apoptotic function 
of codon 72-polymorphic p53. 
 
BERGER, S. L. 2002. Histone modifications in transcriptional regulation. 
 
BERRIGAN, D., PERKINS, S., HAINES, D. & HURSTING, S. D. 2002. Adult-onset calorie 
restriction and fasting delay spontaneous tumorigenesis in p53-deficient mice. 
 
BISHTON, M., KENEALY, M., JOHNSTONE, R., RASHEED, W. & PRINCE, H. M. 2007. 
Epigenetic targets in hematological malignancies: combination therapies with 
HDACis and demethylating agents. Expert Review of Anticancer Therapy, 7, 
1439-1449. 
 
BLONS, H. & LAURENT-PUIG, P. 2003. TP53 and head and neck neoplasms. 
 
BOLAND, C. R. & GOEL, A. 2010. Microsatellite instability in colorectal cancer. 
Gastroenterology, 138, 2073-2087 e3. 
 
BOLAND, C. R., SINICROPE, F. A., BRENNER, D. E. & CARETHERS, J. M. 2000. 
Colorectal cancer prevention and treatment. Gastroenterology, 118, S115-28. 
 
183 | P a g e  
 
BOLDEN, J. E., PEART, M. J. & JOHNSTONE, R. W. 2006. Anticancer activities of 
histone deacetylase inhibitors. Nat Rev Drug Discov, 5, 769-84. 
 
BOOTH, R. A. 2007. Minimally invasive biomarkers for detection and staging of 
colorectal cancer. Cancer Lett, 249, 87-96. 
BOTS, M. & JOHNSTONE, R. W. 2009. Rational combinations using HDAC inhibitors. 
 
BRAITHWAITE, A., ROYDS, J. & JACKSON, P. 2005. The p53 story: layers of 
complexity. 
 
BREEN, L., HEENAN, M., AMBERGER-MURPHY, V. & CLYNES, M. 2007. Investigation 
of the role of p53 in chemotherapy resistance of lung cancer cell lines. 
Anticancer Res, 27, 1361-4. 
 
BRUZZESE, F., ROCCO, M., CASTELLI, S., DI GENNARO, E., DESIDERI, A. & BUDILLON, 
A. 2009. Synergistic antitumor effect between vorinostat and topotecan in 
small cell lung cancer cells is mediated by generation of reactive oxygen 
species and DNA damage-induced apoptosis. 
 
BULL, A. D., BIFFIN, A. H., MELLA, J., RADCLIFFE, A. G., STAMATAKIS, J. D., STEELE, R. 
J. & WILLIAMS, G. T. 1997. Colorectal cancer pathology reporting: a regional 
audit. J Clin Pathol, 50, 138-42. 
 
BULLOCK, A. & FERSHT, A. R. 2001. Rescuing the function of mutant p53. 
 
BURT, R. W., BARTHEL, J. S., DUNN, K. B., DAVID, D. S., DRELICHMAN, E., FORD, J. M., 
GIARDIELLO, F. M., GRUBER, S. B., HALVERSON, A. L., HAMILTON, S. R., 
ISMAIL, M. K., JASPERSON, K., LAZENBY, A. J., LYNCH, P. M., MARTIN, E. W., 
JR., MAYER, R. J., NESS, R. M., PROVENZALE, D., RAO, M. S., SHIKE, M., 
STEINBACH, G., TERDIMAN, J. P. & WEINBERG, D. 2010. NCCN clinical practice 
guidelines in oncology. Colorectal cancer screening. J Natl Compr Canc Netw, 
8, 8-61. 
 
BUTLER, L., ZHOU, X., XU, W., SCHER, H., RIFKIND, R., MARKS, P. & RICHON, V. M. 
2002. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-
regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. 
 
CAI, S. R., ZHANG, S. Z., ZHU, H. H., HUANG, Y. Q., LI, Q. R., MA, X. Y., YAO, K. Y. & 
ZHENG, S. 2011. Performance of a colorectal cancer screening protocol in an 
economically and medically underserved population. Cancer Prev Res (Phila), 
4, 1572-9. 
 
184 | P a g e  
 
CALISTRI, D., RENGUCCI, C., BOCCHINI, R., SARAGONI, L., ZOLI, W. & AMADORI, D. 
2003. Fecal multiple molecular tests to detect colorectal cancer in stool. Clin 
Gastroenterol Hepatol, 1, 377-83. 
 
 
 
CHAPARRO, M., GISBERT, J. P., DEL CAMPO, L., CANTERO, J. & MATE, J. 2009. 
Accuracy of computed tomographic colonography for the detection of polyps 
and colorectal tumors: a systematic review and meta-analysis. Digestion, 80, 
1-17. 
 
CHEAH, P. Y. 2009. Recent advances in colorectal cancer genetics and diagnostics. 
Crit Rev Oncol Hematol, 69, 45-55. 
 
CHEN, C., WANG, Y., YANG, H., HUANG, P., KULP, S., YANG, C., LU, Y., MATSUYAMA, 
S., CHEN, C. & CHEN, C. S. 2007. Histone deacetylase inhibitors sensitize 
prostate cancer cells to agents that produce DNA double-strand breaks by 
targeting Ku70 acetylation. 
 
CHOI, KWON, H., YOON, B., KIM, J., HAN, S., JOO, H. & KIM, D. Y. 2001. Expression 
profile of histone deacetylase 1 in gastric cancer tissues. 
 
CHOU, T. C. 2006. Theoretical basis, experimental design, and computerized 
simulation of synergism and antagonism in drug combination studies. 
 
CHOU, T. C. 2010. Drug combination studies and their synergy quantification using 
the Chou-Talalay method. 
 
CIDON, E. U. 2010. The challenge of metastatic colorectal cancer. Clin Med Insights 
Oncol, 4, 55-60. 
 
CONDEELIS, J. & WEISSLEDER, R. 2010. In vivo imaging in cancer. 
COPPEDE, F. 2011. Epigenetic biomarkers of colorectal cancer: Focus on DNA 
methylation. Cancer Lett. 
 
COUTANDIN, D., LÖHR, F., NIESEN, F., IKEYA T, WEBER TA, SCHÄFER B, ZIELONKA 
EM, BULLOCK AN, YANG A, GÜNTERT P, KNAPP S, MCKEON F, OU HD & V., D. 
2009. Conformational stability and activity of p73 require a second helix in the 
tetramerization domain. 
 
CREA, F., NOBILI, S., PAOLICCHI, E., PERRONE, G., NAPOLI, C., LANDINI, I., DANESI, R. 
& MINI, E. 2011. Epigenetics and chemoresistance in colorectal cancer: An 
opportunity for treatment tailoring and novel therapeutic strategies. Drug 
Resistance Updates, 14, 280-296. 
185 | P a g e  
 
 
CUNNINGHAM, D., ATKIN, W., LENZ, H. J., LYNCH, H. T., MINSKY, B., NORDLINGER, B. 
& STARLING, N. 2010. Colorectal cancer. Lancet, 375, 1030-47. 
 
 
DAI, Y., RAHMANI, M., DENT, P. & GRANT, S. 2005. Blockade of histone deacetylase 
inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates 
apoptosis in leukemia cells through a process mediated by oxidative damage, 
XIAP downregulation, and c-Jun N-terminal kinase 1 activation. 
 
DAVIE, J. R. 2003. Inhibition of histone deacetylase activity by butyrate. J Nutr, 133, 
2485S-2493S. 
 
DE CAMPOS, F. G. C. M., DE FREITAS, I. N., ROCCO IMPERIALE, A., EDMOND SEID, V., 
OLIVA PEREZ, R., CARLOS NAHAS, S. & CECCONELLO, I. 2010. Colorectal cancer 
in familial adenomatous polyposis: Are there clinical predictive factors? 
Cirugía Española (English Edition), 88, 390-397. 
 
DE KOK, T. M. C. M. & VAN MAANEN, J. M. S. 2000. Evaluation of fecal mutagenicity 
and colorectal cancer risk. Mutation Research/Reviews in Mutation Research, 
463, 53-101. 
 
DENNIS, R., TOU, S. & MILLER, R. 2011. Colorectal cancer: prevention and early 
diagnosis. Medicine, 39, 243-249. 
 
DEVERAUX, Q. & REED, J. C. 1999. IAP family proteins--suppressors of apoptosis. 
DI STEFANO, A., IOVINO, F., LOMBARDO, Y., ETERNO, V., HOGER, T., DIELI, F., STASSI, 
G. & TODARO, M. 2010. Survivin is regulated by interleukin-4 in colon cancer 
stem cells. 
 
DICKSON, B. C. 2012. Li–Fraumeni syndrome: a role for surgical pathologists? 
Diagnostic Histopathology, 18, 177-184. 
 
DIETRICH, C. G., VEHR, A. K., MARTIN, I. V., GASSLER, N., RATH, T., ROEB, E., 
SCHMITT, J., TRAUTWEIN, C. & GEIER, A. 2011. Downregulation of breast 
cancer resistance protein in colon adenomas reduces cellular xenobiotic 
resistance and leads to accumulation of a food-derived carcinogen. Int J 
Cancer, 129, 546-52. 
 
DOKMANOVIC, M. & MARKS, P. A. 2005a. Prospects: histone deacetylase inhibitors. 
J Cell Biochem, 96, 293-304. 
 
DOKMANOVIC, M. & MARKS, P. A. 2005b. Prospects: histone deacetylase inhibitors. 
186 | P a g e  
 
DORNAN, D., SHIMIZU, H., BURCH, L., SMITH, A. & HUPP, T. R. 2003. The proline 
repeat domain of p53 binds directly to the transcriptional coactivator p300 
and allosterically controls DNA-dependent acetylation of p53. 
 
DÖTSCH V, BERNASSOLA F, COUTANDIN D, CANDI E & G., M. 2010. p63 and p73, the 
ancestors of p53. 
DUMAZ, N., MILNE, D., JARDINE, L. & MEEK, D. W. 2001. Critical roles for the serine 
20, but not the serine 15, phosphorylation site and for the polyproline domain 
in regulating p53 turnover. 
 
EFEYAN, A. & SERRANO, M. 2007. p53: guardian of the genome and policeman of 
the oncogenes. 
 
EHRLICH, M. 2002. DNA methylation in cancer: too much, but also too little. 
 
EINSPAHR JG, MARTINEZ ME, JIANG R, HSU CH, RASHID A, BHATTACHARRYA AK, 
AHNEN DJ, JACOBS ET, HOULIHAN PS, WEBB CR, ALBERTS DS & SR., H. 2006. 
Associations of Ki-ras proto-oncogene mutation and p53 gene overexpression 
in sporadic colorectal adenomas with demographic and clinicopathologic 
characteristics. 
 
ESPINOSA, J. & EMERSON, B. M. 2001. Transcriptional regulation by p53 through 
intrinsic DNA/chromatin binding and site-directed cofactor recruitment. 
 
ESPINOSA, J. M. 2008. Mechanisms of regulatory diversity within the p53 
transcriptional network. 
 
FANTIN, V. & RICHON, V. M. 2007. Mechanisms of resistance to histone deacetylase 
inhibitors and their therapeutic implications. 
 
FARRIS, A. B., MISDRAJI, J., SRIVASTAVA, A., MUZIKANSKY, A., DESHPANDE, V., 
LAUWERS, G. Y. & MINO-KENUDSON, M. 2008. Sessile Serrated Adenoma: 
Challenging Discrimination From Other Serrated Colonic Polyps. The American 
Journal of Surgical Pathology, 32, 30-35 10.1097/PAS.0b013e318093e40a. 
 
FEARON, E. R. & VOGELSTEIN, B. 1990. A genetic model for colorectal tumorigenesis. 
Cell, 61, 759-67. 
 
FENG Z, HU W, DE STANCHINA E, TERESKY AK, JIN S, LOWE S & AJ., L. 2007. The 
regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and 
tissue specificity, and the role of these gene products in modulating the IGF-1-
AKT-mTOR pathways. 
 
187 | P a g e  
 
FINCH, R., DONOVIEL, D., POTTER, D., SHI, M., FAN, A., FREED, D., WANG, C., 
ZAMBROWICZ, B., RAMIREZ-SOLIS, R., SANDS, A. & ZHANG, N. 2002. mdmx is 
a negative regulator of p53 activity in vivo. 
 
FINLAN, L. & HUPP, T. R. 2004. The N-terminal interferon-binding domain (IBiD) 
homology domain of p300 binds to peptides with homology to the p53 
transactivation domain. 
FINLAN, L. & HUPP, T. R. 2007. p63: the phantom of the tumor suppressor. 
 
FLANAGAN, F. L., DEHDASHTI, F., OGUNBIYI, O. A., KODNER, I. J. & SIEGEL, B. A. 
1998. Utility of FDG-PET for investigating unexplained plasma CEA elevation in 
patients with colorectal cancer. Ann Surg, 227, 319-23. 
 
FRAGA, M., BALLESTAR, E., VILLAR-GAREA, A., BOIX-CHORNET, M., ESPADA, J., 
SCHOTTA, G., BONALDI, T., HAYDON, C., ROPERO, S., PETRIE, K., IYER, N., 
PEREZ-ROSADO, A., CALVO, E., LOPEZ, J., CANO, A., CALASANZ, M., COLOMER, 
D., PIRIS, M., AHN, N., IMHOF, A., CALDAS, C., JENUWEIN, T. & ESTELLER, M. 
2005. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is 
a common hallmark of human cancer. 
 
FREW, A. J., JOHNSTONE, R. W. & BOLDEN, J. E. 2009. Enhancing the apoptotic and 
therapeutic effects of HDAC inhibitors. Cancer Lett, 280, 125-33. 
 
FRIEDBERG, E. C. 2001. How nucleotide excision repair protects against cancer. 
 
FRITSCHE, P., SEIDLER, B., SCHULER, S., SCHNIEKE, A., GOTTLICHER, M., SCHMID, R., 
SAUR, D. & SCHNEIDER, G. 2009. HDAC2 mediates therapeutic resistance of 
pancreatic cancer cells via the BH3-only protein NOXA. 
 
GARTEL, A. L. 2005. The conflicting roles of the cdk inhibitor p21(CIP1/WAF1) in 
apoptosis. Leuk Res, 29, 1237-8. 
 
GINSBURG, O., AKBARI, M., AZIZ, Z., YOUNG, R., LYNCH, H., GHADIRIAN, P., 
ROBIDOUX, A., LONDONO, J., VASQUEZ, G., GOMES, M., COSTA, M., 
DIMITRAKAKIS, C., GUTIERREZ, G., PILARSKI, R., ROYER, R. & NAROD, S. A. 
2009. The prevalence of germ-line TP53 mutations in women diagnosed with 
breast cancer before age 30. 
 
GORE, S. D., BAYLIN, S., SUGAR, E., CARRAWAY, H., MILLER, C. B., CARDUCCI, M., 
GREVER, M., GALM, O., DAUSES, T., KARP, J. E., RUDEK, M. A., ZHAO, M., 
SMITH, B. D., MANNING, J., JIEMJIT, A., DOVER, G., MAYS, A., ZWIEBEL, J., 
MURGO, A., WENG, L.-J. & HERMAN, J. G. 2006. Combined DNA 
Methyltransferase and Histone Deacetylase Inhibition in the Treatment of 
Myeloid Neoplasms. Cancer Research, 66, 6361-6369. 
188 | P a g e  
 
 
GRADY, W. M. 2004. Genomic instability and colon cancer. Cancer Metastasis Rev, 
23, 11-27. 
 
 
 
GREEN, C. & ALMOUZNI, G. 2002. When repair meets chromatin. First in series on 
chromatin dynamics. 
 
GU, B. & ZHU, W. G. 2012. Surf the post-translational modification network of p53 
regulation. 
 
HAJJI, N., WALLENBORG, K., VLACHOS, P., FULLGRABE, J., HERMANSON, O. & 
JOSEPH, B. 2010. Opposing effects of hMOF and SIRT1 on H4K16 acetylation 
and the sensitivity to the topoisomerase II inhibitor etoposide. Oncogene, 29, 
2192-204. 
 
HALKIDOU, K., GAUGHAN, L., COOK, S., LEUNG, H., NEAL, D. & ROBSON, C. N. 2004. 
Upregulation and nuclear recruitment of HDAC1 in hormone refractory 
prostate cancer. 
 
HALL, N. 2011. Colorectal cancer: features and investigation. Medicine, 39, 250-253. 
 
HANIGAN, C. L., VAN ENGELAND, M., DE BRUINE, A. P., WOUTERS, K. A., 
WEIJENBERG, M. P., ESHLEMAN, J. R. & HERMAN, J. G. 2008. An inactivating 
mutation in HDAC2 leads to dysregulation of apoptosis mediated by APAF1. 
Gastroenterology, 135, 1654-1664 e2. 
 
HARRISON, S. & BENZIGER, H. 2011. The molecular biology of colorectal carcinoma 
and its implications: a review. Surgeon, 9, 200-10. 
 
HARVEY, N. & RUSZKIEWICZ, A. 2007. Serrated neoplasia of the colorectum. 
 
HAUG, U., HUNDT, S. & BRENNER, H. 2008. Sensitivity and specificity of faecal 
tumour M2 pyruvate kinase for detection of colorectal adenomas in a large 
screening study. Br J Cancer, 99, 133-5. 
 
HAYAKAWA, T. & NAKAYAMA, J. 2011. Physiological roles of class I HDAC complex 
and histone demethylase. 
 
HIGUCHI, T., SUGIHARA, K. & JASS, J. R. 2005. Demographic and pathological 
characteristics of serrated polyps of colorectum. Histopathology, 47, 32-40. 
 
189 | P a g e  
 
HO, W., FITZGERALD, M. & MARMORSTEIN, R. 2006. Structure of the p53 core 
domain dimer bound to DNA. 
 
HOELLER, D., HECKER, C.-M. & DIKIC, I. 2006. Ubiquitin and ubiquitin-like proteins in 
cancer pathogenesis. Nat Rev Cancer, 6, 776-788. 
 
HOFFMAN, W., BIADE, S., ZILFOU, J., CHEN, J. & MURPHY, M. 2002a. Transcriptional 
repression of the anti-apoptotic survivin gene by wild type p53. 
 
HOFFMAN, W. H., BIADE, S., ZILFOU, J. T., CHEN, J. & MURPHY, M. 2002b. 
Transcriptional Repression of the Anti-apoptoticsurvivin Gene by Wild Type 
p53. Journal of Biological Chemistry, 277, 3247-3257. 
 
IACOPETTA, B. 2003. TP53 mutation in colorectal cancer. 
 
IACOPETTA, B., RUSSO, A., BAZAN, V., DARDANONI, G., GEBBIA, N., SOUSSI, T., KERR, 
D., ELSALEH, H., SOONG, R., KANDIOLER, D., JANSCHEK, E., KAPPEL, S., LUNG, 
M., LEUNG, C. S., KO, J. M., YUEN, S., HO, J., LEUNG, S. Y., CRAPEZ, E., 
DUFFOUR, J., YCHOU, M., LEAHY, D. T., O'DONOGHUE, D. P., AGNESE, V., 
CASCIO, S., DI FEDE, G., CHIECO-BIANCHI, L., BERTORELLE, R., BELLUCO, C., 
GIARETTI, W., CASTAGNOLA, P., RICEVUTO, E., FICORELLA, C., BOSARI, S., 
ARIZZI, C. D., MIYAKI, M., ONDA, M., KAMPMAN, E., DIERGAARDE, B., ROYDS, 
J., LOTHE, R. A., DIEP, C. B., MELING, G. I., OSTROWSKI, J., TRZECIAK, L., 
GUZINSKA-USTYMOWICZ, K., ZALEWSKI, B., CAPELLA, G. M., MORENO, V., 
PEINADO, M. A., LONNROTH, C., LUNDHOLM, K., SUN, X. F., JANSSON, A., 
BOUZOURENE, H., HSIEH, L. L., TANG, R., SMITH, D. R., ALLEN-MERSH, T. G., 
KHAN, Z. A., SHORTHOUSE, A. J., SILVERMAN, M. L., KATO, S. & ISHIOKA, C. 
2006. Functional categories of TP53 mutation in colorectal cancer: results of 
an International Collaborative Study. Ann Oncol, 17, 842-7. 
 
IMAI, K. & YAMAMOTO, H. 2008a. Carcinogenesis and microsatellite instability: the 
interrelationship between genetics and epigenetics. Carcinogenesis, 29, 673-
80. 
 
IMAI, K. & YAMAMOTO, H. 2008b. Carcinogenesis and microsatellite instability: the 
interrelationship between genetics and epigenetics. 
 
IMHOF, A. 2006. Epigenetic regulators and histone modification. Brief Funct 
Genomic Proteomic, 5, 222-7. 
 
ISSA, J. P. 2008. Colon cancer: it's CIN or CIMP. Clin Cancer Res, 14, 5939-40. 
 
190 | P a g e  
 
ITO, A., KAWAGUCHI, Y., LAI, C., KOVACS, J., HIGASHIMOTO, Y., APPELLA, E. & YAO, 
T. P. 2002. MDM2-HDAC1-mediated deacetylation of p53 is required for its 
degradation. 
 
IWABUCHI, K., BARTEL, P., LI, B., MARRACCINO, R. & FIELDS, S. 1994. Two cellular 
proteins that bind to wild-type but not mutant p53. 
 
IWAKUMA, T. & LOZANO, G. 2003. MDM2, an introduction. 
JAIN, S. & ZAIN, J. 2011. Romidepsin in the treatment of cutaneous T-cell lymphoma. 
J Blood Med, 2, 37-47. 
 
JASS, J. R. 2007. Classification of colorectal cancer based on correlation of clinical, 
morphological and molecular features. Histopathology, 50, 113-30. 
 
JENSEN, M., JORGENSEN, J., BINDERUP, T. & KJAER, A. 2008. Tumor volume in 
subcutaneous mouse xenografts measured by microCT is more accurate and 
reproducible than determined by 18F-FDG-microPET or external caliper. 
 
JENUWEIN, T. 2006. The epigenetic magic of histone lysine methylation. FEBS J, 273, 
3121-35. 
 
JIN, S. & LEVINE, A. J. 2001. The p53 functional circuit. 
 
JIN, Y., DAI, M.-S., LU, S. Z., XU, Y., LUO, Z., ZHAO, Y. & LU, H. 2006. 14-3-3[gamma] 
binds to MDMX that is phosphorylated by UV-activated Chk1, resulting in p53 
activation. EMBO J, 25, 1207-1218. 
 
JOERGER, A. & FERSHT, A. R. 2010. The tumor suppressor p53: from structures to 
drug discovery. 
 
JOERGER, A., RAJAGOPALAN, S., NATAN, E., VEPRINTSEV, D., ROBINSON, C. & 
FERSHT, A. 2009. Structural evolution of p53, p63, and p73: implication for 
heterotetramer formation. 
 
JONES, P. A. & BAYLIN, S. B. 2007. The epigenomics of cancer. Cell, 128, 683-92. 
 
JU, R. & MULLER, M. T. 2003. Histone deacetylase inhibitors activate p21(WAF1) 
expression via ATM. 
 
KANEDA, A., WANG, C., CHEONG, R., TIMP, W., ONYANGO, P., WEN, B., IACOBUZIO-
DONAHUE, C., OHLSSON, R., ANDRAOS, R., PEARSON, M., SHAROV, A., 
LONGO, D., KO, M., LEVCHENKO, A. & FEINBERG, A. P. 2007. Enhanced 
sensitivity to IGF-II signaling links loss of imprinting of IGF2 to increased cell 
proliferation and tumor risk. 
191 | P a g e  
 
 
KANWAR, J., KAMALAPURAM, S. & KANWAR, R. K. 2010. Targeting survivin in cancer: 
patent review. 
 
KENNEDY, S., O'DRISCOLL, L., PURCELL, R., FITZ-SIMONS, N., MCDERMOTT, E., HILL, 
A., O'HIGGINS, N., PARKINSON, M., LINEHAN, R. & CLYNES, M. 2003. 
Prognostic importance of survivin in breast cancer. 
KENNELL, J. & CADIGAN, K. M. 2009. APC and beta-catenin degradation. Adv Exp 
Med Biol, 656, 1-12. 
 
KERN, A., TAUBERT, H., SCHEELE, J., RUDROFF, C., MOTHES, H., KAPPLER, M., 
BARTEL, F. & RICHTER, K. K. 2002. Association of p53 mutations, microvessel 
density and neoangiogenesis in pairs of colorectal cancers and corresponding 
liver metastases. Int J Oncol, 21, 243-9. 
 
KEYES, W., WU, Y., VOGEL, H., GUO, X., LOWE, S. & MILLS, A. A. 2005. p63 deficiency 
activates a program of cellular senescence and leads to accelerated aging. 
 
KIM, C., KIM, S., CHUN, H., LEE, W., YUN, S., SONG, S., CHOI, D., LIM, H., KIM, M., 
LEE, J. & LEE, S. J. 2006. Preoperative staging of rectal cancer: accuracy of 3-
Tesla magnetic resonance imaging. 
 
KIM, J., CHOI, J., ROH, S., CHO, D., KIM, T. & KIM, Y. S. 2010. Promoter methylation 
of specific genes is associated with the phenotype and progression of 
colorectal adenocarcinomas. 
 
KIM, P., PLESCIA, J., CLEVERS, H., FEARON, E. & ALTIERI, D. C. 2003. Survivin and 
molecular pathogenesis of colorectal cancer. 
 
KNAUER, S., BIER, C., SCHLAG, P., FRITZMANN, J., DIETMAIER, W., RODEL, F., KLEIN-
HITPASS, L., KOVACS, A., DORING, C., HANSMANN, M., HOFMANN, W., 
KUNKEL, M., BROCHHAUSEN, C., ENGELS, K., LIPPERT, B., MANN, W. & 
STAUBER, R. H. 2007. The survivin isoform survivin-3B is cytoprotective and 
can function as a chromosomal passenger complex protein. 
 
KONDO, Y. & KONDO, S. 2006. Autophagy and cancer therapy. Autophagy, 2, 85-90. 
 
KONDO, Y., SHEN, L., CHENG, A. S., AHMED, S., BOUMBER, Y., CHARO, C., YAMOCHI, 
T., URANO, T., FURUKAWA, K., KWABI-ADDO, B., GOLD, D. L., SEKIDO, Y., 
HUANG, T. H.-M. & ISSA, J.-P. J. 2008. Gene silencing in cancer by histone H3 
lysine 27 trimethylation independent of promoter DNA methylation. Nat 
Genet, 40, 741-750. 
 
192 | P a g e  
 
KOUZARIDES, T. 2007. Chromatin Modifications and Their Function. Cell, 128, 693-
705. 
 
LABIANCA, R., BERETTA, G. D., KILDANI, B., MILESI, L., MERLIN, F., MOSCONI, S., 
PESSI, M. A., PROCHILO, T., QUADRI, A., GATTA, G., DE BRAUD, F. & WILS, J. 
2010. Colon cancer. Crit Rev Oncol Hematol, 74, 106-33. 
 
LAMBERT, P., KASHANCHI, F., RADONOVICH, M., SHIEKHATTAR, R. & BRADY, J. N. 
1998. Phosphorylation of p53 serine 15 increases interaction with CBP. 
 
LANE, D. P. & CRAWFORD, L. V. 1979. T antigen is bound to a host protein in SY40-
transformed cells. Nature, 278, 261-263. 
 
LEGGETT, B. & WHITEHALL, V. 2010. Role of the Serrated Pathway in Colorectal 
Cancer Pathogenesis. Gastroenterology, 138, 2088-2100. 
 
LI, F., AMBROSINI, G., CHU, E., PLESCIA, J., TOGNIN, S., MARCHISIO, P. & ALTIERI, D. 
C. 1998 Control of apoptosis and mitotic spindle checkpoint by survivin. 
 
LI, R., LIU, J., XUE, H. & HUANG, G. 2012. Diagnostic value of fecal tumor M2-
pyruvate kinase for CRC screening: A systematic review and meta-analysis. Int 
J Cancer. 
 
LI, Y.-C., KOROL, A. B., FAHIMA, T. & NEVO, E. 2004. Microsatellites Within Genes: 
Structure, Function, and Evolution. Molecular Biology and Evolution, 21, 991-
1007. 
 
LINDHOLM, E., BREVINGE, H. & HAGLIND, E. 2008. Survival benefit in a randomized 
clinical trial of faecal occult blood screening for colorectal cancer. Br J Surg, 
95, 1029-36. 
 
LISTON, P., FONG, W. & KORNELUK, R. G. 2003. The inhibitors of apoptosis: there is 
more to life than Bcl2. 
 
LIU, Y. & BODMER, W. F. 2006. Analysis of P53 mutations and their expression in 56 
colorectal cancer cell lines. Proceedings of the National Academy of Sciences 
of the United States of America, 103, 976-981. 
 
LJUNGMAN, M. & HANAWALT, P. C. 1992. Efficient protection against oxidative DNA 
damage in chromatin. Molecular Carcinogenesis, 5, 264-269. 
 
LOGAN, R. F., PATNICK, J., NICKERSON, C., COLEMAN, L., RUTTER, M. D. & VON 
WAGNER, C. 2011. Outcomes of the Bowel Cancer Screening Programme 
(BCSP) in England after the first 1 million tests. Gut. 
193 | P a g e  
 
 
LU, W., AMATRUDA JF & JM., A. 2009. p53 ancestry: gazing through an evolutionary 
lens. 
 
LUBIN, D. J., BUTLER, J. S. & LOH, S. N. 2010. Folding of Tetrameric p53: 
Oligomerization and Tumorigenic Mutations Induce Misfolding and Loss of 
Function. Journal of Molecular Biology, 395, 705-716. 
LUCIDARME, O., CADI, M., BERGER, G., TAIEB, J., POYNARD, T., GRENIER, P. & 
BERESNIAK, A. 2012. Cost-effectiveness modeling of colorectal cancer: 
Computed tomography colonography vs colonoscopy or fecal occult blood 
tests. European Journal of Radiology, 81, 1413-1419. 
 
LUCIO-ETEROVIC, A., CORTEZ, M., VALERA, E., MOTTA, F., QUEIROZ, R., MACHADO, 
H., CARLOTTI CG, J., NEDER, L., SCRIDELI, C. & TONE, L. G. 2008. Differential 
expression of 12 histone deacetylase (HDAC) genes in astrocytomas and 
normal brain tissue: class II and IV are hypoexpressed in glioblastomas. 
 
LYONS, S. K. 2005. Advances in imaging mouse tumour models in vivo. 
 
MA, H., NGUYEN, C., LEE, K. & KAHN, M. 2005. Differential roles for the coactivators 
CBP and p300 on TCF/beta-catenin-mediated survivin gene expression. 
 
MA, J. 2005. Crossing the line between activation and repression. Trends Genet, 21, 
54-59. 
 
MAI A, MASSA S, ROTILI D, CERBARA I, VALENTE S, PEZZI R, SIMEONI S & R., R. 2005. 
Histone deacetylation in epigenetics: an attractive target for anticancer 
therapy. 
 
MAISO P, CARVAJAL-VERGARA X, OCIO EM, LÓPEZ-PÉREZ R, MATEO G, GUTIÉRREZ 
N, ATADJA P, PANDIELLA A & JF., S. M. 2006. The histone deacetylase inhibitor 
LBH589 is a potent antimyeloma agent that overcomes drug resistance. 
 
MALKIN D, LI FP, STRONG LC, FRAUMENI JF JR, NELSON CE, KIM DH, KASSEL J, GRYKA 
MA, BISCHOFF FZ & TAINSKY MA, E. A. 1990. Germ line p53 mutations in a 
familial syndrome of breast cancer, sarcomas, and other neoplasms. 
 
MANTOVANI F, TOCCO F, GIRARDINI J, SMITH P, GASCO M, LU X, CROOK T & G., D. S. 
2007. The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation 
from the apoptosis inhibitor iASPP. 
 
MARINE JC, FRANCOZ S, MAETENS M, WAHL G, TOLEDO F & G., L. 2006. Keeping p53 
in check: essential and synergistic functions of Mdm2 and Mdm4. 
 
194 | P a g e  
 
MARKS, P. A. 2010. Histone deacetylase inhibitors: a chemical genetics approach to 
understanding cellular functions. 
 
MARKS, P. A., RICHON, V. M. & RIFKIND, R. A. 2000. Histone deacetylase inhibitors: 
inducers of differentiation or apoptosis of transformed cells. J Natl Cancer 
Inst, 92, 1210-6. 
MAYO MW, DENLINGER CE, BROAD RM, YEUNG F, REILLY ET, SHI Y & DR., J. 2003. 
Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves 
the transcriptional activation of NF-kappa B through the Akt pathway. 
 
MEEK, D. & ANDERSON, C. W. 2009. Posttranslational modification of p53: 
cooperative integrators of function. 
 
MELINO G, BERNASSOLA F, RANALLI M, YEE K, ZONG WX, CORAZZARI M, KNIGHT RA, 
GREEN DR, THOMPSON C & KH., V. 2004. p73 Induces apoptosis via PUMA 
transactivation and Bax mitochondrial translocation. 
 
MEYERHARDT, J. A. & MAYER, R. J. 2005. Systemic therapy for colorectal cancer. N 
Engl J Med, 352, 476-87. 
 
MILLER, C. P., SINGH, M. M., RIVERA-DEL VALLE, N., MANTON, C. A. & CHANDRA, J. 
2011. Therapeutic strategies to enhance the anticancer efficacy of histone 
deacetylase inhibitors. J Biomed Biotechnol, 2011, 514261. 
 
MILLER, L. D., SMEDS, J., GEORGE, J., VEGA, V. B., VERGARA, L., PLONER, A., 
PAWITAN, Y., HALL, P., KLAAR, S., LIU, E. T. & BERGH, J. 2005. An expression 
signature for p53 status in human breast cancer predicts mutation status, 
transcriptional effects, and patient survival. Proceedings of the National 
Academy of Sciences of the United States of America, 102, 13550-13555. 
 
MILLER, T. A., WITTER, D. J. & BELVEDERE, S. 2003. Histone Deacetylase Inhibitors. 
Journal of Medicinal Chemistry, 46, 5097-5116. 
 
MINUCCI, S. & PELICCI, P. G. 2006. Histone deacetylase inhibitors and the promise of 
epigenetic (and more) treatments for cancer. Nat Rev Cancer, 6, 38-51. 
 
MIRZA, A., MCGUIRK, M., HOCKENBERRY, T. N., WU, Q., ASHAR, H., BLACK, S., WEN, 
S. F., WANG, L., KIRSCHMEIER, P., BISHOP, W. R., NIELSEN, L. L., PICKETT, C. B. 
& LIU, S. 2002. Human survivin is negatively regulated by wild-type p53 and 
participates in p53-dependent apoptotic pathway. Oncogene, 21, 2613-2622. 
 
MOGI, A. & KUWANO, H. 2011. TP53 mutations in nonsmall cell lung cancer. 
 
195 | P a g e  
 
MOLL, U. & SLADE, N. 2004. p63 and p73: roles in development and tumor 
formation. 
 
MOMAND, J., ZAMBETTI, G., OLSON, D., GEORGE, D. & LEVINE, A. J. 1992. The mdm-
2 oncogene product forms a complex with the p53 protein and inhibits p53-
mediated transactivation. 
MORAN, A., ORTEGA, P., DE JUAN, C., FERNANDEZ-MARCELO, T., FRIAS, C., 
SANCHEZ-PERNAUTE, A., TORRES, A. J., DIAZ-RUBIO, E., INIESTA, P. & BENITO, 
M. 2010. Differential colorectal carcinogenesis: Molecular basis and clinical 
relevance. World J Gastrointest Oncol, 2, 151-8. 
 
MORROW CS, NAKAGAWA M, GOLDSMITH ME, MADDEN MJ & KH., C. 1994. 
Reversible transcriptional activation of mdr1 by sodium butyrate treatment of 
human colon cancer cells. 
 
NACCARATI, A., PARDINI, B., HEMMINKI, K. & VODICKA, P. 2007. Sporadic colorectal 
cancer and individual susceptibility: a review of the association studies 
investigating the role of DNA repair genetic polymorphisms. Mutat Res, 635, 
118-45. 
 
NACHMIAS B, ASHHAB Y & D., B.-Y. 2004. The inhibitor of apoptosis protein family 
(IAPs): an emerging therapeutic target in cancer. 
 
NASIF WA, LOTFY M, EL-SAYED IH, EL-KENAWY AEL-M, EL-SHAHAT M & NG., E.-H. 
2006. Implications of CEA and p53 overexpression in the poor prognosis of 
colorectal cancer. 
 
NAUMOVSKI, L. & CLEARY, M. L. 1996. The p53-binding protein 53BP2 also interacts 
with Bc12 and impedes cell cycle progression at G2/M. 
 
NEW, M., OLZSCHA, H. & LA THANGUE, N. B. 2012. HDAC inhibitor-based therapies: 
Can we interpret the code? Molecular Oncology, 6, 637-656. 
 
NIEKEL, M., BIPAT, S. & STOKER, J. 2010. Diagnostic imaging of colorectal liver 
metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-
analysis of prospective studies including patients who have not previously 
undergone treatment. 
 
NOFFSINGER, A. E. 2009. Serrated polyps and colorectal cancer: new pathway to 
malignancy. Annu Rev Pathol, 4, 343-64. 
 
NOH, J. H., JUNG, K. H., KIM, J. K., EUN, J. W., BAE, H. J., XIE, H. J., CHANG, Y. G., KIM, 
M. G., PARK, W. S., LEE, J. Y. & NAM, S. W. 2011. Aberrant Regulation of 
196 | P a g e  
 
HDAC2 Mediates Proliferation of Hepatocellular Carcinoma Cells by 
Deregulating Expression of G1/S Cell Cycle Proteins. PLoS ONE, 6, e28103. 
 
NOLAN L, JOHNSON PW, GANESAN A, PACKHAM G & SJ., C. 2008. Will histone 
deacetylase inhibitors require combination with other agents to fulfil their 
therapeutic potential? 
NOTARI M, HU Y, KOCH S, LU M, RATNAYAKA I, ZHONG S, BAER C, PAGOTTO A, 
GOLDIN R, SALTER V, CANDI E, MELINO G & X., L. 2011. Inhibitor of apoptosis-
stimulating protein of p53 (iASPP) prevents senescence and is required for 
epithelial stratification. 
 
NOWAK, S. J. & CORCES, V. G. 2004. Phosphorylation of histone H3: a balancing act 
between chromosome condensation and transcriptional activation. Trends 
Genet, 20, 214-20. 
 
O'BRIEN, M., YANG, S., MACK, C., XU, H., HUANG, C., MULCAHY, E., AMOROSINO, M. 
& FARRAYE, F. A. 2006. Comparison of microsatellite instability, CpG island 
methylation phenotype, BRAF and KRAS status in serrated polyps and 
traditional adenomas indicates separate pathways to distinct colorectal 
carcinoma end points. 
 
OCKER, M. & SCHNEIDER-STOCK, R. 2007. Histone deacetylase inhibitors: Signalling 
towards p21cip1/waf1. The International Journal of Biochemistry &amp; Cell 
Biology, 39, 1367-1374. 
 
OLIVIER M, HOLLSTEIN M & P., H. 2010. TP53 mutations in human cancers: origins, 
consequences, and clinical use. 
 
OREN, M. 2003. Decision making by p53: life, death and cancer. 
 
OREN, M. & ROTTER, V. 2010. Mutant p53 gain-of-function in cancer. 
 
OTA, T., SUTO, S., KATAYAMA, H., HAN, Z. B., SUZUKI, F., MAEDA, M., TANINO, M., 
TERADA, Y. & TATSUKA, M. 2002. Increased mitotic phosphorylation of 
histone H3 attributable to AIM-1/Aurora-B overexpression contributes to 
chromosome number instability. Cancer Res, 62, 5168-77. 
 
PARK, S. J., RASHID, A., LEE, J. H., KIM, S. G., HAMILTON, S. R. & WU, T. T. 2003. 
Frequent CpG island methylation in serrated adenomas of the colorectum. Am 
J Pathol, 162, 815-22. 
 
PATEL S, GEORGE R, AUTORE F, FRATERNALI F, LADBURY JE & PV., N. 2008. 
Molecular interactions of ASPP1 and ASPP2 with the p53 protein family and 
the apoptotic promoters PUMA and Bax. 
197 | P a g e  
 
 
PATEL, S. S., FLOYD, A., DOORLY, M. G., ORTEGA, A. E., AULT, G. T., KAISER, A. M. & 
SENAGORE, A. J. 2012. Current controversies in the management of colon 
cancer. Curr Probl Surg, 49, 398-460. 
PEART MJ, TAINTON KM, RUEFLI AA, DEAR AE, SEDELIES KA, O'REILLY LA, 
WATERHOUSE NJ, TRAPANI JA & RW., J. 2003. Novel mechanisms of apoptosis 
induced by histone deacetylase inhibitors. 
 
PELLER, S. & ROTTER, V. 2003. TP53 in hematological cancer: low incidence of 
mutations with significant clinical relevance. 
 
PESERICO, A. & SIMONE, C. 2011. Physical and functional HAT/HDAC interplay 
regulates protein acetylation balance. 
 
PHELPS, R. A., CHIDESTER, S., DEHGHANIZADEH, S., PHELPS, J., SANDOVAL, I. T., RAI, 
K., BROADBENT, T., SARKAR, S., BURT, R. W. & JONES, D. A. 2009. A two-step 
model for colon adenoma initiation and progression caused by APC loss. Cell, 
137, 623-34. 
 
PIERCE, B. A. 2011. Genetics: A Conceptual Approach, W H Freeman & Company. 
 
PONZ DE LEON, M. & RONCUCCI, L. 2000. The cause of colorectal cancer. Digestive 
and Liver Disease, 32, 426-439. 
 
POULOGIANNIS, G., FRAYLING, I. M. & ARENDS, M. J. 2010. DNA mismatch repair 
deficiency in sporadic colorectal cancer and Lynch syndrome. Histopathology, 
56, 167-79. 
 
POWIS, G. & KIRKPATRICK, D. L. 2007. Thioredoxin signaling as a target for cancer 
therapy. 
 
PRABHUDESAI, S. G., REKHRAJ, S., ROBERTS, G., DARZI, A. W. & ZIPRIN, P. 2007. 
Apoptosis and chemo-resistance in colorectal cancer. Journal of Surgical 
Oncology, 96, 77-88. 
 
PRITCHARD, C. C. & GRADY, W. M. 2011. Colorectal cancer molecular biology moves 
into clinical practice. Gut, 60, 116-29. 
 
PRUITT K, ZINN RL, OHM JE, MCGARVEY KM, KANG SH, WATKINS DN, HERMAN JG & 
SB., B. 2006. Inhibition of SIRT1 reactivates silenced cancer genes without loss 
of promoter DNA hypermethylation. 
 
198 | P a g e  
 
RABENECK L, PASZAT LF, HILSDEN RJ, SASKIN R, LEDDIN D, GRUNFELD E, WAI E, 
GOLDWASSER M, SUTRADHAR R & TA., S. 2008. Bleeding and perforation 
after outpatient colonoscopy and their risk factors in usual clinical practice. 
 
RAJENDRAN P, HO E, WILLIAMS DE & RH., D. 2011. Dietary phytochemicals, HDAC 
inhibition, and DNA damage/repair defects in cancer cells. 
RIVLIN, N., BROSH, R., OREN, M. & ROTTER, V. 2011. Mutations in the p53 Tumor 
Suppressor Gene: Important Milestones at the Various Steps of 
Tumorigenesis. Genes & Cancer, 2, 466-474. 
 
RODRIGUEZ, J., FRIGOLA, J., VENDRELL, E., RISQUES, R. A., FRAGA, M. F., MORALES, 
C., MORENO, V., ESTELLER, M., CAPELLA, G., RIBAS, M. & PEINADO, M. A. 
2006. Chromosomal instability correlates with genome-wide DNA 
demethylation in human primary colorectal cancers. Cancer Res, 66, 8462-
9468. 
 
ROPERO, S., FRAGA, M. F., BALLESTAR, E., HAMELIN, R., YAMAMOTO, H., BOIX-
CHORNET, M., CABALLERO, R., ALAMINOS, M., SETIEN, F., PAZ, M. F., 
HERRANZ, M., PALACIOS, J., ARANGO, D., ORNTOFT, T. F., AALTONEN, L. A., 
SCHWARTZ, S., JR. & ESTELLER, M. 2006. A truncating mutation of HDAC2 in 
human cancers confers resistance to histone deacetylase inhibition. Nat 
Genet, 38, 566-9. 
 
ROSATO, R., ALMENARA, J. & GRANT, S. 2003. The histone deacetylase inhibitor MS-
275 promotes differentiation or apoptosis in human leukemia cells through a 
process regulated by generation of reactive oxygen species and induction of 
p21CIP1/WAF1 1. 
 
ROSATO RR, MAGGIO SC, ALMENARA JA, PAYNE SG, ATADJA P, SPIEGEL S, DENT P & 
S., G. 2006. The histone deacetylase inhibitor LAQ824 induces human 
leukemia cell death through a process involving XIAP down-regulation, 
oxidative injury, and the acid sphingomyelinase-dependent generation of 
ceramide. 
 
ROSENBERG, G. 2007. The mechanisms of action of valproate in neuropsychiatric 
disorders: can we see the forest for the trees? 
 
ROSENBLUTH, J. & PIETENPOL, J. A. 2008. The jury is in: p73 is a tumor suppressor 
after all. 
 
ROWAN, A., HALFORD, S., GAASENBEEK, M., KEMP, Z., SIEBER, O., VOLIKOS, E., 
DOUGLAS, E., FIEGLER, H., CARTER, N., TALBOT, I., SILVER, A. & TOMLINSON, I. 
2005. Refining molecular analysis in the pathways of colorectal 
carcinogenesis. Clin Gastroenterol Hepatol, 3, 1115-23. 
199 | P a g e  
 
 
RUBBI, C. & MILNER, J. 2003. p53 is a chromatin accessibility factor for nucleotide 
excision repair of DNA damage. 
 
RUEFLI, A. A., BERNHARD, D., TAINTON, K. M., KOFLER, R., SMYTH, M. J. & 
JOHNSTONE, R. W. 2002. Suberoylanilide hydroxamic acid (SAHA) overcomes 
multidrug resistance and induces cell death in P-glycoprotein-expressing cells. 
Int J Cancer, 99, 292-8. 
 
RUNDALL BK, DENLINGER CE & DR., J. 2004. Combined histone deacetylase and NF-
kappaB inhibition sensitizes non-small cell lung cancer to cell death. 
 
RUSSO A, BAZAN V, IACOPETTA B, KERR D, SOUSSI T, N;, G. & GROUP., T.-C. C. S. 
2005. The TP53 colorectal cancer international collaborative study on the 
prognostic and predictive significance of p53 mutation: influence of tumor 
site, type of mutation, and adjuvant treatment. 
 
SAKAJIRI S, KUMAGAI T, KAWAMATA N, SAITOH T, SAID JW & HP., K. 2005. Histone 
deacetylase inhibitors profoundly decrease proliferation of human lymphoid 
cancer cell lines. 
 
SAMPATH J, SUN D, KIDD VJ, GRENET J, GANDHI A, SHAPIRO LH, WANG Q, ZAMBETTI 
GP & JD., S. 2001. Mutant p53 cooperates with ETS and selectively up-
regulates human MDR1 not MRP1. 
 
SAMUELS-LEV Y, O'CONNOR DJ, BERGAMASCHI D, TRIGIANTE G, HSIEH JK, ZHONG S, 
CAMPARGUE I, NAUMOVSKI L, CROOK T & X., L. 2001. ASPP proteins 
specifically stimulate the apoptotic function of p53. 
 
SANDMEIER, D., BENHATTAR, J., MARTIN, P. & BOUZOURENE, H. 2009. Serrated 
polyps of the large intestine: a molecular study comparing sessile serrated 
adenomas and hyperplastic polyps. 
 
SARELA AI, MACADAM RC, FARMERY SM, MARKHAM AF & PJ., G. 2000. Expression 
of the antiapoptosis gene, survivin, predicts death from recurrent colorectal 
carcinoma. 
 
SAUNDERS, L. R. & VERDIN, E. 2006. Ornithine decarboxylase activity in tumor cell 
lines correlates with sensitivity to cell death induced by histone deacetylase 
inhibitors. Mol Cancer Ther, 5, 2777-85. 
 
SAWAN, C. & HERCEG, Z. 2010. 3 - Histone Modifications and Cancer. In: ZDENKO, H. 
& TOSHIKAZU, U. (eds.) Advances in Genetics. Academic Press. 
 
200 | P a g e  
 
SCHON O, FRIEDLER A, BYCROFT M, FREUND SM & AR., F. 2002. Molecular 
mechanism of the interaction between MDM2 and p53. 
 
SCHUIJER, M. & BERNS, E. M. 2003. TP53 and ovarian cancer. 
SEIDEL, C., FLOREAN, C., SCHNEKENBURGER, M., DICATO, M. & DIEDERICH, M. 2012. 
Chromatin-modifying agents in anti-cancer therapy. Biochimie. 
 
SENA, P., SAVIANO, M., MONNI, S., LOSI, L., RONCUCCI, L., MARZONA, L. & DE POL, 
A. 2006. Subcellular localization of beta-catenin and APC proteins in colorectal 
preneoplastic and neoplastic lesions. Cancer Lett, 241, 203-12. 
 
SHAH NP, TRAN C, LEE FY, CHEN P, NORRIS D & CL., S. 2004. Overriding imatinib 
resistance with a novel ABL kinase inhibitor. 
 
SHAO, Y., GAO, Z., MARKS, P. A. & JIANG, X. 2004. Apoptotic and autophagic cell 
death induced by histone deacetylase inhibitors. Proc Natl Acad Sci U S A, 101, 
18030-5. 
 
SHEN, L., TOYOTA, M., KONDO, Y., LIN, E., ZHANG, L., GUO, Y., HERNANDEZ, N. S., 
CHEN, X., AHMED, S., KONISHI, K., HAMILTON, S. R. & ISSA, J. P. 2007. 
Integrated genetic and epigenetic analysis identifies three different subclasses 
of colon cancer. Proc Natl Acad Sci U S A, 104, 18654-9. 
 
SHIEH SY, IKEDA M, TAYA Y & C., P. 1997. DNA damage-induced phosphorylation of 
p53 alleviates inhibition by MDM2. 
 
SIEGEL, R., WARD, E., BRAWLEY, O. & JEMAL, A. 2011. Cancer statistics, 2011: the 
impact of eliminating socioeconomic and racial disparities on premature 
cancer deaths. CA Cancer J Clin, 61, 212-36. 
 
SIGAL, A. & ROTTER, V. 2000. Oncogenic mutations of the p53 tumor suppressor: the 
demons of the guardian of the genome. 
 
SIMPSON NE, LAMBERT WM, WATKINS R, GIASHUDDIN S, HUANG SJ, OXELMARK E, 
ARJU R, HOCHMAN T, GOLDBERG JD, SCHNEIDER RJ, REIZ LF, SOARES FA, 
LOGAN SK & MJ., G. 2010. High levels of Hsp90 cochaperone p23 promote 
tumor progression and poor prognosis in breast cancer by increasing lymph 
node metastases and drug resistance. 
 
SMITH, K. T. & WORKMAN, J. L. 2009. Histone deacetylase inhibitors: anticancer 
compounds. Int J Biochem Cell Biol, 41, 21-5. 
 
201 | P a g e  
 
SONG J, NOH JH, LEE JH, EUN JW, AHN YM, KIM SY, LEE SH, PARK WS, YOO NJ, LEE JY 
& SW., N. 2005. Increased expression of histone deacetylase 2 is found in 
human gastric cancer. 
 
SONG, J. H., KIM, Y. S., YANG, S. Y. & CHUNG, S. J. 2011. Physical Activity and Risk of 
Colorectal Adenomas. Gastroenterology, 140, S-399. 
SPINZI, G. & MINOLI, G. 2001. A comparison of colonoscopy and double-contrast 
barium enema for surveillance after polypectomy. Gastrointest Endosc, 54, 
417-8. 
 
STALLMACH, A., SCHMIDT, C., WATSON, A. & KIESSLICH, R. 2011. An unmet medical 
need: advances in endoscopic imaging of colorectal neoplasia. J Biophotonics, 
4, 482-9. 
 
STEELE, R. J. 2006. Modern challenges in colorectal cancer. Surgeon, 4, 285-91. 
 
STERNER, D. E. & BERGER, S. L. 2000. Acetylation of histones and transcription-
related factors. Microbiol Mol Biol Rev, 64, 435-59. 
 
STEVENS JB, LIU G, BREMER SW, YE KJ, XU W, XU J, SUN Y, WU GS, SAVASAN S, 
KRAWETZ SA, YE CJ & HH., H. 2007. Mitotic cell death by chromosome 
fragmentation. 
 
STIRZAKER, C., SONG, J., DAVIDSON, B. & CLARK, S. J. 2004. Transcriptional gene 
silencing promotes DNA hypermethylation through a sequential change in 
chromatin modifications in cancer cells. 
 
SVEC J, ERGANG P, MANDYS V, KMENT M & J., P. 2010. Expression profiles of 
proliferative and antiapoptotic genes in sporadic and colitis-related mouse 
colon cancer models. 
 
TABE Y, KONOPLEVA M, CONTRACTOR R, MUNSELL M, SCHOBER WD, JIN L, 
TSUTSUMI-ISHII Y, NAGAOKA I, IGARI J & M., A. 2006. Up-regulation of MDR1 
and induction of doxorubicin resistance by histone deacetylase inhibitor 
depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells. 
 
TO KK, POLGAR O, HUFF LM, MORISAKI K & SE., B. 2008. Histone modifications at 
the ABCG2 promoter following treatment with histone deacetylase inhibitor 
mirror those in multidrug-resistant cells. 
 
TOLEDO, F. & WAHL, G. M. 2006. Regulating the p53 pathway: in vitro hypotheses, 
in vivo veritas. 
 
202 | P a g e  
 
TORLAKOVIC, E. E., GOMEZ, J. D., DRIMAN, D. K., PARFITT, J. R., WANG, C., 
BENERJEE, T. & SNOVER, D. C. 2008. Sessile serrated adenoma (SSA) vs. 
traditional serrated adenoma (TSA). Am J Surg Pathol, 32, 21-9. 
 
TOTH, M., BOROS, I. & BALINT, E. 2012. Elevated level of lysine 9-acetylated histone 
H3 at the MDR1 promoter in multidrug-resistant cells. 
UNGERSTEDT, J. S., SOWA, Y., XU, W. S., SHAO, Y., DOKMANOVIC, M., PEREZ, G., 
NGO, L., HOLMGREN, A., JIANG, X. & MARKS, P. A. 2005. Role of thioredoxin in 
the response of normal and transformed cells to histone deacetylase 
inhibitors. Proc Natl Acad Sci U S A, 102, 673-8. 
 
VAN DEN BRANDT, P. A. & GOLDBOHM, R. A. 2006. Nutrition in the prevention of 
gastrointestinal cancer. Best Pract Res Clin Gastroenterol, 20, 589-603. 
 
VAN ENGELAND, M., DERKS, S., SMITS, K. M., MEIJER, G. A. & HERMAN, J. G. 2011. 
Colorectal cancer epigenetics: complex simplicity. J Clin Oncol, 29, 1382-91. 
 
VASEN, H. F. 2005. Clinical description of the Lynch syndrome [hereditary 
nonpolyposis colorectal cancer (HNPCC)]. Fam Cancer, 4, 219-25. 
 
VOGELSTEIN, B., LANE, D. & LEVINE, A. J. 2000. Surfing the p53 network. 
 
VOGTMANN E, SHANMUGAM C, KATKOORI VR, WATERBOR J & U., M. 2013. 
Socioeconomic status, p53 abnormalities, and colorectal cancer. 
 
VOUSDEN, K. & PRIVES, C. 2009. Blinded by the Light: The Growing Complexity of 
p53. 
 
WAGNER, J. M., HACKANSON, B., LUBBERT, M. & JUNG, M. 2010. Histone 
deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin 
Epigenetics, 1, 117-136. 
 
WAGNER, S. & ROEMER, K. 2005. Retinoblastoma protein is required for efficient 
colorectal carcinoma cell apoptosis by histone deacetylase inhibitors in the 
absence of p21Waf. Biochemical Pharmacology, 69, 1059-1067. 
 
WALTHER, A., JOHNSTONE, E., SWANTON, C., MIDGLEY, R., TOMLINSON, I. & KERR, 
D. 2009. Genetic prognostic and predictive markers in colorectal cancer. Nat 
Rev Cancer, 9, 489-99. 
 
WATSON, A. J. M. 2006. An overview of apoptosis and the prevention of colorectal 
cancer. Critical Reviews in Oncology/Hematology, 57, 107-121. 
 
203 | P a g e  
 
WEI CL, WU Q, VEGA VB, CHIU KP, NG P, ZHANG T, SHAHAB A, YONG HC, FU Y, 
WENG Z, LIU J, ZHAO XD, CHEW JL, LEE YL, KUZNETSOV VA, SUNG WK, MILLER 
LD, LIM B, LIU ET, YU Q, NG HH & Y., R. 2006. A global map of p53 
transcription-factor binding sites in the human genome. 
 
WEI, J., ZAIKA, E. & ZAIKA, A. 2012. p53 Family: Role of Protein Isoforms in Human 
Cancer. 
WEINBERG, R. L., VEPRINTSEV, D. B. & FERSHT, A. R. 2004. Cooperative Binding of 
Tetrameric p53 to DNA. Journal of Molecular Biology, 341, 1145-1159. 
 
WEISZ, L., OREN, M. & ROTTER, V. 2007. Transcription regulation by mutant p53. 
Oncogene, 26, 2202-2211. 
 
WEN, K., FU, Z., WU, X., FENG, J., CHEN, W. & QIAN, J. 2013. Oct-4 is required for an 
antiapoptotic behavior of chemoresistant colorectal cancer cells enriched for 
cancer stem cells: Effects associated with STAT3/Survivin. Cancer Letters, 333, 
56-65. 
 
WILSON, A. J., BYUN, D. S., POPOVA, N., MURRAY, L. B., L'ITALIEN, K., SOWA, Y., 
ARANGO, D., VELCICH, A., AUGENLICHT, L. H. & MARIADASON, J. M. 2006. 
Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell 
maturation and p21 expression and are deregulated in human colon cancer. J 
Biol Chem, 281, 13548-58. 
 
WITT, O. & LINDEMANN, R. 2009. HDAC inhibitors: Magic bullets, dirty drugs or just 
another targeted therapy. Cancer Lett, 280, 123-124. 
 
WORTHLEY, D. L. & LEGGETT, B. A. 2010. Colorectal cancer: molecular features and 
clinical opportunities. Clin Biochem Rev, 31, 31-8. 
 
WORTHLEY, D. L., WHITEHALL, V. L., SPRING, K. J. & LEGGETT, B. A. 2007. Colorectal 
carcinogenesis: road maps to cancer. World J Gastroenterol, 13, 3784-91. 
 
XU, W. S., PARMIGIANI, R. B. & MARKS, P. A. 2007. Histone deacetylase inhibitors: 
molecular mechanisms of action. Oncogene, 26, 5541-52. 
 
YANG A, SCHWEITZER R, SUN D, KAGHAD M, WALKER N, BRONSON RT, TABIN C, 
SHARPE A, CAPUT D, CRUM C & F., M. 1999. p63 is essential for regenerative 
proliferation in limb, craniofacial and epithelial development. 
 
YANG A, WALKER N, BRONSON R, KAGHAD M, OOSTERWEGEL M, BONNIN J, 
VAGNER C, BONNET H, DIKKES P, SHARPE A, MCKEON F & D., C. 2000. p73-
deficient mice have neurological, pheromonal and inflammatory defects but 
lack spontaneous tumours. 
204 | P a g e  
 
 
YANG, S. Y., SALES, K. M., FULLER, B., SEIFALIAN, A. M. & WINSLET, M. C. 2009. 
Apoptosis and colorectal cancer: implications for therapy. Trends in Molecular 
Medicine, 15, 225-233. 
 
YANG, X. J. & SETO, E. 2007. HATs and HDACs: from structure, function and 
regulation to novel strategies for therapy and prevention. Oncogene, 26, 
5310-8. 
 
YASUI, W., OUE, N., ONO, S., MITANI, Y., ITO, R. & NAKAYAMA, H. 2003. Histone 
acetylation and gastrointestinal carcinogenesis. Ann N Y Acad Sci, 983, 220-31. 
 
YOSHIDA, M., KIJIMA, M., AKITA, M. & BEPPU, T. 1990. Potent and specific inhibition 
of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. 
 
YOUNG, J., JENKINS, M., PARRY, S., YOUNG, B., NANCARROW, D., ENGLISH, D., GILES, 
G. & JASS, J. 2007. Serrated pathway colorectal cancer in the population: 
genetic consideration. Gut, 56, 1453-9. 
 
ZAUBER, A. G., WINAWER, S. J., O'BRIEN, M. J., LANSDORP-VOGELAAR, I., VAN 
BALLEGOOIJEN, M., HANKEY, B. F., SHI, W., BOND, J. H., SCHAPIRO, M., 
PANISH, J. F., STEWART, E. T. & WAYE, J. D. 2012. Colonoscopic polypectomy 
and long-term prevention of colorectal-cancer deaths. N Engl J Med, 366, 687-
96. 
 
ZHANG C, LI H, ZHOU G, ZHANG Q, ZHANG T, LI J, ZHANG J, HOU J, LIEW CT & D., Y. 
2007. Transcriptional silencing of the TMS1/ASC tumour suppressor gene by 
an epigenetic mechanism in hepatocellular carcinoma cells. 
 
ZHANG T, OTEVREL T, GAO Z, GAO Z, EHRLICH SM, FIELDS JZ & BM., B. 2001. 
Evidence that APC regulates survivin expression: a possible mechanism 
contributing to the stem cell origin of colon cancer. 
 
ZHANG Y, ADACHI M, KAWAMURA R, ZOU HC, IMAI K, HAREYAMA M & Y., S. 2006. 
Bmf contributes to histone deacetylase inhibitor-mediated enhancing effects 
on apoptosis after ionizing radiation. 
 
ZHANG, Y., FENG, J., LIU, C., ZHANG, L., JIAO, J., FANG, H., SU, L., ZHANG, X., ZHANG, 
J., LI, M., WANG, B. & XU, W. 2010. Design, synthesis and preliminary activity 
assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel 
Histone deacetylases (HDACs) inhibitors. Bioorg Med Chem, 18, 1761-72. 
 
ZHU P, MARTIN E, MENGWASSER J, SCHLAG P, JANSSEN KP & M., G. 2004. Induction 
of HDAC2 expression upon loss of APC in colorectal tumorigenesis. 
205 | P a g e  
 
